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SUMMARY
Colorectal cancer is one of the most common fonns of cancers worldwide and the 
second most coimiion cause of cancer death in the European Union. Surgical resection of 
the tumour is the primary choice of treatment as it is the only option that offers a chance of 
permanent cure. However, approximately half the patients who undergo apparently 
curative surgery will die witliin five years. It has been shown that up to 30% of patients 
undergoing apparently curative surgery for colorectal cancer harbour occult liver 
métastasés at the time of presentation and it is the presence of these hepatic métastasés that 
deteiiuines the likelihood of death from disseminated disease.
The liver possesses a dual blood supply, approximately 75% of the blood coming
.7
from the portal vein and 25% from the hepatic artery in the normal subject. There is 
evidence that these proportions are altered shortly after metastatic seeding in the liver.
Previous investigations using Doppler ultrasonography have shown that hepatic arterial 
blood flow is increased in the presence of liver métastasés, while some studies suggest that 
portal venous blood flow is reduced. The Doppler Perfusion Index (DPI), defined as the 
ratio of hepatic arterial to total liver blood flow, increases as a result of both these changes.
An elevated DPI at the time of apparently curative surgery has been shown to be highly 
predictive of subsequent recurrence in the liver.
It is not known, however, whether the DPI is the most effective index for 
quantifymg the tumour-induced changes in liver blood flow. There is also only limited 
evidence on whether the primary colorectal tumour alters liver blood flow. To address 
these questions, hepatic arterial and portal venous blood flow were measured in a series of 
patients with colorectal liver métastasés and normal control subjects.
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There was no significant difference in either component of liver blood flow between 
métastasés patients with and without a primary or recuiTcnt colorectal tumour. This 
confirms previous reports that the presence of a synchronous primary does not affect 
métastasés driven blood flow changes. Hepatic arterial flow was increased in patients with 
liver métastasés relative to controls, and portal venous flow was reduced. However, the 
latter difference was attributable to age mismatching, as portal venous blood flow was 
found to decline significantly with increasing age. An optimised index, the Dual Flow 
Index (DFI), was developed by logistic regression analysis to distinguish between 
métastasés and control patients on the basis of the blood flow measurements. This was 
found to only marginally improve on the DPI in accuracy of discrimination (84% vs. 82% 
after age adjustment of blood flow). It was concluded that the DPI was close to optimal as 
a diagnostic index, but that the age-dependence of blood flow should be considered in 
clinical practice.
Doppler ultrasonography is recognised to be an operator-dependent teclmique, and 
this may account for conflicting reports in the literature about the blood flow changes 
associated with liver métastasés. It has been suggested that functional Computed 
Tomography (CT) may provide equivalent information about liver blood flow in a less 
operator-dependent manner. However, reports on the effectiveness of functional computed 
tomography in detecting liver métastasés are conflicting.
Dual-phase contrast-enhanced spiral CT scans were used to assess tire varying 
parameters of tumour-induced changes in liver blood flow. Abdominal scans were 
perfomied in patients with liver métastasés, colorectal cancer patients without overt 
metastatic disease, and patients with small benign hepatic haemangiomas.
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No significant differences were found between these patient groups after adjustment 
for age imbalances. It was concluded that too many variables affect CT parameters in the 
routine clinical scanning procedure employed in this and other reported studies for them to 
be useful for studying blood flow changes. Further work is required in tliis area using a 
disease-free normal control population, however Doppler ultrasound currently remains the 
method of choice for the non-invasive assessment of splanclmic blood flow.
Most patients with colorectal liver métastasés have evidence of a systemic 
inflammatory response as manifested by an elevated plasma C-reactive protein 
concentration. There is evidence that pro-inflammatory cytoldnes, in particular interleukin- 
6, are released from colorectal tumours. It is possible that pro-inflaimnatory agents are 
associated with a hypermetabolic state in the liver, increasing oxygen demand and blood 
flow, or that they modulate hepatic arterial or portal venous blood flow in some other 
maimer. It may therefore be that the systemic inflammatory response is important in 
determining the changes in hepatic haemodynamics that occur in patients with colorectal 
liver métastasés. The relationships between liver blood flow, tumour volume and the 
systemic inflammatory response were subsequently examined in patients with colorectal 
liver métastasés to shed further light on the mechanisms underlying the blood flow changes.
Hepatic arterial blood flow and total liver blood flow increased significantly, though 
not strongly, with both increasing tumour volume and increasing C-reactive protein 
concentration. Tumour volume and increasing C-reactive protein concentration were 
themselves positively correlated, and it was not possible to determine which of them was 
more directly related to blood flow. Total liver blood flow was more strongly correlated 
with plasma interleuldn-6 concentration, and tliis relationship did not appear to be due to a 
common dependence on tumour size. Portal venous flow increased non-significantly with
22
tumour volume, C-reactive protein and interleukin-6, wliile the DPI showed a marked lack 
of correlation with any of these variables.
It was concluded that, in patients with colorectal liver métastasés, hepatic arterial 
and total liver blood flow may be modulated by circulating interleukin-6, a mediator of the 
systemic inflammatory response. They also vary with tumour volume, although the basis 
of tliis relationship remains unclear. It is unlikely, however, that these mechanisms are 
responsible for tlie elevated Doppler Perfusion Index in patients with colorectal liver 
métastasés.
:r ï
To test these conclusions, and further elucidate the haemodynamic effects of the 
systemic inflammatory response, a double-blind, randomised, placebo-controlled study was 
perfoiined to determine the effect of an anti-inflammatory treatment (ibuprofen
Is?1200mg/day for 7 days) on liver blood flow in patients with colorectal liver métastasés. 
The power of the study was limited by a lower recmitnient rate and a higher rate of failm e 
to complete the study than expected, largely due to treatment inteiwentions. It was also 
limited by an unexpectedly low level of systemic inflammation at baseline. The proportion 
of patients with an elevated DPI fell non-significantly from 67% to 42% in the ibuprofen 
group and remained static at 73% in the placebo gmup. None of the other blood flow 
variables changed significantly fi'om baseline in either treatment group, and none of the 
changes differed significantly between treatment groups. The low recruitment rate of the 
study limits its final conclusions to some degree, however it can be seen that the systemic 
inflammatory response does not wholly explain the abnonnalities m liver blood flow in 
patients with colorectal liver métastasés, and that its contribution to the elevated Doppler 
Perfusion hidex in these patients is likely to be small.
23
Chapter 1 : Introduction
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1.1 Colorectal Cancer: Incidence and Mortality
Colorectal cancer is one of the most common fonns of cancers worldwide, with an 
estimated 783,000 new cases diagnosed in 1990, and approximately one million new cases 
diagnosed in the year 2000. It accounts for 9.7% of all new cancer cases in the world 
(Parldn et al., 1990; Ferlay et al., 2001). Each year there are approximately 437,000 (8.4% 
of the world total) cancer deaths from colorectal cancer, making it the second most 
common cause of cancer death in the European Union (Parkin et al., 1990; GRC 
Cancer Stats, 1999).
Colorectal cancer is more common in Westernised countries; the US has the highest 
incidence with 53 cases per 100,000 (Parkin et ah, 1997). hi Europe, the highest rates are
'
in the Northern countries of Demnark, Belgium and Germany and the lowest rates are in the 
Southern countries of Poiiugal and Spain. More specifically, the UK had over 30,000 new 
cases of colorectal cancer in 1995 with a higher incidence rate in Scotland, where colorectal 
cancer accounted for 13.8% of newly diagnosed malignancies (excluding non-melanoma 
skin cancer), hi Scotland the lifetime risk of developing colorectal cancer is 4.6% for men 
and 3.2% for women (Moir et al., 1999). Overall, the incidence of colorectal cancer has 
been increasing since 1971 where 20,400 cases were reported, to 1997 where 28,900 cases 
were reported; an overall increase of 42% (Hayne et al., 2001).
The majority of colorectal cancers in the UK occur in the colon compared with the 
rectum (2:1). hicidence rates are strongly related to age, over 80% of patients are aged 60 
years or more at the time of initial diagnosis. However, colon cancer rates are slightly 
higher in females and rectal cancers are slightly higher in males (CRC CancerStats, 1999).
25
1.2 Aetiology
Colorectal cancers can arise from genetic or environmental factors. However the 
large majority of cases are sporadic in nature, most likely caused by an interaction of these 
two factors (Wilmink, 1997).
L 2J Genetic Factors
Genetic factors account for a relatively small proportion of all colorectal cancers 
(approximately 3-5%). It is generally accepted from epidemiological and histopathological 
studies that the majority of colorectal adenocarcinomas originate from premalignant 
adenomatous polyps. The multi-step process involving complex genetic mutations which
underlie the progression from benign disease to a malignant state, is known as the 
adenoma-carcinoma sequence (Jass, 1989; Fearon & Vogelstein, 1990; Wilminlc, 1997). 
Benigi adenomatous polyps can develop from normal colonic mucosa and are present in 
approximately one third of the European and US population. Tubular adenomas account 
for the majority of benign polyps (approximately 75%), tubulovillous adenomas and villous 
adenomas are less frequent (approximately 15%, 10% respectively). The malignant 
potential of these polyps has an inverse relationship with their incidence. However, 
approximately 40% of villous adenomas will become malignant (van Stolk et al., 1998; 
CRC CancerStats, 1999). Overall, approximately 5% of these benign polyps will be 
malignant over a 5-10 year period (CRC CancerStats, 1999).
There are several types of genetic alterations involved in the advanced stages of 
carcinoma formation. Mutations on tumour suppressor genes may be involved in the early 
stages of carcinoma formation. These genes inliibit tumorigenesis by inducing apoptosis or
26
by inteiiTiptmg the mitogenic signai tiansdnction pathways. They can promote cancer 
growth when inactive in both alleles and are often associated with metastatic disease and 
poor prognosis (Younes & Johnson, 1997). A mutation present on clnomosome 5 has been 
demonstrated in approximately 40% of colorectal cancers, but was not shown on early stage 
polyps (Vogelstein et al, 1988).
Another early event, may be the mutation in the K-ras oncogene. This mutation has 
been found in 58% of intermediate and late stage adenomas and 47% of carcinomas. 
Although it is less common in early stage adenomas, its presence in benign colonic 
abnormalities indicates that it is unlikely to be the sole cause of malignancy (Fearon et al, 
1987; Vogelstein, 1988; Fearon & Vogelstein, 1990; McLeod & Murray, 1999).
1.2.2 Hereditary Nonpolyposis Colorectal Cancer (HNPCC)
FTNPCC is the most common familial colorectal cancer syndrome, accounting for 
approximately 5% of all colorectal cancers (CRC CancerStats, 1999). It results from a 
DNA mismatch repair gene deficiency leading to either tumour growth in the colon alone at 
an early age (Lynch I syndrome) or in the colon with additional tumours arising in the 
stomach, liver, biliary system, urinary tract, endometrium and pancreas (Lynch II 
syndi'ome; Wilminic, 1997). Lynch II syndrome is mostly associated with right sided 
colonic lesions (Lynch & Lynch, 1993).
Cunently, five mismatch repair genes have been identified and mutations in two of 
them account for more than 95% of HNPCC families. The percentage risk of cancer in 
patients carrying an HNPCC gene is approximately 85-90% (Wilmink, 1997). Despite the 
characteristic large, proximal and poorly differentiated tumour, HNPCC patients usually 
have a better prognosis than other colorectal carcinomas. Testing for micro satellite
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instability (MSI) from tumour tissue samples taken at the time of surgery can indicate 
damage to a mismatch repair gene. MSI occurs in nearly all HNPCC and 15% of sporadic 
cancers. If samples test positive for microsatellite instability, familial screening for 
HNPCC could be beneficial (Starkey, 2002).
In younger colorectal cancer patients approximately 41% have been shown to be 
carriers of DNA mismatch repair genes. In Scotland alone there are approximately 12,500 
carriers of these DNA mismatch repair genes (90% risk for males, 69% risk females; CRC 
CancerStats, 1999).
1.2.3 Familial Adenomatous Polyposis (FAP)
FAP accounts for around 1% of all colorectal cancers in Westernised populations. 
It can be identified by numerous benign polyps in the colon and/or rectum and the 
percentage risk of malignancy by the age of 40 years is extremely high (CRC CancerStats, 
1999). A mutation on the adenomatous polyposis coli (APC) gene has been identified as 
one of the earliest changes in colorectal cancer and is found specifically in the germline of 
FAP patients. Currently APC mutations are detectable in 80-90% of FAP cases and APC is 
mutated in 70% of all colorectal cancers; certain polymorphisms of APC have been shown 
to give an increased risk for colorectal cancer (Laken et al., 1997; Starkey, 2002).
28
FAP
NORMAL
ADENOMA
CARCINOMA
APC mutation
LOH 5q 
LOH 17q, 18q
Figure 1.1 Genetic familial adenomatous polyposis (Adapted from Younes & Johnson,
1997).
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1.2.4 Environmental Factors
The large majority of colorectal cancers are sporadic and genetic damage is thought 
to occur primarily tlnough environmental factors. It has been suggested that approximately 
80% of cases of colorectal cancer may be preventable by diet (Cummings & Bingham,
1998). However, there is considerable controversy as to which specific dietary constituents 
contribute to increased risk of colorectal cancer and those wliicli have a protective effect.
Despite growing evidence of an increased risk of colorectal cancer with increased 
intake of fat or red meat, it is not possible to fiiinly conclude that there is a modulatory
V-effect on colorectal carcinogenesis (Woutersen et al.,1999). Many studies have failed to 
demonstrate a direct relationship between incidence and animal fat intake, which may be 
due to variations in cooking methods, methodological limitations of studies and a varying 
combination of foods, such as fish in the diet. It has been suggested that the high 
polyunsaturated fat content (rich in n-3 fatty acids) in fish and fish oil reduces the 
promotional effects of diets high in animal fats (n-6 fatty acids) and/or unsaturated acids in 
colorectal or breast cancer. This suggests that the overall type and composition of ingested 
dietary fat is more important than the total dietary fat intake (Woutersen et ah, 1999; Rao et 
ah, 2001).
It has been questioned whether alcohol drinkers are at higher risk due to the lack of 
protective antioxidant vitamins from vegetables and fruits, or whether there is a 
carcinogenic effect of alcohol that is independent of dietary deficiencies (Jedrychowski et 
al., 2002). The effect of tobacco on colorectal cancer incidence has also been presented 
recently. Giovaimucci and co-workers have recently estimated that around one in five 
colorectal cancers in the US may be associated with tobacco use (Giovamiucci, 2001).
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Inflammation may play a key role in colorectal tumour development since it has 
long been recognised that dysplasia found in patients with inflammatory bowel disease, 
ulcerative colitis and Crohn’s disease is associated with increased incidence of colorectal 
cancer (Glotzer, 1985; Wilmink, 1997).
It was initially obseiwed in 1969 by Burkitt that incidence rates of colorectal cancer 
are much lower in populations where the diet consists of high fibre and low fat (Burkitt, 
1971). This led to the hypothesis that dietary fibre prevents colorectal cancer by diluting or 
absorbing faecal carcinogens, reducing colonic transit time, altering bile acid metabolism, 
reducing pH in the colon or increasing the production of short chain fatty acids 
(Kritchevsky, 1995). However, many studies since Burkitf s initial observation have been 
unable to find such a link between colorectal cancer and dietary fibre (Platz et ah, 1997). 
For example, in a study of 88,757 women, Fuchs and co-workers (1999) followed the 
intake of dietary fibre and incidence of colorectal cancer for 16 years. During this period,
787 cases of colorectal cancer and 1012 cases of adenomas of the distal colon and rectum
were found in 27,530 of the participants who underwent colonoscopy investigation. This 
prospective study failed however to find an association with dietary fibre and protection 
fr om colorectal cancer or adenoma (Fuchs, 1999).
A recent study into the effect of fruit and vegetable intake on the incidence rate of 
colorectal cancers, investigated two large cohorts (88,764 women and 47,325 men). No 
association between consumption and incidence was found (Michels et ah, 2000).
In contrast, physical exercise may play a protective role against colorectal 
carcinogenesis. However, reasons for this remain unclear. The effect of exercise on bile 
composition, the faster and more regular colonic transit associated with exercise, and the
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effect of exercise on insulin levels (hyperinsulinaemia is associated with increased colon 
cancer) may offer some explanation for decreased risk (Hill, 1999).
Hormone replacement therapy has also been associated with a decrease in colorectal 
cancer prevalence. There are several studies showing this relationship with some also 
showing a reduction in risk of death from the disease (McMichael & Potter, 1980; Jacobs et 
ah, 1994; Newcomb & Sti'orer, 1995; Calle et ah, 1995; Chlebowsld et ah, 2004; Slattery et 
ah, 2005). Further studies are required to explain this effect and investigate the potential 
for preventative therapy (Boyle & Langman, 2000).
1.3 Clinical Features of Colorectal Carcinoma
Presentation of cancer of the colon and rectum can occur from the effects of the 
primary, secondary or from the typical symptoms of malignant disease. It is widely 
accepted that during the early stages, an uncomplicated carcinoma of the colon is usually 
symptomless.
Coimnonly recognised symptoms of colorectal cancer include altered bowel habit, 
bleeding per rectum of a short duration and blood in the stool, however symptoms are 
dependent on the site and stage of disease (CRC Cancer Stats, 1999; McArdle, 2000).
Right sided tumours in the large bowel wall are often relatively large as they are 
free to expand in the caecum. They are less likely to cause obstructive symptoms and any 
bleeding may mix within the stool and can be invisible by the time it reaches the rectum. 
Therefore right sided tumours are typically more advanced at diagnosis. Left sided colonic 
tumours are characteristically annular and the intraluminal contents are more solid. 
Therefore the mode of presentation is more often abdominal pain, constipation or
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obstruction. Overt rectal bleeding and altered bowel habit are more often a manifestation 
of rectal disease (Allum et al., 1994).
1.4 Staging and Prognosis of Colorectal Cancer
The main objectives of staging cancer, defined by the unified American Joint 
Coimnittee on Cancer (AJCC) and the Union Internationale Contre le Cancer (UICC), are 
to aid the clinician in the plamiing of treatment; give an indication of prognosis; help 
evaluate results of treatment; contribute to continuing investigation of human cancer; and to 
assist in the exchange of infonnation between centres.
Colorectal cancer spreads by direct extension to adjacent organs, by lymphatic 
pathways, and by haematogenous routes. Although lymph node métastasés represent 
regional disease, it is also presumed that such disease represents the potential for 
disseminated disease as well (Enker et al., 1981).
Turnbull et al., 1967; McArdle & Hole, 2002).
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1.4.1 Dukes’ Classification
To date, one of the most important and effective methods of staging uses 
pathological information based at the time of presentation. Following from the first 
classification system designed by Locldiart Mummery, Dr Cuthbert Dukes (1932) produced 
a simple, reproducible and clinically helpful prognostic classification system intended for 
rectal cancer. Classification of Dukes’ stage is illustrated in Table 1.1 and is based on the
...
direct and lymphatic spread found in the surgically excised tumour specimen (Dukes, 1932;
Table 1.1 Dukes’ classification and outcome in colorectal cancer (adapted from 
McArdle & Hole, 2002).
Dukes’
Stage
Indication Proportion of 
Patients
5-Year 
Survival
A tumour limited to bowel wall 7% 85-95%
B
tumour extends beyond the wall 
without metastatic regional lymph 
nodes
47%
70 -  75%
Cl
direct spread in continuity limited to 
the bowel wall
30% 35 -  45%
C2
highest node contained metastatic 
tumour
D
distant métastasés or advanced local 
disease
15% 0 -  5%
■4
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1.4.2 TNM Staging
Due to disadvantages of the conventional Dukes’ staging, such as lack of precision 
as it does not assess the exact depth of tumour penetration, number of lymph nodes 
involved and the extent of spread outside the bowel wall, the TNM classification has now 
been widely adopted. Originally introduced in the early 1950s, a single version was 
internationally approved in the late 1980s. The TNM system is now used for carcinomas of 
the upper gastrointestinal tract, breast, ovary, urinary bladder, prostate and the colon and 
rectum. The basis for TNM classification includes assessment of tumour size and depth of 
penetration (‘T’), nodal involvement (‘N ’) and the presence of distant métastasés (‘M’). 
TNM provides the clinician with more information and it can be easily translated into other 
staging classifications, such as Dukes’ staging (Hermanek et al, 1990). The principles of 
TNM classification are illusti'ated in Figure 1.2 and the association between TNM and 
Dukes’ staging is illustrated in Table 1.2.
,4;
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Primary tumour, clinical (T):
TX Primary tumour camiot be assessed.
TO No evidence of primary tumour.
Tis Carcinoma in situ.
T1 Tumoui’ invades submucosa.
T2 Tumour- invades tlri'ough muscularis propria.
T3 Tumour invades tlmough muscularis propria into subserosa.
/ or into non-peritonealized pericolic or perirectal tissues.
T4 Tumour invades other organs of structures and/ or perforates visceral 
Peritoneum.
Regional lymph nodes (N):
NX Regional lymph nodes cannot be assessed.
NO No regional lymph node metastasis.
N1 Metastasis in 1 to 3 regional lymph nodes.
N2 Metastasis in 4 or more regional lymph nodes.
Distant Metastasis (M):
MX Distant metastasis cannot be assessed.
MO No distant metastasis.
Ml Distant metastasis.
Figure 1.2 TNM Classification (American Joint Committee on Cancer -  Union 
Internationale Contre le Cancer, 1995).
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Table 1.2 TNM classification in relation to Dukes’ staging.
TNM
Classification
Dukes’ Stage s
£
■
Tis NO MO £?£1:T1 NO MO A 1
T2 NO MO A I1
T3 NO MO B 7:
T4 NO MO B 3;:
Any T N1 MO C
Any T N2 MO C
1Any T Any N Ml D i:'£
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1.5 Treatment of Colorectal Cancer
Surgical resection of the tumour remains the primary choice of treatment as it is the 
only option that offers a chance of permanent cure. However, approximately half the 
patients who undergo apparently curative surgery, will die within five years (McArdle, 
2000).
The majority of patients who present with colorectal cancer are elderly and many 
have significant co-morbidity, especially due to cardiovascular or respiratory disease. 
Nevertheless, approximately 80% of patients will receive a surgical resection of their 
primary tumour (CRC CancerStats, 1999; McArdle, 2002).
1.5.1 Surgical Treatment
Before surgery is undertaken, histological confirmation of the diagnosis should be 
obtained, usually by colonoscopy. For rectal cancers, the height of the tumour is 
determined using a rigid sigmoidoscope and the degree of fixity is established by palpation. 
Endoluminal ultrasound also plays an important part in assessing the depth of tumour 
penetration. Additionally, all patients should be screened for liver or lung métastasés prior 
to surgery (Domdi et al., 2002).
It has been reported recently that sumval rates following colorectal surgery have 
improved over the last two decades. Tliis has been attributed to the development of 
specialist centres, improvements in teclmiques and the use of adjuvant and neoadjuvant 
therapies rather than earlier presentation. If there is a continual increase in the proportion 
of patients undergoing treatment by specialist colorectal surgeons and oncologists at 
specialist centi'es, further improvements in survival are likely (McArdle & Hole, 2002;
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McArdle et al., 2005). Moreover, in rectal surgery, if the principles of niesorectal excision 
are adhered to, overall local recunence rates should be less than 10%. As local recurrence 
is difficult to treat and ultimately fatal, good surgical teclmique lends itself to better long
Adjuvant Therapy
term survival for patients with rectal cancer (Leslie & Steele, 2002).
01.5.2 Chemotherapy and Radiotherapy
Neo-adiuvant Chemotherapy
Neo-adjuvant therapy aims to treat distant micro-métastasés as early as possible and 
.downstage primary tumours for more effective and less radical surgical treatment without ?
compromising overall survival or cure. Bismuth and co-workers (1996) were amongst the 
first to document a successful outcome from neo-adjuvant treatment. It was reported that a 
small cohort of patients with disseminated disease (53 of 330) were down staged following 
neo-adjuvant chemotherapy to such a degree that surgical resection of colorectal liver 
métastasés became possible.
More recently, these findings have been supported by Adam and co-workers (2001).
The ability to respond to neo-adjuvant chemotherapy demonstrates a significant potential 
for increased survival however the extent of this may take many years to define (Adam et |
ah, 2001).
The benefit of adjuvant chemotherapy in suitable patients with Dukes’ C colorectal |
1:
cancers has been illustrated in several large studies (Wolmark et ah, 1990; Moertel et al.,
1990; Wolmark et al., 1993). However, adjuvant treatment in Dukes’ B colorectal patients 
is still under debate. It is still generally accepted that adjuvant chemotherapy should only ’■"3;
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be offered to those Dukes’ B patients presenting with high-risk prognostic factors, due to 
the toxicity and cost of adjuvant therapy. However, a study reported by Mamounas and co­
workers (1999) investigated four protocols of adjuvant treatment in 1,565 patients with 
Dukes’ B and 2,255 patients with Dukes’ C colon cancer, with 5-year follow-up. The study 
showed that smvival was increased in both Dukes’ B and Dukes’ C patients who received 
some form of adjuvant chemotherapy. Although the study was not large enough to 
compare which regimen of treatment was the most effective, it was able to confirm the 
benefits of chemotherapy in all stage B and C patients, irrespective of high-risk prognostic 
factors.
Post-operative adjuvant therapy usually consists of treatment for 6 months or longer 
with 5-fluorouracil based regimens. Increasing understanding of the molecular 
pharmacology of fluorouracil has given rise to the co administration of other dings, with the 
intention of increasing the efficacy (Midgley & Kerr, 2000). However, there is some 
uncertainty as to which regimen is the most effective. Two of the most promising 
combinations are fluorouracil plus levimasole and fluorouracil plus folinic acid (QUASAR 
group, 2000). More recent chemotherapy agents may be more effective. However at tliis 
pomt they are only administered as part of a clinic trial (Leslie & Steele, 2002).
Possible side effects from fluorouracil based regimens include nausea, vomiting, 
increased susceptibility to infection, oral mucositis, diaiahoea, desquamation of the palms 
and soles, and less commonly, cardiac and neurological effects (Midgley & Keir, 2000).
Adjuvant radiotherapy is only suitable for patients with rectal cancer as the 
morbidity associated with abdominal radiotherapy is prohibitive (Leslie & Steele, 2002). 
Studies in Europe have mamly focused on the application of preoperative radiotherapy. 
The Uppsala trial in particular, showed preoperative radiotherapy improved local control
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and decreased toxicity in comparison to postoperative radiotherapy (Fryldiolm et ah, 1993). 
However, studies in North America have shown that postoperative radiotherapy can be 
more effective when combined with 5-fluorourarcil based chemotherapy (Colorectal 
Cancer Collaborative Group, 2001).
Palliative Therapy
In patients with inoperable advanced colorectal cancer, palliative chemotherapy is 
the mainstay of treatment, approximately doubling the survival in comparison to controls 
(Scheithauer et al., 1993; Smyth et al., 1997). The most widely used regimen to date is 
bolus 5-fluorouracil and folinic acid (Mayo regimen). However, it has been reported that 
inteiinittently infused 5-fluorouracil and folinic acid (de Gramont regimen) or continuously 
infused 5-fluorouracil (Lokich regimen) may be more effective and less toxic (Lokich et ah, 
1989; Leslie & Steele, 2002).
In patients with inoperable rectal cancer, the main aim of treatment by radiation is 
to kill the primary gross tumour. Endocavitary irradiation (contact x-ray therapy, 
brachytherapy) is the main teclmique used to deliver high doses to the tumour but low 
doses to normal tissue. External-beam radiotherapy is a complementary teclmique used to 
control subclinical disease in the rectal wall and perirectal lymph nodes (Gerard et al., 
2003).
In spite of improvements in surgical teclmique, increased access to chemotherapy 
and radiotherapy treatments, overall results are still unsatisfactory and long term smwival 
and improvement is disappointing.
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1.6 Colorectal Liver Métastasés
I
The liver is the largest organ in the body, some of its main functions are: secretion
of bile; storage of glycogen and the production of plasma proteins; the breakdown of
proteins and the formation of urea, and the desaturation of fats; the storage of iron and
vitamin B 12; and the destmction of various toxic substances and the production of heparin
and fibrinogen concerned in the clotting of blood. All of these functions depend on the
.maintenance of an adequate blood supply and are vital to the correct functioning of the 
body (Woodcock, 1975).
1.6.1 Incidence and Mortality
It has been shown that up to 30% of patients undergoing apparently curative surgery 
for colorectal cancer are harbouring occult liver métastasés at the time of presentation 
(Finlay & McArdle, 1986) and it is the presence of these hepatic métastasés that determines 
the likelihood of death from disseminated disease. Cunently, only half of the patients 
undergoing curative surgery will suiwive five years; the majority of deaths are due to 
disseminated disease within the first three years (McAi'dle, 2002).
Due to the unique venous drainage of the gastrointestinal tract through the portal 
vein, the liver is the most common site of distant métastasés. Around one quarter of the 
patients who develop liver métastasés will have disease isolated to the liver. The majority 
of these patients will have umesectable disease and will eventually succumb to liver failure 
(Silen, 1989; Sasson & Sigurdson, 2002). Factors influencing survival include the number 
and position of liver métastasés and the percentage hepatic replacement by the tumour. If
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left untreated, patients with liver métastasés have a poor prognosis, with a median survival 
of less than twelve months (Wood et al, 1976; Stangl et al., 1994).
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1.7 Detection of Liver Métastasés
1.7.1 Imaging o f Liver Métastasés
Detection of liver métastasés is fundamental in the accurate staging and subsequent 
management of patients with colorectal cancer. Intraoperative ultrasound has been widely 
used for the detection of liver lesions for a number of years. This teclmique may detect 
solid lesions down to 3-5nmi and the sensitivity has been previously reported as high as 
98%. In addition, intraoperative ultrasound can detect tumours deep in the liver, which 
may evade surgical palpation (Choi et ah, 1991; Maclii et al., 1991; Sclmiidt et al., 2000).
Currently the most coimnon methods of choice for liver screening in colorectal 
cancer are computed tomography (CT) or magnetic resonance imaging (MRI). Both of 
these teclmiques routinely use conti*ast media to enlrance tire liver parenchyma to tumour 
ratio. There are mixed reports as to which method produces the highest detection and 
characterisation rates, however it is generally accepted that both methods are highly 
effective at detecting métastasés of 1cm or larger, hi contrast, the sensitivity of imaging 
methods (CT and MRI) for detecting liver lesions smaller than 1cm is approximately 50% 
when surgery with intraoperative ultrasound is used as the “gold standard”. The true 
accuracy of the reference standard itself is however difficult to establish (Ward et al., 1999; 
Robinson, 2000).
Conventional ultrasound was previously used for the detection of liver métastasés as 
it is non-invasive, has minimal costs and widespread availability. With the emergence of 
contrast-enlianced CT and MRI the efficacy of conventional ultrasound has been 
questioned. However, recent advances in ultrasound teclmology have improved the 
sensitivity and specificity of this teclmique. The development of microbubble contrast
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agents allow a safe and simple method for improving the liver to tumour ratio and can 
provide valuable infonnation on the blood flow through smaller vessels to malignant 
tumours (Blomley et al., 2001). Additionally a multi-centre trial has recently reported a 
higher rate of lesion detection for contrast-enhanced ultrasound, than both CT and MRI 
(Leen et ah, 2002).
The growth of previously undocumented liver métastasés following apparently 
curative surgery, may be a result of subsequent seeding and growth of micrometastases 
following incomplete or palliative resection of the primary tumom*. It has also been 
proposed that the primary tumour inliibits angio gene sis of its metastasis (Peeters et al., 
2004; Peeters et ah, 2005; Peeters et ah, 2006). However, in the majority of cases it is 
likely that occult liver métastasés went undetected at the time of diagnosis. Advances in 
radiological teclmiques are therefore focusing on improving the detection and 
characterisation of lesions to provide a more accurate method of staging patients (Machi et 
ah, 1991).
1.7.2 Liver Haemodynamics
Despite advances in the detection of liver métastasés, the cuuent minimum 
detection size of lesions by CT and MRI is approximately 3-4mm diameter, however, the 
majority of lesions in this size range are not visualised. It has been suggested that liver 
blood flow is altered shortly after metastatic seeding in the liver and this has been the focus 
of many studies designed to improve detection of lesions in the size range 0.1-2mm 
(Robinson, 2000).
The liver is unique in the fact that it possesses a dual blood supply, approximately 
75% of the blood coming from the portal vein and 25% from the hepatic artery. The
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hepatic artery is a branch of the coeliac axis coming from the abdominal aorta; the portal 
vein channels blood from the stomach, spleen and intestines. Hepatic arterial blood is rich
Both hepatic arterial and portal venons vessels branch and divide until they reach the 
hepatic sinusoids. Therefore each cell within the liver is supplied with oxygenated and 
nutrient-bearing blood. Blood is drained from the liver via numerous small hepatic veins 
into the tlnee main hepatic veins: right, middle and left. The middle vein marks the plane 
between the right and left lobes of the liver. The hepatic veins connect into the inferior
in oxygen, whereas blood from the portal vein is deficient in oxygen but rich in nutrients.
I
I
vena cava and then to the right side of the heart (Woodcock, 1975; Fan & Chang, 2002).
' IIt has been shown that métastasés are seeded in the liver via the portal venous 
system and initially derive most of their nutrients via the portal venous flow. However, as 
they grow and develop a vasculature their blood supply is predominantly derived from the 
arterial component of liver blood flow, which increases to meet the metabolic demand 
causing an increase in the ratio of arterial to portal venous blood flow (Ridge et ah, 1987).
These alterations in liver blood flow can be exploited for the detection of 
micrometastases tlii'ough techniques such as scintigraphy, ultrasound and CT. However, 
there are teclmical limiting factors to the measurement of liver blood flow and conflicting 
reports on the accuracy.
1.7.3 Hepatic Perfusion Research 
Human Studies
It is clear that any permanent improvement in survival rate from colorectal cancer 
will greatly depend on the ability to significantly improve detection of occult metastatic 
disease to the liver. As teclmology advances, the ability to image micrometastatic liver
46
lesions will continue to improve, however, for the foreseeable fliture there will always be 
limiting factors preventing 100% specificity and sensitivity. By assessing the alterations in 
hepatic haemodynamics and combining with routine radiological screening methods, the 
detection and characterisation rates of liver métastasés may be enhanced which will 
ultimately lead to improvements in survival rates. There have been a number of studies 
over the last 25 years utilising radiological techniques to exploit hepatic haemodynamics 
aiming for an improvement in detection and suiwival rates.
Alterations in the hepatic blood flow of patients witli colorectal liver métastasés 
were first measured by Leveson and co-workers (1983). Dynamic flow scintigraphy was 
used to assess liver perfusion and the ratio of hepatic arterial to total liver blood flow was 
used as an indicator of the presence of hepatic métastasés.
Liver perfusion was studied by injecting a bolus of contrast agent or radiotracer into 
a peripheral vein where the hepatic arterial component anives in the liver approximately 6- 
10 seconds ahead of the start of the portal venous component. If the rate of anival of the 
contrast agent or tracer is measured it is possible to derive a measurement of the ratio of 
arterial to portal or to total hepatic inflow. Results from studies using a radioactive colloid 
tracer indicated that patients harbouring liver métastasés have a higher hepatic arterial to 
total liver blood flow ratio, termed the Hepatic Perfusion Index (HPI; Leveson et al., 1983; 
Parkin at ah, 1983; Goldberg et al., 1991a; Robinson, 2000).
Initial studies using HPI produced high sensitivity values for the detection of liver 
métastasés. A prospective study in normal healthy controls and patients with 
gastrointestinal cancers reported that 96% (24/ 25) of patients with metastatic disease at 
laparotomy had an elevated HPI value, in comparison the sensitivity of isotope scanning of 
the same cohort was a less remarkable 64% (Leveson et al., 1983).
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In addition, approximately half of the colorectal cancer patients with no overt liver ^
disease at laparotomy had abnonnally elevated HPI values (Leveson et al., 1983). It was 
later reported that 18 patients witli apparently normal livers at laparotomy, had developed 
liver métastasés at one year follow-up. It is of interest that all of these patients had an 
abnomial HPI value at the time of initial investigations. In contrast, all of the patients with
%
low HPI values remained free from hepatic disease and it was suggested that dynamic flow 
scintigraphy had a potential role for the staging and identification of patients with occult 
liver métastasés from gasti'ointestinal cancers (Leveson et al., 1985).
However, other centres reported less encouraging results and were unable to 
reproduce the high sensitivity and specificity described by Leveson and co-workers. 
Ballantyne and co-workers (1987) found raised HPI values in only 68% (17/ 25) of patients 
with overt liver métastasés. Likewise, a study by Laird and co-workers (1987) reported a 
liigh number of false-negative HPI values in patients with hepatic tumour involvement.
Despite this, further studies have since confirmed the original reports by Leveson 
and co-workers. Hemingway and co-workers (1992) reported a diagnostic sensitivity of 
96% for the HPI teclmique compared with 79% for static scintigraphy in patients with 
colorectal cancer. More recently, Wanen and co-workers (1998) reported that an elevated 
HPI was associated with poor outcome in patients having a potentially curative resection 
for colorectal cancer.
In response to the reports of poor reproducibility and accuracy, the HPI teclmique 
was investigated by Maughan and co-workers (1992) in a multicentre study using a 
phantom to simulate the dual blood supply of the liver. Furthermore, in order to assess 
non-instrumental differences, 28 patients underwent HPI measurements at two different 
centres. There was a generally good agreement between calculated HPI values in the
48
phantom study, variations occumng only as a result of statistical variations and uncertainty 
in the gradient calculation. For the patient studies, there were no statistically significant 
differences in the pooled HPI results from the two centres. Nevertheless there was a poor 
correlation between the two sets of values between centres, with comespondence in only 
79% of patients. It was thought that the ‘grey area' between normal and abnormal HPI 
values was responsible for this result and it was concluded that each centre using the HPI 
teclmique should establish its own range of nonnal values by studying a control population 
(Maughan et ah, 1992).
The HPI teclmique is prone to several errors. Selection of ‘regions of interest’ 
(ROI) and variations in the time period over which the gradient of the curves are calculated 
can all affect the accuracy of the HPI. The presence of intrahepatic porto-systemic 
shunting, sometimes associated with large liver tumours, may affect the HPI, causing false- 
negative values (Leen, 1999). A further limitation is the interpretation of results and the 
fact that the hepatic arterial flow and portal venous flow caimot be assessed individually.
Advances in Doppler ultrasonography have provided a more direct method for the 
measurement of hepatic blood flow. The flow in a particular vessel can be calculated by 
measuring the flow velocity and multiplying this by the cross sectional area of the vessel. 
As an analogy to the HPI, the Doppler Perfusion Index was calculated as the ratio of 
hepatic arterial to the sum of hepatic arterial and portal venous blood flows (DPI: HAF/ 
HAF + PVF; Leen et al., 1991a). Initial studies showed an increased DPI in patients with 
overt colorectal liver métastasés, compared with normal control subjects. Liver blood flow 
was measured in 30 patients with colorectal cancer (19 with proven hepatic métastasés) and 
16 control subjects. It was found that both the hepatic arterial blood flow and portal venous 
blood flow differed significantly between the metastatic patients and conti*ol group.
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However, better discrimination was provided by the Doppler Flow Ratio (DFR: HAF/PVF) 
and the DPI. It was suggested that the DFR and the DPI may have the potential to detect 
occult métastasés below the limits of conventional imaging techniques (Leen et ah, 1991a).
Further studies indicated the potential for the DPI teclmique in the detection of 
occult liver métastasés. A study to compare DPI with intraoperative ultrasound for the 
detection of liver métastasés was performed in 90 patients undergoing an apparently 
curative operation for colorectal cancer. After one year of follow-up, 23 patients developed 
liver métastasés, all of which had abnormal pre-operative DPI values. Intraoperative 
ultrasound was abnonnal in only six cases and after one year of follow-up, four of these 
patients had developed liver métastasés. Furthermore, all patients with a normal DPI value 
remained disease free after one year (Leen et al., 1994).
More recently, five-year outcome in 120 patients who undeiwent potentially 
curative surgery for colorectal cancer was reported (Leen et al., 2000). Liver métastasés 
occurred in 56 (47%) of patients, 50 (42%) died of recurrent disease and a further six 
patients died with clinical evidence of recurrence but without pathological confirmation. 
Of the patients with abnormal DPI, 73% developed recurrent disease, hi addition, 89% of 
patients with a normal DPI remained disease free. Furthermore, all patients who had local 
recuiTence alone had an elevated DPI. The suggested explanation for this obseiwation was 
that most patients with apparently isolated local recunence also have occult liver 
métastasés (Gilbert et al., 1984; Leen et al., 2000). It was concluded that the DPI teclmique 
can accurately predict recurrence after a potentially curative resection for colorectal cancer 
and therefore has a potential role in the selection of patients who may benefit from adjuvant 
chemotherapy (Leen et ah, 2000).
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A further study was performed to examine the role of the primary tumour in 
inducing abnormal liver blood flow. Blood flow was measured in 14 patients before and 
after resection of a colorectal primary tumour. Five patients had nonnal DPI values before 
surgery and there was no change in DPI or blood flow in this group after surgery. Nine of 
the patients had an abnonnally elevated pre-operative DPI; there were only minimal 
changes in DPI following resection of the primary tumour, predominantly due to a decrease 
in mean hepatic arterial blood flow. It was concluded that the primary tumour plays a 
relatively minor role in influencing changes in liver blood flow. It was further suggested 
that these changes may be more closely linked to the presence of occult métastasés and the 
associated host response (Oppo et al., 2000). There is however no data available on 
patients with overt liver métastasés undergoing liver blood flow measurements before and 
after resection of a primary tumour.
As with the HPI technique the DPI teclmique is subject to eiTors. Potential sources 
of eiTor involved in the DPI technique include non-unifonn insonation of the vessel, 
spectral broadening, angle correction, area estimation and errors in the post processing 
facilities of the ultrasound system. These eiTors can be minimized by standardising the 
teclmique used for each measurement and the addition of colour" Doppler provides gieater 
identification of vessel anatomy.
Patient variables that may alter liver blood flow measurements include variations in 
hepatic arterial anatomy, which occurs in approximately 30% of patients. A dual hepatic 
arterial supply may result in an underestimation of the true arterial supply to the liver. 
Despite this, only a small proportion of these variations are likely to affect the 
determination of whether the DPI is tmly abnormal or normal. Cirrhosis of the liver may 
result in elevated DPI values due to the increased hepatic arterial flow and decreased portal
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venous flo^v. To distinguish this from metastasis, clinical reports and radiological 
investigations should be examined. It is also suggested that the portal vein congestive 
index should be measured, as cirrhosis is associated with increased intrahepatic portal 
resistance. In order to minimize these sources of en'or, it is recommended that as with the 
HPI, each centre should establish their own normal range of DPI values (Leen et ah, 1993b; 
Leen, 1999).
There have been conflicting reports on the accuracy and clinical usefulness of the 
DPI technique. A comparative study of screening for asymptomatic colorectal liver 
métastasés was performed in cuiative resection patients. It was found that CT and MRI 
were the most sensitive techniques and that DPI and HPI teclmiques had low diagnostic 
accuracies (CT, sensitivity 0.67, specificity 0.91; DPI, sensitivity 0.58, specificity 0.57; 
HPI, sensitivity 0.50, specificity 0.55; Glover et al., 2002).
Furthermore, Roumen and co-workers (2005) presented disappointing results in a 
study of DPI measurements in 133 patients. Numerous problems were encountered during 
data measurement such as air in the colon, troubling contrast from previous radiological 
investigations (barium enema), location of common hepatic artery, obesity, scar tissue and 
insufficient fasting. Subsequently, 29 patients were excluded as the DPI was um'eiiable. 
Of the remaining subjects, a trend for higher hepatic arterial blood flow was found in the 
primary liver métastasés gi'oup compared to the disease free cohort. However it was not 
possible to demonstrate any clear separation of DPI or hepatic arterial blood flow values 
between the tliree study groups (disease free n=57, metaclii'onous métastasés n=ll, 
synchronous métastasés n=19).
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Despite the potential sources of eiTor and conflicting reports, the clinical results 
suggest that the DPI technique is a useful method of studying the blood flow changes 
associated with liver métastasés.
The DPI is a function of blood flow in two vessels, the hepatic artery and the portal 
vein, in which the blood flow changes are in opposite directions. It is unclear whether the 
DPI combines the effect of these changes in an optimal manner.
The technique of using Doppler ultrasound to investigate alterations in hepatic 
haemodynamics has several advantages over hepatic scintigraphy. Doppler ultrasound 
provides a direct measurement of flow in the vessels supplying the liver for example, hi 
comparison, scintigraphy provides perfusion data within a region of interest which is 
arguably a more speculative method of assessing liver blood flow. Patient safety, cost and 
accessibility also have major implications when selecting a research method. Ultrasound 
teclinology has become more readily available over the last 10 years as a widespread 
method of screening tluoughout medical and surgical disciplines, however with the 
exception of a few centres, scintigraphy is not as readily accessible as a low risk efficient 
research tool.
As there were serious challenges to the operator dependency of the DPI method, it 
was crucial to tliis project that all measurements be carried out to test the technique as a 
viable and novel source of haemodynamic information.
Animal Studies
In order to clarify the observed alterations in hepatic haemodynamics in humans 
using the HPI teclmique, a dynamic hepatic scintigraphy teclmique was developed in tlie rat 
by Nott and co-workers (1987). Micrometastases were induced in Fisher rats using an
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intraportal inoculation of Walker 256 carcinosarcoma cells. An additional control group 
comprised of rats wliich received noimal saline. A significant decrease in portal venous 
flo-vv occurred in the inoculated rats at 4 and 6 days when compared to controls (Nott et al., 
1987).
Following on from this initial report a second study was described in animals by 
Nott and co-workers (1989), As before, micrometastases were induced using Walker 256 
carcinosarcoma cells which were inoculated into the portal vein of anaesthetized male 
Fisher rats. A control group of rats were similarly inoculated with Walker cells killed by 
temperature reduction. The rats were then studied at 2, 4 and 6 days after an injection of 
either viable or dead Walker cells. In addition to the radionuclide studies (HPI teclmique), 
microsphere teclmique (for quantification of absolute changes in both hepatic arterial and 
portal venous inflow), electi*oniagnetic flowmetry (to determine relative changes in hepatic 
arterial and portal venous flow), portal pressure studies and measurement of intrahepatic 
shunting, were all carried out in order to investigate the alterations in hepatic 
haemodynamics.
It was found that rats bearing live tumour cells demonstrated increased HPI values 4 
and 6 days after inoculation. As previously reported in the animal model, it was found that 
the increased HPI values were the result of decreased portal venous flow and not increased 
hepatic arterial flow, as previously assumed by Leveson and co-workers (1985). As the 
liver tumour developed, the portal flow decreased, portal pressure increased and in turn, 
splanchnic vascular resistance and portal venous resistance were also significantly elevated. 
It was suggested that the decrease in portal venous flow was due to arteriovenous shunting 
or a mechanical effect resulting from compression of the portal triad by the tumour.
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Furthermore an increased passage of microaggregated albumin through the liver 
occurred at 4 and 6 days after inoculation of live tumour cells, suggesting that increased 
portal resistance may be due to the development of new arteriovenous shunts within or 
surrounding the tumours rather than at pre-existing presinusoidal arterioportal 
coimnunications (Ackennan, 1974; Nott et al., 1989).
Subsequently, similar studies were carried out in animal models in order to provide 
a better understanding of altered hepatic haemodynamics. It was described that in humans, 
colorectal liver métastasés rarely exhibit significant arterio systemic shunting and are 
relatively hypovascular (Taylor et al., 1978; Goldberg et al., 1987). Therefore, Hemingway 
and co-workers (1991) utilised the hypovascular FISN sarcoma cells as a more realistic 
model of human liver métastasés than the previously described hypeiwascular Walker 256 
tumour. It was confinned that the HPI increased when the tumours were at a microscopic 
stage of development and that this was due to a reduction in portal venous blood flow rather 
than an increase in hepatic arterial flow. However in contrast to the findings in the Walker 
256 model, there was no evidence of a significant increase in portal venous pressure, 
intrahepatic portal vascular resistance or arteriovenous shunting. The authors concluded 
that, in this model, the reduction in portal venous blood flow was unlikely to be due to 
mechanical compression of branches of the portal vein. As there was a substantial increase 
in vascular resistance in the organs draining into the portal vein, the authors suggested that 
circulating vasoactive agents that elicit splanclmic vasoconstriction may contribute to the 
blood flow changes.
This suggestion received further support from a study by Carter and colleagues 
(1994) who cross-perfused normal rat bowel segments with arterial blood alternately from 
rats with intrahepatic HSN tumours and fiom control animals. There was a significant
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increase in vascular resistance when the bowel was perfused by blood from tumour-bearing 
animals, consistent with the hypothesis that circulating vasoconstrictors active in the bowel 
are increased in the presence of hepatic tumours (Carter et al., 1994).
The link between the haemodynamic alterations obseiwed using colour Doppler 
ultrasound and the pathophysiology of liver métastasés was also investigated in animal 
models. Yarmenitis and co-workers (2000) implanted Walker 256 carcinosarcoma cells 
subcutaneously into 30 male Wistar rats. A flirther 10 rats comprised the control group. 
The animals were assigned into groups of 10 and liver blood flow measurements were 
performed at 0, 4, 7 and 15 days after tumour inoculation. Liver histology followed each 
Doppler measurement.
Both the hepatic arterial flow volume and the DPI were increased in the last tliree 
gi'oups ( 4 - 1 5  days) compared with the first group (0 days: controls). There was a less 
prominent decrease in the portal vein flow volume in the 4 - 1 5  days. Resistive index of 
the hepatic artery peaked at day 15 and portal venous resistive index was overlapping in all 
gi'oups. Wlien histological examination of the livers was performed there was a uniform 
pattern of neoplastic infiltration, and malignant cells were detected in the livers of all rats as 
early as day 4.
The results of the study indicate that significant haemodynamic changes can occur 
without the presence of fully developed and well-vascularised metastatic infiltrates. 
Furthennore it is suggested that changes can be triggered by isolated neoplastic cells in the 
liver comiective tissue, even before the hepatocytes are involved. It is of great interest 
therefore that alterations in the hepatic arterial flow and DPI occuiTed as early as day 4 and 
remained constant until the study ended at day 15.
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In conclusion it is clear that the animal model can provide a useful tool to elucidate 
the altered hepatic haemodynamics in colorectal cancer. It has been shown that both HPI 
and DPI were increased in rats bearing liver métastasés however the mechanisms behind 
these alterations were contradictory. There was a significant decrease in portal venous flow 
with HPI (Nott et ah, 1987; Nott et ah, 1989; Hemingway et ah, 1991) and a primary 
increase in hepatic arterial flow with a less prominent decrease in portal venous flow with 
DPI (Yarmenitis et ah, 2000). It is possible that the alterations in hepatic flow that occur
in the rat differ from those that occur in the human liver. The type of carcinoma cell line I
(Walker 256 or HSN Sarcoma) can lead to a hyper- or hypo-vascular tumour respectively, 
which can have significant implications on the study design and any conclusions and. 
comparisons drawn to human colorectal cancer.
It is clear that there is a large amount of interesting data presented from centres 
aiming to define a novel prognostic method for the detection of occult liver métastasés. 
However there are still gaps in the cunent knowledge, including (i) the clinical accuracy 
and usefulness of the Doppler Perfusion Index teclmique (Glover et ah, 2002; Roumen et 
ah, 2005); (ii) a clear definition of the alterations in hepatic arterial and portal venous blood 
flow occurring in patients with colorectal liver métastasés (Nott et ah, 1987; Leen et ah, 
1991a; Kruger et ah, 2000; Yarmenitis et ah, 2000); and (hi) the effect of a primary 
colorectal tumour on liver métastasés driven blood flow changes.
1.7.4 Functional Computed Tomography
Functional computed tomography (CT) scans have also been used for the 
measurement of changes in liver haemodynamics and the possible detection of occult liver 
métastasés. Using perfusion measurements of single-slice dynamic CT scans. Miles and
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co-workers (1993) described a teclmique similar to the HPI method but one which provides 
a gi'eater spatial resolution and is applicable to the left lobe of the liver.
In a small study of controls, patients with liver métastasés, patients with cirrhosis 
and patients with miscellaneous disease, dynamic CT was performed at a single level on the 
liver while a bolus injection of contrast media was administered intravenously. Data 
acquisition was performed at several time points until 44 seconds after injection. By 
placing a region of interest over the aorta, spleen and right and left lobes of the liver, 
enhancement data was used to produce time-density cuiwes for each region of interest. 
Hepatic arterial perfusion was then calculated by dividing the maximum rate of 
enliancement of the liver before the splenic peak by the peak aortic enhancement. 
Similarly, portal perfusion was measured by taldng the maximum slope after the splenic 
peak enhancement and dividing by the aortic enliancement. The HPI was then calculated 
by a method analogous to that used in dynamic colloid scintigraphy, namely the ratio of 
arterial perfusion to total liver perfusion.
Initial results indicated that CT-deteimined HPI was significantly correlated with 
colloid scintigi'aphy HPI. Additionally, the CT determined arterial perfusion ratio was 
elevated in patients with cirrhosis and those with métastasés; furthermore the portal 
perftision index was lower in the cirrhotic group. Several possible clinical applications of 
CT perfusion measurements were suggested, namely identification of cirrhosis, screening 
for liver métastasés, vascular assessment in ti'ansplant patients and assessment of treatment 
for cirrhosis. In addition, it was suggested that with some modification, the technique 
might provide a means to evaluate tumour perfusion characteristics in patients undergoing 
radiation therapy or chemotherapy (Miles et al., 1993).
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Subsequently, Platt and colleagues (1997) investigated the use of dual-phase helical 
CT scanning to perfonn hepatic perfusion-related measurements in cancer patients. As the 
contrast material was delivered under a 50 second infusion rather than a bolus, it was not 
possible to calculate absolute perfusion values. The enhancement at selected time points 
during the arterial phase of scamiing, and their ratios to peak liver enhancement, were 
effectively used as a surrogate. All enliancement values and ratios were found to be 
significantly elevated in those patients who developed liver métastasés during an 18-month 
follow-up compared with those who did not, the overall prognostic accuracy being reported 
as 89% (Platt et al., 1997). However, a later study using a similar protocol in breast cancer 
patients failed to identify patients who subsequently developed métastasés (Sheafor et al, 
2000).
Some of the potential limitations of the functional CT technique include: patient 
weight, wliich may affect the degree of liver enhancement when a standard amount of 
contrast media is used; fatty infiltration and cirrhosis, which may affect baseline liver 
attenuation measurements; and altered liver blood flow associated with cirrhosis, which 
may simulate metastatic disease (Platt et al, 1997).
Furthermore, the radiation burden of constant single slice scanning and moreover 
during triple-phase scanning, cannot be readily justified on a large population cohort as an 
experimental method. There are also inconsistencies in chemotherapy intervals reported 
between different studies. Chemotherapy can certainly influence hepatic haemodynamics 
and potentially reduce the effects of occult disease on measured attenuation and 
enliancement values. This may explain the differences in study results (Sheafor et al, 
2000).
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1.7.5 Percentage Hepatic Replacement (PHR)
The extent of metastatic disease within the liver is instmmental in the assessment 
and prognosis of patients with colorectal cancer. The extent, number and position of liver 
métastasés were previously described in terms of solitary, multiple in one lobe or multiple 
in both lobes. However, Mansfield and co-workers (1969) suggested that it might be more 
useful to express the degree of invasion as the ratio of tumour volume to total liver volume. 
The ‘percentage hepatic replacement’ (PHR) provides a potentially more sensitive measure 
of tumour burden and may be used for assessment and staging of patients (Jaffe et al., 1968; 
Wood et al., 1976; Finan et al., 1985).
The measurement of PHR has been performed using various methods such as 
isotope scanning, angiography, ultrasound, computed tomography (CT) or laparotomy. It is 
generally accepted that intraoperative assessment of the liver can underestimate the true 
extent of tumour replacement, as only the surface of the liver can be tmly evaluated, 
thereby missing lesions deep in the parenchyma. Of the other methods, it has been shown 
that CT is the most sensitive method for evaluating PHR (Ward et al., 1988; Hunt et al., 
1989a).
Using a computer-assisted method to evaluate CT images, Purkiss and Williams 
(1992) reported a positive correlation between suiwival and PHR in 23 patients with liver 
métastasés. It was then reported by Dworkin and co-workers (1995) that tumour volume 
and not PHR, was the most sensitive teclmique for assessing the extent of disease. The 
relationship between the liver parenchymal volume and the change in métastasés volume is 
not clear. It was suggested that parenchymal regeneration may occur during metastatic 
growth in order to sustain liver function, subsequently PHR may underestimate métastasés 
volume change.
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It was later reported by Purkiss (1996) that subjective inteipretation of CT scans to 
estimate PHR was inaccurate and should be abandoned for an objective computer assisted 
method which was more precise, specific and reproducible.
Percentage hepatic replacement has also been investigated with respect to liver 
blood flow. A study performed by Hunt and co-workers (1989b) used laparotomy, isotope 
scamiing, ultrasound and CT to measure PHR, and dynamic scintigraphy to assess liver 
blood flow in control subjects and 45 patients with liver métastasés. The amount of PHR 
was separated into tln*ee groups: <25%; 25-50%; and >50%. Neither the colloid clearance 
rate or the ‘liver to spleen’ ratio demonstrated any significant change with PHR. However, 
the total hepatic arterial blood flow was significantly raised in the patients with métastasés, 
in accordance with Leveson and co-workers (1985). More importantly, there was an 
increasing trend with hepatic arterial flow and PHR staging. It was concluded that both 
tumour gi'owth and prediction of response to therapy may be more closely related to 
haemodynamic factors than to physical size estimates. Despite this, there was poor 
separation between the PHR groups preventing the recoimnendation of dynamic 
scintigi'aphy for staging disease.
1.7.6 Mechanisms o f Haemodynamic Changes
Metastasis of cancer is a highly selective process consisting of a series of linlced 
steps favouring the survival of a subpopulation of metastatic cells pre-existing within the 
primary tumour mass. Growth of small micrometastases requires the development of a 
vascular supply and continuous evasion of host defence cells (Tidier, 1990; Takeda et al., 
2002). As gi'owth of métastasés occurs, the majority of their blood supply is derived from
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the hepatic arterial component of liver blood flow, which increases to meet the higher 
metabolic demand (Ridge et al., 1987),
Studies investigating the changes in hepatic perfusion index in the Fisher rat 
inoculated with Walker carcinosarcoma cells, reported a significant decrease in portal 
venous flow and no alteration in hepatic arterial flow, resulting in increased HPI values. It 
was reported that these changes were accompanied by increases in the portal and 
splanchnic vascular resistance and consequently an increased amount of arteriovenous 
shunting tliroughout the liver (Nott et al., 1987; Nott et al., 1989; Nott et al., 1991).
In contrast, studies were carried out using technetium-labelled micro spheres of f
serum albumin to measure baseline shunting during hepatic arterial perfusion scintigi'aphy 
in a small cohort of patients with colorectal liver métastasés. It was reported that the 
degree of shunting was low (less than 5% in all cases). Furthermore, there was no evidence 
to suggest that the use of angiotensin II significantly increases baseline shunting (Goldberg 
et ah, 1987; Goldberg et al., 1991b). The low level of shunting was also confinned in 
animal studies by Hemingway and co-workers (1991).
Dynamic scintigraphy was perfonned on male Hooded Lister rats inoculated with 
HSN sarcoma cells. It was shown that the HPI can change in the absence of 
arterio systemic shunting despite an increase in portal vascular resistance. There was no 
formation of a collateral circulation as portosystemic shunting was not increased. It was 
concluded that the decrease in portal venous flow, which was accompanied by a significant 
rise in splanclmic vascular resistance, was unlikely to be due to mechanical obstruction and 
more likely related to other factors such as the release of vasoactive agents wliich bring 
about splanclmic vasoconstriction (Hemingway et al., 1991).
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There have been numerous studies into the effects of the vasoconstrictor angiotensin
II on liver and tumour blood flow. In particular it has been shown that an infusion of
angiotensin II significantly increases tumour:liver blood flow (Hemingway et al., 1992;
Leen et al., 1993c; Dworkin et al., 1996). This vasoactive manipulation has been proposed
in the past as a targeted method of improving tumour blood flow and drag uptake for
hepatic tumours. Carter and co-workers (1992) used a methylene diphosphonate marker,
degradable starch microspheres and angiotensin II to test the potential for drug delivery to
liver tumour site in animal models. By introducing via the hepatic artery, it was found that 
,degradable starch micro spheres alone and degradable starch micro spheres with angiotensin 
II significantly increased the retention in liver and tumour displaying a 12 fold 
improvement over eontrols. It has also been confirmed that continuous infusion of 
angiotensin II increases flow to liver tumour site (Burke et al., 2001) and that this waiaants 
further investigation to enhance tumour targeting in patients with um*esectable liver 
métastasés. Furthermore it has been shown that noradrenaline may also improve the blood 
flow to tumour sites and hence offer an effective method for improving drag delivery to 
liver métastasés (Shanlcar et al., 1999).
i
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1.8 Splanchnic Flow
The gastrointestinal tract and associated organs require an adequate supply of 
oxygen and nutrients to meet their metabolic needs. The blood vessels which supply the 
digestive organs located in the abdomen (and the spleen) comprise the splanchnic 
circulation. Over 25% of the output from the left ventricle of the heart can flow through the 
splanclmic circulation. A major function of the splanchnic circulation is to provide fuel to
:enable the processes of secretion, motility, digestion, absorption and excretion to take
place. It also functions as a storage site for a large volume of blood which can be mobilised
when the need arises (Smith & Morton, 2001).
The coeliac artery contributes approximately 20% of the blood supply to the liver,
providing it with oxygenated arterial blood. The rest of the output of the coeliac artery
provides oxygenated blood to the stomach and spleen. The superior mesenteric artery
supplies the pancreas and small intestines and provides part of the oxygenated blood supply
to the large intestine. The inferior mesenteric artery also supplies the large intestine with
oxygenated blood. The venous blood arising from the abdominal organs contains the
absorbed nutrients intestines. Tins constitutes the portal blood wliich transports the
nutrients in the portal vein to the liver (Smith & Morton, 2001).
It has been shown that a reciprocal relationship exists between hepatic arterial and
portal venous flow (Leen et al., 1991). Quantitative flowmetry has described a substantial
reduction in portal venous flow in response to an increased hepatic artery flow in patients
.with an elevated perftision index. This has also been demonstrated in animal models where
:■an increase in Hepatic Perfusion Index (HPI) was due entirely to reduced portal venous
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inflow secondary to increased splanchnic vascular resistance (Nott et al., 1989; Hemingway 
et al., 1991; Hemingway et al., 1993; Carter et al., 1994).
There are numerous factors which are known to alter hepatic haemodynamics by 
affecting the splanchnic or intra-hepatic circulation.
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L8.1 Serotonin
...
Serotonin (5-hydroxytryptamine, or 5-HT) is known to have several biological 
functions. Derived from the amino acid tryptophan, it acts as a neurotransmitter in the 
central and sympathetic neiwous systems and as an activator of blood platelets. There are 
numerous reports that serotonin production is increased in colorectal cancer in both human 
and animal models (Quinn et al., 1979; Tutton & Barkla, 1982; Nitta et al., 2001; Seretis et 
al., 2001). Nitta and co-workers (2001) demonstrated that serotonin content of the small 
intestine of colon-26 tumour-bearing mice increased significantly 2 weeks post inoculation 
of tumour cells. This increase was associated with an increase in tryptophan hydroxylase 
activity and the number of enterochromaffm cells compared to control mice.
It has also been shown that Irigh serotonin levels may be an indicator of 
neuroendocrine differentiation in colorectal adenocarcinomas (Seretis et al., 2001). 
Furthermore it has been reported that selective serotonin reuptake inliibitors (SSRI) can 
reduce the growth of colorectal tumours, possibly occurring tlnough an antipromoter effect 
or direct cytotoxic effect (Xu et al., 2006).
It is also known that the plasma concentration of serotonin is particularly high in 
patients with liver cirrhosis and portal hypertension. It has therefore been suggested that 
serotonin may increase splanchnic blood flow and hence portal pressure. This may also be
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linked to the development of liver cirrhosis and portal hypertension (Lebrec, 1990; Hoyer et 
ah, 1994; Li et ah, 2006).
1.8.2 Somatostatin
Studies have shown that somatostatin, a peptide hormone, may inhibit the release of 
some hormones in vivo resulting in a reduction in the portal venous pressure. Furthermore,
Zhu and co-workers (2000), reported that this decrease in portal venous blood pressure was 
reduced specifically as a result of decreased blood velocity and blood flow.
Animal studies with somatostatin have also shown a decreased portal venous in­
flow and consequently a decrease in portal venous pressure. It has been suggested that tins 
may be attributed to a reduction in the release of glucagon, a vasodilatory gastrointestinal a
hoimone (Hori et ah, 1993).
1.8.3 Nitric Oxide
Nitric oxide is known to be a potent vasodilator and inliibitor of platelet function. 
Since initial investigations into the pharmacological role of nitric oxide in the late 1970s, it 
has been shown that nitric oxide is involved with almost every aspect of human physiology 
for example blood pressure, memory and cellular apoptosis (Wallis, 2005).
Nitric oxide is produced in the liver by sinusoidal endothelial cells, Kupffer cells, 
hepatic stellate cells and hepatocytes. It has recently been shown that nitric oxide can 
modulate the intrahepatic vascular tone in nonnal rats (Kawada et ah, 1993; Gasull et ah, 
2001; Moal et al., 2006). Furthennore, it has been shown that portal hypertension in 
cirrhosis is partly due to a decreased liver nitric oxide production from the liver sinusoidal 
endothelial cells. This results in an increased vascular tone with a further increase in
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hepatic resistance and portal pressure. In contrast to liver nitric oxide level, systemic nitric 
oxide production is increased in cinhosis, resulting in splanchnic vasodilatation and 
subsequent increased portal inflow, which contributes to portal hypertension (Gupta et al.,
î
1998; Rockey et al., 1998; Gonzalez-Abraldes et al., 2002; Moal et al., 2006). ?
1.8.4 Tumour Necrosis Factor
Studies in animal models have reported that an increased production of tumour f
necrosis factor-alpha (TNFa), a pro-inflammatory cytoldne, may exert an indirect role in 
the vasodilatation associated with portal hypertension by inducing the production of nitric 
oxide (Lopez-Talavera et ah, 1995; Wang et ah, 2004).
1.8.5 Endothelin-1
There is gi'owing evidence that endothelin-1, a potent vasoconstiictive mediator, has 
a detrimental effect on portal venous and arterial blood flow resulting in an overall increase |
in portal venous pressure. It has been shown that endothelin-1 causes a reduction in 
sinusoid diameter and sinusoidal flow as well as increasing total portal resistance in the 
nonnal rat liver (Mylu'e et ah, 1993; Hongzhi et ah, 2005; Kuro et ah, 2006). Endothelin-1 
is also produced by colorectal tumours and there is increasing interest into the potential 
prognostic value of pre-operative serum endothelin-1 levels (Arun et ah, 2004; Elahi &
Everson, 2004).
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1.8.6 Prostaglandin
High concentrations of prostaglandin (an endogenous vasodilator) in human and
animal tumour tissues were first documented over 20 years ago. It has since been
suggested that an increased biosynthesis of endothelial substances such as nitric oxide and
prostacyclin may play a major role in the hyperhaemodynamics of portal hypertension
(Fernandez et al., 1996; Laleman et al,, 2005). Cyclooxygenase (COX) is a key enzyme
involved in the conversion of arachidonic acid to prostaglandins. Two isoenzymes exist in
the mammalian body : COX-1 which is expressed constitutively in many cell types and
COX-2 wliich is expressed only in response to certain stimuli such as trauma, growth
factors, tumour promoters and cytokines (Smith, 1996; Taketo, 1998a).
Studies with portal hypertensive rats have shown enhanced release of nitric oxide
after long-term prostacyclin inliibition. This suggests a linlc between both vasodilatory 
. . .substances, nitric oxide and prostacyclin causing increased splanchnic hyperaemia in portal 
hypertension (Fernandez et al., 1996).
1.8.7 Oestrogen
It is known that seram oestrogen levels are increased in patients with liver ciiThosis 
(Maruyama et al., 1991; Sakamoto et al., 2005). Oestrogens and progestogens also increase 
the gene expression of prostacyclin and other important vessel dilating factors (Kuhl, 1996; 
Mendelsohn & Karas, 1999). hiterestingly, Sakamoto and co-workers (2005) reported that 
treatment of ciniiotic rats with exogenous oesti'ogen resulted in an increase in hepatic blood 
flow and a decrease in portal venous pressine. The administration of exogenous oestrogen 
may increase tire number of oestrogen receptors and promote the production of nitric oxide 
by the sinusoidal endothelial cells (Sakamoto et ah, 2005).
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1.9 Factors Affecting Liver Blood Flow in Colorectal Cancer
There are a number of factors tliat have been consistently reported to alter liver 
blood flow in the healthy subject. These are the fasting/fed state and the systemic 
inflammatory response.
It is widely accepted that, in the nonnal subject, there is a physiological hyperaemic 
response which is thought to be part of the increased metabolic demand during the digestive 
process, hr an early study, Bums and co-workers (1969) described the effects of digestion 
oir intestinal blood. They reported that mesenteric blood flow, measured using 
electromagnetic flow probes, began to increase within 5 minutes of feeding. This reached a 
plateau at about 30 minutes and was still above the fasting blood flow at 3 hours. 
Similarly, Moneta and co-workers (1988) using Duplex sonogmphy and following a 
stairdard meal in healthy volunteers, found that mesenteric flow was increased, maximally 
at 20-30 nrins following the meal, and this flow increase persisted for at least 90 mins 
after-wards. More receirtly Kelly (1997), usiirg Duplex ultrasomrd equipirreirt, reported that 
portal verrous blood flow was increased at 1 hour followirrg a test meal, but had returrred to 
normal at 4 hours. Lycklarrra a Nijeholt and co-workers (1997) using a magnetic resonance 
velocity mapping teclmique in volurrteers, also found that portal verrous flow was irrcreased 
by approximately two thirds following a test meal. More specifically, both portal venous 
flow arrd hepatic venous flow are increased with the onset of digestion (Kelly et al., 1997). 
Therefore, if the corrrporrents of liver blood flow are examined in a rrorr-fasting state then 
there may be an increase in portal verrous flow arrd this will reduce the Doppler perfusion 
irrdex.
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It has long been recognised that splanchnic blood flow is altered as part of the 
systemic response to injury (Aulick et al., 1981; Daim et al., 1987). hideed, there is 
considerable evidence to show that splanclmic hypermetabolism explains most of the 
hypermetabolic response to injury (Takala, 1997).
It is therefore of interest that as part of the systemic inflammatory response 
following surgical injury, portal venous blood flow has been reported to fall whereas 
hepatic arterial flow as been reported to increase (Souba & Wilmore, 1983). Also, that 
interleukin-6, an important mediator of the systemic inflammatory response, including the 
increase in acute phase proteins such as C-reactive protein (Gabay & Kuslmer, 1999) has 
been reported to stimulate splanclmic blood flow (Lyngso et al., 2002).
It has been shown that in patients undergoing potentially curative surgery for 
colorectal cancer, elevated C-reactive protein concentrations eitlier pre- or post-operatively 
are associated with increased recurrence and poorer suiwival independent of Dukes’ stage 
(McMillan et ah, 1995; Nozoe et ah, 1998; Nielsen et ah, 2000). It may therefore be that 
tlie systemic inflammatory response is important in determining the changes in Doppler 
Perflision Index reported in patients with colorectal liver métastasés.
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1,10 Treatment of Liver Métastasés
In spite of improved surgical teclmique and increased access to chemotherapy and 
ablative ti'eatments, long term survival and progress is disappointing. Critically, it is the 
presence of metastatic liver disease that presents a poor prognosis.
The most commonly used liver nomenclature is based on the original classification 
by Couinaud (1957) which divides the liver into eight functionally independent segments. 
Each segment has a branch of the portal vein, hepatic artery and bile duct with hepatic 
veins located in the periphery of each segment for outflow (Strasberg, 1997; Sasson & 
Sigurdson, 2002).
1.10.1 Surgical Treatment
Surgical resection of hepatic métastasés remains the only potentially curative 
intervention and current techniques are becoming more aggressive, especially in patient 
selection. Previous indications for the selection of resectable patients included those with a 
maximum of four lesions in one lobe; the presence of four or more métastasés being 
associated with a poor prognostic factor (Fong et ah, 1999; Iwatsuki et al., 1999). However 
other criteria such as the patient’s condition, liver function, the extent of the disease 
(including extrahepatic disease), suspected primary liver tumour, possible exposure to 
hepatitis and alcohol use all play a major role in selection for surgery (Fan & Chang, 2002; 
Peima & Nordlinger, 2002).
In patients with suspected primary liver tumour, thorough laboratory tests and 
hepatitis panel should be obtained. Also in patients with any degree of ciiThosis,
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hemihepatectomy will not be tolerated, a maximum resection of one or two segments is 
generally accepted (Fan & Chang, 2002).
In the majority of patients with liver métastasés, it is generally agreed that liver 
function will be maintained after an upper limit resection of 75% of the volume of the liver, 
or six of the eight anatomical segments. Liver function at this level is only maintained if 
the remaining liver parenchyma is normal, especially in patients who have undergone 
chemotherapy, which may alter liver parenchyma (Penna & Nordlinger, 2002).
Surgical resection of liver métastasés can be divided into two gi'Oups: (a) anatomical 
resections of one or several segments; and (b) atypical or wedge resection removing a 
portion of liver parenchyma suiTounding a tumour (Starzl et al., 1975; Starzl et al., 1982;
Bismuth et al., 1982; Makuuchi et al., 1987).
There have been many large studies investigating the outcome after resection of 
colorectal liver métastasés. Mortality and morbidity rates are summarized in Table 1.3,
A s ig n i f i c a n t  p r o p o r t io n  (60-70%) of p a t ie n t s  will h a v e  r e c u iT e n c e  o f  l iv e r
métastasés following liver resection (Scheele et al., 1991; Fong et al., 1999). Although
:::
only a small proportion of these patients will be suitable for repeat hepatic resection, rates 
of death and complications are comparable to those of initial hepatic resections (Petrowsky 
et al., 2002).
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Table 1.3 Mortality and morbidity following liver resection for colorectal liver 
métastasés (Sasson & Sigurdson, 2002).
Study
Mortality
(30-day)
Morbidity Hepatobiliary
Complications^
Infectious
Complications
Scheele et al. 4% 16% 8% 3%
Iwatsuki et al. 1%** 8% - -
Nordlinger et al. 2% 23% - -
Cady et al. 4% - 3% 6%
Fong et al. 3% 24% 4% 6%
Doci et al. 2% 18% 6% 8%
V;
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^Hepatobiliary complications include liver failine, biliary fistulas and bile duct injuries. 
60-day mortality.
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The majority of patients with colorectal liver métastasés will have uimesectable 
disease. Tliis may be due to tumour burden, involvement of major vascular stractures or 
extrahepatic disease. Treatment options for such patients is usually limited to 
chemotherapy and more recently, to ablative techniques such as radiofrequency ablation 
(Solbiati et ah, 1997; Sasson & Sigurdson, 2002).
Some studies have indicated that liver resection or hepatectomy is associated with 
the post-operative growth of residual tumour, however the mechanisms by which this occur 
are not clearly defined. It has been suggested that surgical resection may remove the source 
of a variety of growth inliibitors resulting in angiogenesis and the subsequent growth of 
previously donnant métastasés. Alternatively residual tumour cells may exhibit receptors 
for cytokines that are released in response to surgery (O’Reilly et ah, 1994; Folkman J 
1995; Whitworth et al., 2006). It has been previously demonstrated that Hepatocyte 
Growth Factor (HGF) and interleukin-6 are likely to be early markers of postoperative liver 
failure following hepatectomy (Chijiiwa et al., 2002).
A recent study performed by Whitworth and co-workers (2006) demonstrated an 
increase in the peritoneal fluid concentration of HGF after cancer and non-cancer 
laparotomy, suggesting that it is the surgery, rather than the malignancy that is associated 
with the increased concentrations of the cytokine concentration. Receptors for this 
cytokine have been detected in a number of tumours but particularly in colorectal 
carcinoma, suggesting that an increase in concentration of this magnitude might stimulate 
the gi'owth of residual tumour cells (Wliitworth et al., 2006).
Furthermore, it has been shown that the over-expressions of HGF and c-met 
indicate an adverse prognosis for patients with Hepatocellular Carcinoma. It has been 
proposed that a sustained high level of serum hepatocyte growth factor after hepatectomy
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may be a factor related to early tumour recuneiice and metastasis. Liver regeneration may 
be a main factor leading to a high level of serum HGF in the early postoperative stage (Wu 
et ah, 2006).
There is evidence that the effect of anaesthesia and surgery can inhibit the immune 
system to a degree tliat residual tumour can grow and progress more rapidly. Doenicke and 
Kropp (1976) showed that halothane-nitrous oxide can depress the phagocytic activity of 
the reticulo-endothelial system. In addition it has been shown that halothane and isoflurane 
can inliibit the function of the nitiic oxide signalling pathway in blood vessels and the brain 
(Zuo & Johns, 1997). Surgical stress can also rapidly inliibit neutrophil phagocytic activity 
and have a detrimental effect on the immune system from the early period of surgery 
(Kawasaki et al., 2007). This may in turn have implications on the body’s ability to cope 
with infection and metastatic seeding and growth in colorectal cancer.
:
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1.10.2 Chemotherapy
For patients with advanced disease, it is clear that systemic chemotherapy with 
fluorouracil still remains the therapeutic mainstay 40 years after it was first introduced. 
This treatment has greater survival and quality of life benefits than the best supportive care, 
however long-teim suiwival after treatment by intravenous chemotherapy alone is rare 
(Nicum et al., 2000; Ruo et al., 2001).
Results of a large randomised trial investigating tliree regimens in metastatic 
colorectal cancer have recently been published. The study compared overall survival 
between the de Gramont regimen (fluorouracil bolus and infusion with folinic acid given 
over two consecutive days every two weeks; de Gramont et al., 1988), the Lokich regimen 
(protracted fluorouracil infusion; Lokich et al., 1989) and raltitrexed (Jackman et al, 1991).
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An average survival of 10 months and a 2-year suiwival of approximately 15% v^ as reported 
for all three groups; however, progression free survival and quality of life were superior in 1
the de Gramont and Loldch groups. Overall, the study confirmed the benefits of the de 
Gramont regimen with low toxicity despite the high financial costs (Maughan et al., 2002).
...1X
4Hepatic Aiderv Infusion
The rationale for chemotherapy delivery via the hepatic artery is based on both 
anatomical and pharmacological factors. It is known that established liver métastasés 
derive the large majority of blood flow via the arterial component and in addition, the liver 
extracts a high proportion of certain drugs during their first pass through the arterial system. T
Therefore, when administered via the hepatic artery, the regional exposure to chemotherapy 
drugs is increased and systemic toxicity is limited (Ruo et al., 2001).
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1.10.3 Ablative Treatment
Ablative therapies for both liver métastasés and primary liver tumours are becoming 
a popular treatment option in the case of unresectable lesions. Methods of physical ablation 
include; percutaneous ethanol injection, focused ultrasound, hyperthermia, direct cuiTent 
fulguration, laser photocoagulation, cryoablation and radiohequency ablation (Dick et al.,
2002).
Percutaneous ethanol injection has shown effective response in patients with small 
Hepato Cellular Carcinomas (HCC) but there have been no studies to date showing any 
positive impact on colorectal liver métastasés (Amin et ah, 1993).
Treatment of liver métastasés using cryoablation involves freezing the tumour area 
with the aid of circulating liquid nitrogen through a probe placed within the tumour. Cell
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death and microvascular tlii'ombosis occurs due to the freeze-thaw process of the tumour 
tissue and tumour destruction is complete (Ruers & Bleiclu'odt, 2002). Survival rates for 
one and two years after cryoablation have been reported to be 76% and 61% respectively 
(Ruers et al., 2001).
The technique of radiofrequency ablation is based on the principle of converting 
radiofrequency waves into heat using a Ingh-frequency alternating current. In a study of 
117 patients by Solbiati and co-workers (2001 a,b) an overall 2-year survival rate of 69% 
was reported. One of the major advantages of radiofrequency ablation for treatment of 
liver métastasés is the relatively low morbidity in comparison to liver resection or other 
ablative therapies. The procedure can be performed as a minimally-invasive percutaneous 
or laparoscopic operation, reducing hann to noiinal liver. Patient selection is less restricted 
and can be offered to patients undergoing partial resection of liver métastasés for residual 
disease or un-resectable lesions (Solbiati et al., 1997; Pearson et al., 1999; Bilchik et al., 
2000; Solbiati et al., 2001a,b; Parikh et al., 2002; Ruers & Bleiclrrodt, 2002).
In conclusion, these observations indicate that major improvements in survival will 
most likely result from better detection of colorectal primary tumours and métastasés at an 
earlier stage in their growth and development. By exploiting the alterations in hepatic 
haemodynamics as a marker of metastatic spread to the liver, there may be significant 
improvements in colorectal cancer survival rates.
J
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1.11 The Role Of Cyclooxygenase in the Pathogenesis of Colorectal Cancer
It has been reported that the presence of an inflammatory response plays a major 
role in the progression of several solid organ tumours (Coussens & Werb, 2002). Studies 
have also shown that non-steroidal anti-inflammatory diugs (NSAIDs) that inhibit 
prostaglandin synthesis, may reduce the incidence of colorectal cancers (Taketo, 1998a). It 
is suggested that NSAIDs exert their chemopreventive actions by inhibition of cell growth 
and proliferation, and induction of apoptosis (Smith et al., 2000). The mechanisms by 
which these processes are achieved are still not fully understood. One commonly studied 
mechanism is via the COX-2 dependent pathways.
There is increasing evidence of a link between overexpression of COX-2 in 
colorectal cancer tumorigenesis and other solid organ tumours (Taketo, 1998a, b; Hwang 
et ah, 1998; Uefliji et al., 2000). The overexpression of COX-2 in colorectal cancer is also 
associated with a several-fold increase in concentration of prostaglandin Ez. One possible 
mechanism may be that colorectal cancer cell proliferation and gi'owth is promoted tlixough 
transactivation of epidermal growth factor receptor and its mitogenic signalling. However 
the mechanism by which prostaglandins promotes colorectal cancer cell invasiveness 
remains unknown (Pai et al, 2002; Pai et al., 2003; Huang et al., 2006).
There have been numerous retrospective and prospective studies into the use of non­
steroidal anti-inflaimnatory diugs and COX-2 inliibitors for the prevention of colorectal 
cancer. Huang and co-workers (2006) have suggested that a nonselective COX inhibitor 
and a COX-2 selective inliibitor trigger apoptosis in human colon cancer cells tlumigh at 
least two known pathways, extrinsic death receptor-transmembrane pathway and an 
intrinsic mitochondrial pathway. Members of the tumour necrosis factor (TNF) ligand and
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receptor superfainily are involved in the transmembrane pathway of apoptosis, such as 
TNFa, Fas ligand and TNF-related apoptosis-inducing ligand. These ligands when 
coupling to their respective receptors, trigger a number of intracellular events that lead to 
apoptotic cell death. Studies have shown that NSAIDs may induce apoptosis in human 
colorectal cancer cells by up-regulating genes of the TNF ligand and receptor pathway, 
wliich may be mediated by TNF receptors and TNF-related apoptosis-inducing ligand 
receptors (Huang et al., 2006).
Despite increasing evidence of the potential positive effects of COX-2 inhibitors 
and NSAIDs in the prevention of colorectal cancer, chemoprevention in average-risk 
individuals is still not favoured. Cardiovascular events and gastrointestinal risks along with 
cost-effectiveness of chemoprevention need to be considered carefiilly when comparing 
with other strategies, such as colorectal cancer screening alone (Rostom et al., 2007).
It has also been reported that pro-inflammatory cytokines such as interleukin-6 are 
released from colorectal tumours (Kinosliita et al., 1999; Mild et al., 2004). Furthermore 
there is increasing evidence of an association between raised circulating concentrations of 
C-reactive protein, tumour growth and poor outcome of patients with colorectal cancer 
(McMillan et al., 2001; McMillan et al., 2003; Erlinger et al., 2004).
The role of the systemic inflammatory response in altered hepatic haemodynamics 
in colorectal cancer has yet to be defined. There may be an association between altered 
metabolic rate in normal liver tissue induced by pro-inflammatory cytokines, or that 
alterations in liver blood flow are manipulated by inflanunatory mediators thi'ough other 
pathways.
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AIMS
The aims of this project were to:
1. Establish the effects of colorectal liver métastasés and primary or recurrent 
colorectal tumours on hepatic arterial and portal venous blood flow, and examine 
the potential for an optimised index to express the haemodynamic changes.
2. Examine the potential value of fanctional Computed Tomography for the 
assessment of liver blood flow alterations in patients with colorectal liver 
métastasés.
3. Evaluate the effect of tumour volume and the systemic inflammatory response on 
liver blood flow in patients with colorectal liver métastasés.
4. Investigate the effect of anti-inflanunatory treatment on the components of liver 
blood flow in patients with colorectal liver métastasés.
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Chapter 2 : The effect of liver métastasés on liver 
blood flow measured by Doppler ultrasound in 
patients with colorectal cancer.
81
V®
■‘X
ri1
2.1 Introduction and Aims
Advances in Doppler ultrasound have provided the means to investigate altered 
liver blood flow and measure hepatic arterial and portal venous flow independently. The 
Doppler Perfusion Index (DPI) provides a measure of changes in both hepatic arterial and 
portal venous blood flow in a single index. This has been shown in a number of studies to 
be useful for the detection of occult métastasés and may play a role in the selection of 
patients for adjuvant chemotherapy (Leen et ah, 1991a; Leen et ah, 1993a; Leen et ah, 
2000). However, the DPI is a blood flow ratio, and does not make use of all the 
infoimation present in absolute blood flow measurements. It was defined in analogy with 
the earlier Hepatic Perfusion Index (HPI), which was based on scintigraphic measurements 
that yielded only relative rather than absolute measurements of blood flow. It is therefore 
unclear whether the DPI combines the arterial and portal blood flow measurements in the
-1:
optimum maimer from the point of view of detecting liver métastasés.
The first aim of the present study was to examine the relationship between 
ultrasound-measured hepatic arterial and portal venous liver blood flow in order to 
determine the most appropriate way of utilising these measurements to discriminate 
between patients with and without liver métastasés. The model derived from this analysis 
was then compared with the DPI to determine whether a significant improvement in 
discriminatory power could be obtained.
It has been shown that a colorectal primary tumour may inliibit growth of its own 
metastasis (Peeters et al., 2004; Peeters et al., 2006). The role of the primary tumour in 
inducing changes in liver blood flow has previously been investigated in a small cohort of 
patients undergoing potentially curative surgery for colorectal carcinoma (Oppo et al.,
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2000). However, the influence of the primary tumour has not previously been examined in 
patients with overt liver métastasés. A further aim of the present study was therefore to 
investigate whether the presence of the primary or recurrent colorectal tumour alters the 
relationship between hepatic arterial and portal venous blood flow in patients with liver 
métastasés.
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Null Hypotheses
There have been conflicting reports on the clinical accuracy of the Doppler 
Perfusion Index technique (Glover et al., 2002; Roumen et al., 2005). Therefore, the first 
part of the study was designed to test the null hypothesis that the Doppler Perfusion Index 
does not discriminate between patients with colorectal liver métastasés and normal subjects.
The second null hypothesis states that altered Doppler Perfusion Index in patients 
with liver métastasés, is due to a reduction in portal venous blood flow (Leen et al., 1991a; 
Di Giulio et al. 1997; Kopljar et al. 2004; Oktar et al, 2006).
Finally, it has been shown that the presence of a primary colorectal tumour may 
inhibit the growth of liver métastasés (Peeters et al, 2004; Peeters et al, 2006). Therefore 
the null hypothesis states that the presence of a colorectal primary tumour influences liver 
métastasés driven hepatic blood flow alterations.
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2.2 Patients and Methods
2.2J Patients
Patients with colorectal cancer attending the Glasgow Royal hifirmary between 
April 2000 and April 2003 were studied. Blood flow measurements were performed before 
surgery in patients presenting with colorectal cancer.
Inclusion criteria consisted of : Histologically proven colorectal cancer; Liver 
métastasés confirmed histologically, by progression on CT, Ultrasound or intraoperative 
investigation.
Exclusion criteria consisted of : Anticancer treatment during the study period or 
during the preceding montli; Patients currently receiving or who have had non-steroidal 
anti-inflammatory dmgs in the last two weeks; Patients receiving warfarin; Diagnosis of 
other liver disease or suspected cirrhosis.
The presence or absence of overt liver métastasés in these patients was determined 
on the basis of pre-operative CT and ultrasound scamiing and intmoperative findings. 
Measurements were also perfoimed in patients known to have liver métastasés who had 
previously been treated and were attending a follow up clinic. None of these patients had 
received chemotherapy within four months prior to the blood flow measurements. Clinical 
records were consulted to establish whether or not the primary tumour had been completely 
resected in these patients. Patients who had no evidence of residual tumour at the time of 
surgery or of local recuiTcnce at the time of scamiing were deemed to have isolated liver 
métastasés.
Normal healthy control subjects were recruited from patients who had negative 
investigations including abdominal CT scans; and from healthy members of staff in the
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Department of Surgery. Clinical details, Dukes’ stage and where relevant, details from 
ultrasound and CT scans were recorded.
The study was approved by the research ethics committee of North Glasgow 
University Hospitals NHS Trust. All subjects were infonned of the purpose and procedure 
of the study and were given a patient information sheet. Infonned consent was given by all 
subjects in the study, a small number of patients (n=5) declined to take part in the study.
2.2.2 Methods
Hepatic blood flow measurements were perfoimed using an HDI 5000 (Philips- 
ATL, Bothell, USA) ultrasound system with duplex-colour Doppler and a 3.5 MHz 
curvilinear scanhead. The angle between the Doppler beam and the vessel was steerable 
and an angle of 50° to 68° was used for velocity measurements. Using software loaded on 
the ultrasound seamier it was possible to compute the time averaged mean velocity (the 
time-average of the weighted mean velocities).
All subjects were fasted for 12 hom's prior to examination. Each subject was 
scaimed in the supine position and all measurements were perfonned during respiratory 
suspension. A transverse scan was obtained at the epigastrium to locate the coimnon 
hepatic artery on its longitudinal axis. Hepatic arterial blood velocity was measured by 
placing the Doppler cursor over the lumen of the coimnon hepatic artery, close to the origin 
at the coeliac axis at the point where the artery becomes horizontally straight. The time 
average mean velocity was calculated automatically by placing callipers over a minimum of 
four cardiac cycles. A minimum of tlnee measurements of the hepatic aitery cross- 
sectional area were then taken at the same point at right angles to the vessel and the mean 
was calculated off-line.
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Portal venous flow was measured using a right intercostal approach. The time 
average mean blood velocity was measured as above, in the intra-hepatic section of the 
portal vein before it branches into the right and left portal trunks. Cross sectional area 
measurements of the vessel were taken using a right subcostal approach, with the patient in 
suspended inspiration.
Hepatic arterial and portal venous blood flow (HAT, PVF; ink min) were calculated 
from the product of time average mean velocity (cm/s) and average cross sectional area of 
the vessel (cm^) multiplied by sixty. Total liver blood flow (TLBF) was calculated as the 
sum of hepatic arterial and portal venous flow. The Doppler Perfusion Index (DPI) was 
then calculated as the ratio of hepatic arterial flow to total liver blood flow.
2.23 Intm-observer and Inter-observer Variation 
hitra-observer Variation
Repeat liver ultrasound scans were performed by myself as described in section
2.2.2 on 18 subjects with a minimum 10 minutes rest between each scan. Measurement 
values were saved directly to the ultrasound scanner to avoid imconscious bias dming scans 
and data was analysed at the end of the procedure.
Inter-observer V ariation
Ultrasound scans of 14 patients, chosen at random, were performed by Dr Paul Glen 
and myself. Two studies were excluded by one observer due to problems locating the 
common hepatic artery and hence DPI values were unobtainable, a third patient was 
excluded due to incomplete examination. Each subject was scanned using the same 
Ultrasound scanner and methods as previously described in section 2.2.2. As the scans
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were perfonned separately, each observer was blind to the placement of Doppler callipers 
and cross sectional area measurements.
2.2.4 Statistical Analysis
As the distribution of most measured variables was skewed, the summary statistics 
reported are the median and interquartile range. Differences between groups in raw data 
were tested for significance using the Mann-Whitney test. For comparison with published 
data, means and standard deviations of some variables were also calculated.
As there was a substantial imbalance in age between patient groups, the age- 
dependence of blood flow values was investigated to detennine whether it could bias 
comparisons of blood flow between groups. Spearman rank correlation analysis 
demonstrated a significant association between portal venous blood flow and age, therefore 
age-adjusted blood flow values were calculated to allow unbiased comparisons between 
groups. Exploratory analysis showed that logaritlnnically transformed portal venous blood 
flow had an approximately linear relationship with age, with homogeneous, normally 
distributed residuals, and a gi'adient that that was similar in patients with and without liver 
métastasés. Hence, age adjusted blood flow values were calculated using linear regression 
analysis of logarithmically transformed data, and the age-adjusted comparison of blood 
flow between patient groups was by analysis of covariance.
The relationship between hepatic arterial and portal venous blood flow within each 
patient gi'oup was also expressed in a simple parametric form using linear regression 
analysis after logarithmic transformation to normalise residuals. The relationship between 
hepatic arterial and portal venous blood flow and the presence of liver métastasés was also 
analysed using a logistic regression model, in order to derive a blood-flow-dependent index
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reflecting the odds of a patient having métastasés. The appropriateness of the logistic 
regression model was confinned using the Hosmer-Lemeshow goodness-of-fit test.
A p-value of 0.05 or less was defined as significant. All statistical analysis was 
performed using SPSS software (SPSS Inc., Chicago, USA).
2.3 Results
2.3.1 Intra-obsen^er and Inter-observer Variation
The coiTelation of duplicate Doppler Perfusion Index (DPI) measurements for a 
single observer are shown in Figure 2.1. The mean difference and standard deviation 
between the two replicate observations was -0.01 (0.13). The intraclass correlation 
coefficient was 0.63, Speamian rank coiTelation coefficient was 0.65 (p=0.004 that a 
significant correlation did not exist) and conventional (Pearson) correlation coefficient was 
0.62 (p=0.006), 95% Confidence Intervals were -0.07 and 0.05.
The mean difference (standard deviation) between the DPI values measured by both 
obseiwers was -0.01 (0.07). The Intraclass correlation coefficient was 0.71, Spearman rank 
correlation coefficient was 0.75 (p=0.008) and conventional (Pearson) correlation 
coefficient was 0.70 (p=0.016), 95% Confidence Inteiwals were -0.05 and 0.03. The inter- 
obseiwer variation is shown in Figure 2.2.
2.3.2 Blood Flow Measurements in Patients with Liver Métastasés and Control Subjects 
Sixty-nine patients with colorectal liver métastasés and 37 control subjects were
studied; their demographic characteristics and liver blood flow parameters are shown in 
Table 2.1.
The cancer patients were significantly older than the control subjects (p<0.001). 
There was a significant increase in hepatic arterial velocity (p<0.001), hepatic artery cross 
sectional area (p<0.001), hepatic arterial flow (p<0.001) and Doppler perfusion index 
(p<0 .0 0 1 ), and a significant reduction in portal vein cross sectional area (p=0.016) and 
portal venous blood flow (p=0 .0 0 2 ) in patients with liver métastasés compared to noiinal 
subjects.
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2.3.3 Effect o f Colorectal Tumours on Liver Blood Flow in Patients with Métastasés
Twenty-six of the 69 patients with liver métastasés also had primary or recurrent
colorectal tumours, while 43 had apparently isolated liver métastasés. The demographic 
characteristics and liver blood flow parameters of these two subgroups are shown in 
Table 2.2.
There was no significant difference in any of the demogi’aphic or blood flow 
parameters between these two groups of patients. Therefore, métastasés patients with and 
without colorectal tumours were pooled in all subsequent analyses.
2.3.4 Liver Blood Flow and Age
Because of the difference in age between controls and patients with liver 
métastasés, it was necessary to examine the relationship between blood flow values and age 
before considering the differences in blood flow in gieater detail. The relationship between 
hepatic arterial and portal venous flow with age, are shown in Figures 2.3 and 2.4 
respectively.
Linear regression models of the following form were separately fitted to the data for 
hepatic arterial and portal venous blood flow:
log (blood flow) = Ao + (A] x group) + (A% x age) 
where group is an indicator variable equal to zero for contiols and one for métastasés 
patients, and Ao, Ai and Ki are tlie coefficients determined by the model fitting procedure.
Ai is a measure of the difference in flow between gioups adjusted for age differences, and 
A2 is the slope of the relationship between blood flow and age within each gi'oup. A 
preliminary analysis showed that there was no evidence that this slope differed between
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groups for either hepatic arterial (p=0.79) or portal venous (p=0.48) blood flow, and so a 
common value of Aj was assumed to apply to both groups.
The results of the analysis are shown in Table 2.3, Hepatie arterial flow did not 
vary signifleantly with age (p=0.47), but differed significantly between controls and 
métastasés patients (Ai>0, p<0.001). By contrast, portal venous flow decreased 
significantly with age within each group (A2<0 , p=0.027), and there was no significant 
difference in flow between gi'oups after adjusting for age (p=0.37).
For the purpose of further analysis, an age-adjusted value for portal venous flow 
was calculated for each patient using the following equation;
log(PVF7o) = log(PVF) + A2 X (70 - age) 
where PVF70 and PVF are the adjusted and the originally measured values of portal venous 
flow respectively, and A2 is the slope coefficient calculated for PVF. This equation 
adjusted the flow for each patient to an equivalent age of 70 years, an arbitrarily chosen 
value equal to the median age of patients with métastasés. Although the relationsliip 
between hepatic arterial flow and age was not significant, age-adjusted hepatic arterial flow 
values (HAF7 0) were calculated on a similar basis so that flow in both vessels was treated in 
a consistent manner. This procedure allowed the relationship between portal venous and 
hepatic arterial flow to be studied for the two groups as if they had similar ages. An age- 
coiTected DPI70 was also calculated using the standard formula with age-corrected blood 
flow values. In most of the following analyses, both unconected and age-corrected blood 
flow values are reported so that the effect of age-correction can be assessed.
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2.3.5 Relationship Between Hepatic Arterial and Portal Venous Blood Flow and the 
Presence o f Liver Métastasés 
Figures 2.5 and 2.6 show the relationship between hepatic arterial (HAF) and portal 
venous (PVF) flow in the presence and absence of liver métastasés, before and after age 
adjustment. There was a significant, and similar, positive coiTelation between log(HAF) 
and log(PVF) in both métastasés patients (i~0.32, p=0.007) and control subjects (i-=0.34, 
p=0.04). These coiTelations were not altered by age eoiTection.
After verifying that the slope of the regi'ession line did not differ significantly 
between groups, a linear regression model of the following fonn was fitted to the data for 
hepatic arterial and portal venous blood flow, with and without age correction: 
log(HAF) = Bo + (Bi X group) + (B] x log(PVF)) 
where Bo, Bi and B2 are the regression coefficients. The results are shown in Table 2.4. 
Age correction made vei*y little difference to the regression coefficients, which confirmed a 
significant association between HAF and PVF within groups (B2>0 , p^O.OOl) and a 
significant difference in HAF between groups for a given level of PVF (Bi>0, p<0.001).
Substituting the age-corrected values of the coefficients from Table 2.4 into the
above equation and taking antilogs yields the following relationships:
HAF70 = 10.2 X  {FYFjof '^^  in control subjects 
HAF70 = 25.5 X (PVF7o)°'^  ^in métastasés patients 
Hence, the presence of métastasés is associated with a 2.5-fold increase in hepatic arterial 
flow for a given level of portal venous flow.
2.3.6 Derivation o f a Potential Diagnostic Index
To derive an optimised index to distinguish between subjects with and without 
métastasés, the following equation was fitted to the hepatic arterial (HAF) and portal 
venous (PVF) blood flow data using logistic regression analysis:
P/(l-P) = exp[Co + Cl log(HAF) + Cz log(PVF)] 
where P is the probability of a subject having métastasés, and Co, C| and Cz are the 
calculated coefficients of the model.
The results of the logistic regi'ession analysis for both age-adjusted and non­
adjusted blood flow values are shown in Table 2.5. Both Ci and Cz were significantly 
different from zero, indicating that a combination of hepatic arterial flow and portal venous 
flow was the best predictor of group membersliip. Despite the fact that, after age 
correction, only hepatic arterial flow differed significantly between the two gioups, flow in 
both vessels needs to be taken into account to distinguish between groups. This 
corresponds to the fact that, in Figures 2.5 and 2.6, the line that best separates the groups is 
not a horizontal line (i.e. a fixed level of HAF) but a sloping one (i.e. a function of flow in 
both vessels).
P/(l-P) is the odds of a subject having métastasés. The log of the odds, which we 
term the Dual Flow hidex (DFI), was calculated by taking the logaritlun of the above 
equation:
DFI = log(P/(l-P) = Co + Cl log(HAF) + Cz log(PVF)
Using the coefficients in Table 2.6, the age uncorrected DFI is given by:
DFI -  6.05 + 3.21 log(HAF) - 3.53 log(PVF) 
and the age-correeted DFI is:
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DFIyo = “0.37 + 3.10 log(HAF7o) - 2.48 log(PVF7o)
The difference between the DFI and the DPI is illustrated schematically in Figure 2.7, 
which shows the hypothetical population distribution of log(HAF) and log(PVF) in 
métastasés and control patients. There is a boundary zone where the groups overlap, and 
where the odds of a patient having métastasés is close to one. Lines of constant DFI have 
the equation:
log(HAF) = (DFLCo)/Ci - (C2/C1) log(PVF)
Hence they are straight lines with a gi'adient of -C2/C1 and an intercept that varies with the 
DFI. Since they are lines of constant odds by definition, they are parallel to the boundary 
zone.
The corresponding equation for the DPI can be derived from its definition:
DPI = HAF / (HAF + PVF)
Rearranging this equation and taking logs:
log(HAF) = log[DPI/(l-DPI)] + log(PVF)
Henee lines of constant DPI have a fixed gradient of one, and an intercept that varies with 
the DPI. Unlike the DFI, their gradient does not necessarily parallel the boundary zone, 
and so the DPI may not provide optimal discrimination between groups.
In practice, the optimised gradient -C2/C1 was close to one for both uncorrected (-C2/C1 = 
1.1) and age-conected data (-C2/C] = 0.8). This implies that the DPI would be expected to 
provide close to optimal discrimination.
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2.3.7 Comparison o f Diagnostic Indices
The distributions of the DFI and the DPI in control subjects and patients with liver 
métastasés are shown in Figures 2.8 and 2.9 respectively. Despite the theoretical 
superiority of the DFI, its ability to distinguish the groups was very similar to that of the 
DPI, as predicted above. Age correction somewhat increased the overlap in values of both 
indices between control subjects and patients with liver métastasés, reducing their 
discriminatory power.
Figure 2.10 shows the receiver-operator characteristic (ROC) curve for the DFI, in 
which sensitivity in predicting the presence of métastasés is plotted against specificity for 
varying thi*eshold values. Also shown for comparison are the ROC curves for hepatic 
arterial and portal venous blood flows m isolation. The ROC curve for the DPI was very 
similar to that for the DFI and is not plotted. The DFI was more efficient than hepatic 
arterial flow alone, which in turn was more effieient than portal venous flow, although all 
tlrree variables were better than chance alone, as represented by the diagonal line.
Figure 2.11 shows ROC curves for the coiTesponding age corrected variables, 
DFI7 0 , HAF70 and PVF7 0 . Age-eorrection reduced the efficiency of portal venous flow as a 
diagnostic parameter to the point where it was not significantly better than chance alone. 
Hepatic arterial flow was little affected, and the DFI and DPI were somewhat less efficient, 
becoming only slightly better than hepatic arterial flow alone.
Table 2.6 suimnarises the sensitivity and specificity for all the indices considered. 
The tlireshold values were chosen so that sensitivity and specificity were approximately 
equal. The results confirm that the DFI provides only a marginal increase in accuracy when 
compared with the DPI. Without age coiTection, 8 8 % of patients were correctly classified
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using the DFI, as compared with 8 6 % using the DPI. With age-correction, the accuracy of 
the two indices was reduced to 84% and 82% respectively.
2.3.8 Blood Flow Measurements in Patients Undergoing Apparently Curative Resection
Blood flow measurements were performed pre-operatively in 38 patients with 
colorectal cancer who, on the basis of imaging investigations and intraoperative findings, 
had no evidence of liver métastasés at the time of investigation. The median age of the 
patients was 72 years (interquartile range 62-79, range 42-88) and 24 were male. Thirty 
patients had colonic and 8  had rectal tumours; and 2, 11 and 25 were classed as Dukes' 
stage A, B and C respectively.
Figures 2.12 to 2.15 show the hepatic arterial blood flow, portal venous blood flow, 
the DPI and the DFI in these patients in comparison to non-cancer control subjects and 
patients with liver métastasés. All values are age-corrected. The box-and-whisker plot 
format shows the median, the upper and lower quartiles and the range, with extreme values 
being plotted individually. Patients undergoing apparently curative reseetion had 
intennediate values of these variables that overlapped the values in the other two groups. 
With or without age correction, none of the variables differed significantly from conti'ol 
values (p>0.05), but hepatic arterial flow, the DPI and the DFI were all significantly lower 
than in patients with métastasés (p<0.001). Twelve patients (32%) had a DFI that exceeded 
the tlrresliold in Table 2.6, and 13 (34%) had a DPI that exceeded the coiTesponding 
tlmeshold.
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2.4 Discussion
Doppler ultrasound measurements of liver blood flow are recognised to be subject 
to several sources of error. Errors in mean blood velocity measurement can arise from non- 
uniform insonation of the vessel, speetral broadening, inaccurate angle correction and 
errors in the processing facilities of the system. The estimation of mean blood vessel cross 
sectional area is subject to eiTors associated with ultrasound machine resolution limits, non­
perpendicularity of the beam-to-vessel angle and the variation of cross sectional area with 
time, hi addition, the technique is dependent on the operator’s accuracy and consistency in 
selecting the locations for velocity and area measurements, and the ability of the patient to 
cooperate with respiratory suspension. Some of these errors were minimized by 
standardizing the teclinique used for each measurement and by the use of colour Doppler to 
give precise assessment, geometry and identification of the vessel (Leen, 1999).
It is reported that anatomical variation in the hepatic artery are present in 
approximately 30% of the population (Leen et al., 2000); however only a small proportion 
of these variations are likely to affect the determination of whether the actual blood flow is 
truly normal or abnormal. During the study, accessory hepatic arteries were only identified 
in two such patients. In order to avoid underestimation of the DPI, the total flow in each 
vessel was added together in order to give the total hepatic arterial supply.
In subjects with normal arterial anatomy, the hepatic artery becomes the hepatic 
artery proper after the right gastric artery branch. However, this branch is rarely visualised 
on Doppler ultrasound images, hence it is difficult to ensure accurate flow measurements 
from the hepatic artery proper. Measurements were therefore performed in the coimnon 
hepatic artery, accepting that this would result in a small overestimation of arterial flow to
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the liver. All subjects were fasted for 12 hours prior to the Doppler ultrasound examination 
to ensure that blood flow tlirough the right gastric and gastroduodenal arteries was 
minimized and to standardise conditions for flow measurements (Oppo et al., 1998).
Hepatic blood flow values may also be altered by the presence of liver cirrhosis 
(Leen et al., 1993b); however none of the patients in the study had clinical evidence of 
ciii'hosis at the time of measurement. It has been previously shown by Leen and co­
workers (1993b) that the changes in hepatic haemodynamics between patients with 
métastasés and those with ciinhosis was clearly differentiated by the measurement of portal- 
vein congestive index (ratio of portal-vein cross sectional area to velocity averaged over 
time) which was only elevated in the cirrhotic patients.
Approximately 40% of the patients in this study with liver métastasés had either a 
primary or recurrent colorectal tumour. There was no evidence that either hepatic arterial 
or portal venous blood flow differed between these patients and those in whom tumour was 
apparently confined to the liver. This suggests that the presence of a colorectal tumour 
does not affect métastasés driven blood flow changes, and is consistent witli the results of 
Oppo and colleagues who studied patients with colorectal cancer before and after they 
underwent apparently curative resection (Oppo et al., 2000).
The results of the present study confirm that hepatic arterial blood flow, as 
measured by Doppler ultrasomid, is increased in patients with colorectal liver métastasés, as 
has been shown by several other research gimps (Leen et ah, 1991a, 1991b; Di Giulio et 
al., 1997; Guadagni et al., 2000; Kiuger et al., 2000; Kopljar et al., 2004; Oktar et al., 
2006). Increases primarily in both blood velocity but also, to a lesser extent, in vessel cross 
sectional area contributed to the change in blood flow, which was more than doubled 
relative to non-cancer control subjects. Portal venous blood flow was lower in patients
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with liver métastasés relative to controls. However, portal venons flow was negatively
i,correlated with age and the difference in blood flow between groups after adjustment for 
differences in age was not statistically significant. Previous reports in the literature are in Iconflict on whether portal venous flow is reduced (Leen et al. 1991a, 1991b; Di Giulio et
.4
al. 1997; Kopljar et al. 2004; Oktar et al., 2006) or unaltered (Kiuger et al. 2000; Guadagni
et al. 2000) in patients with liver métastasés. In the present study, the DPI was significantly
:?
increased in patients with métastasés, mainly because of the increase in hepatic arterial 
blood flow.
These results are largely consistent with those of Leen and colleagues (1993a), with 
wliich they are compared in Table 2.7. Hepatic arterial blood flow values in the two studies 
were very similar in control subjects, but were some 30% lower in the present study in 
patients with métastasés. Conversely, portal venous blood flow values were similar in 
cancer patients but 30% lower in the present study in controls. As a consequence, 
differences between groups in hepatic arterial and portal venous blood flow and the DPI 
were all smaller in the present study. The reason for these discrepancies is unclear, but they 
are not associated with any single patient group, blood vessel or type of measurement 
(velocity or area). Hence, it is likely that a combination of factors is responsible, including 
the composition of the patient samples and the different ultrasound scanners and operators.
Leen and co-workers (1991b) found no significant coiTelation between age and 
blood flow in either vessel. However, an inverse relationship between age and liver blood 
flow has previously been demonstrated in normal subjects using Doppler ultrasonogiaphy 
(Zoli et ah, 1989; Zoli et ah, 1999). In particular it has been documented that portal venous 
flow and total liver blood flow are reduced without any additional intrahepatic shunting and 
this is particularly evident after 75 years, wliich may explain the well-known age-related
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reduction in liver function and ability to metabolise drugs. Furthermore, Zoli and co­
workers (1999) reported that a decrease in portal flow, which was partly counterbalanced 
by an increase in hepatic artery flow, was obseiwed in subjects between the ages of 45 and 
75.
Age related reductions in liver weight and volume may also be attributed to reduced 
liver blood flow. It was shown by Zoli and co-workers (1999) that semm concentrations of 
liver enzymes (such as alkaline phosphatase, alanine and aspartate aminotransferase) and 
semm albumin concentrations were all within the normal range in elderly subjects. It has 
also been shown that with age, there is a reduction in hepatocyte mass rather than a 
reduction in morphological liver size (Wynne et al., 1989; Wakabayashi et al., 2002).
It is significant that there was a negative coiTelation between portal venous blood 
flow and age in this study. This suggests that age should be considered when interpreting 
liver blood flow measurements in patients with colorectal cancer. Furthermore patient age 
may play a role in the conflicting DPI data presented from various centies so far. This may 
have positive implications for the selection of younger, fitter patients undergoing 
assessment for more aggressive chemotherapy treatment. For example, approximately one 
third of patients with Dukes’ stage B tumour will have recurrent disease, but are generally 
denied chemotherapy. Also, around one third of patients with a Dukes’ stage C tumour 
survive 5 years following curative resection, but are exposed to the unnecessary toxic side- 
effects of adjuvant therapy (Leen et al., 2000).
The differences in age between the métastasés group and the control subjects in this 
study were mainly due to difficulties in recmiting healthy volunteers over the age of sixty. 
A large cohort of healthy controls was measured throughout the study consisting of 
relatives, colleagues and laiown healthy patients with small benign liver haemangioma.
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There was a significant correlation between hepatic arterial and portal venous blood 
flow in both control subjects and métastasés patients. This may simply reflect a common 
dependence of both components of liver blood flow on tissue mass. A consequence of this 
relationship is that tire "nonnal range" of hepatic arterial blood flow varies with the level of 
portal venous flow. Hence, for the purpose of detecting the presence of liver métastasés on 
the basis of blood flow measurements, both hepatic arterial and portal venous flow should 
be taken into account regardless of whether the latter is altered by the presence of 
métastasés.
The DPI is a function of the ratio of hepatic arterial to portal venous blood flow. 
Leen and co-workers (1993a) found complete separation in DPI values between métastasés 
and control patients (i.e. 1 0 0 % sensitivity and specificity), tire minimum value in the former 
group being 0.30 and the maximum control value being 0.25 (Leen et al., 1993a). In the 
present study the DPI without age correction had a sensitivity of 84% and specificity of 
89% using a tlrreshold value of 0.25. As discussed above, the greater overlap in DPI values 
between patient groups in the present study, and hence tire lower sensitivity aird specificity, 
cannot be ascribed to any siirgle cause. Nonetheless, the DPI remains a reasonably 
powerful diagnostic index.
The DPI is an alternative index, similarly based on hepatic arterial and portal 
venous blood flow measurements, which was optimised to discriminate betweerr métastasés 
and control patients according to a logistic régression model. However, it provided oirly a 
marginal increase in accuracy when compared with the DPI. Tlris suggests that the DPI, or 
equivalently the ratio of hepatic arterial to portal venous blood flow, reflects essentially all 
the diagirostic information present in the two blood flow measuremeirts, and that there is 
little to be gained from the use of a more complex index such as the DPI.
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discriminate between patients with liver métastasés and normal subjects. This study rejects 
the hypothesis and accepts the alternative. Secondly, it was stated that the Doppler 
Perfusion Index is increased as a result of reduced portal venous blood flow. This null 
hypothesis cannot be supported due to the primary increase in hepatic arterial blood flow 
and age dependent alterations in portal venous blood flow observed in this study. Finally, it 
was proposed that tire presence of a colorectal primary tumour influences liver métastasés 
driven hepatic blood flow alterations. Tlris hypothesis can also be rejected as there were no 
significant differences obseiwed in relation to the presence of a primary tumour.
The potential clinical value of the DPI and similar blood flow indices lies in their 
ability to predict outcome in colorectal cancer patients undergoing apparently curative 
resection, possibly by reflecting the presence of occult liver métastasés. It has been 
reported that 91% of such patients survived five years if they had a normal DPI at the time 
of surgery, as compared with 29% of patients with an abnormal DPI (Leen et al. 2000). It 
was not an aim of the present study to investigate the relationship of the DPI or DPI with 
survival, but the distribution of pre-operative DPI and DPI values in patients undergoing 
apparently curative resection overlapped the ranges found in control and métastasés 
patients. Approximately one third of these patients had high values of the DPI and DPI, as 
compared with less than 2 0 % of control subjects.
The first null hypothesis states that the Doppler Perfusion hidex does not
"■i.
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In summary, this study has confirmed that hepatic arterial blood flow and the DPI 
are increased in patients with colorectal liver métastasés, and has shown that the presence 
of a primary or recuiTent colorectal tumour does not significantly alter liver blood flow in 
patients with métastasés. The DPI, an optimised index of abnormal liver blood flow, only 
marginally improved on the DPI as a diagnostic test. Portal venous blood flow, and derived 
indices such as the DPI and DPI, are age-dependent, and this should be considered when 
interpreting haemodynamic data in patients with colorectal cancer.
1
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Table 2.1 Demographic characteristics and Doppler ultrasound based liver blood flow 
parameters in control subjects and patients with colorectal liver métastasés.
Data given as median (interquartile range); (95% confidence intervals).
Control subjects 
(n=37)
Liver métastasés 
(n=69)
P-vaiue
1
■:;Si
Demographics
Age (years)
Sex (male/female)
49(29,59) 
(34, 56)
20/17
70 (64, 75) 
(66,71)
42/27
<0 . 0 0 1
0.54
Hepatic artery ,/
Time-average velocity 15.7(12.4, 19.5) 24.8 (18.7,36) <0 . 0 0 1 3(cm/s) (13.5, 17.6) (21.5, 28.9)
Cross sectional area 0.17(0.14,0.24) 0.23 (0.18,0.30) <0 . 0 0 1 T
(cm^) (0.15,0.19) (0.20, 0.25) :l
Blood flow (ml/min) 154(120, 224) 334(238,535) <0 . 0 0 1
(135,193) (286,428)
/Portal vein T
Time-average velocity 13.5 (9.8, 16.2) 11.4 (9.0, 14.1) 0.084
(cm/s) (10.2, 15.6) (10, 12.5)
Cross sectional area 0.95 (0.82, 1.2) 0.81 (0.64, 1.2) 0.016
(ciif) (0.87, 1.08) (0.73, 0.89)
Blood flow (ml/min) 762 (515, 1014) 542 (403, 727) 0 . 0 0 2
(615, 8 8 6 ) (432,608)
Whole liver
Blood flow (ml/min) 930 (6 8 6 , 1203) 933 (708, 1183) 0.93
:::
a;
(783.1, 1120.96) (803,1024) 3
Doppler Perfusion Index 0.17(0.13,0.21) 0.37 (0.28, 0.49) <0 . 0 0 1
(0.14, 0.20) (0.33, 0.42)
104
Table 2.2 Demographic characteristics and Doppler ultrasound liver 
parameters in patients with colorectal liver métastasés, with and without the 
colorectal tumour.
blood flow
presence of
Liver métastasés + 
colorectal tumour 
(n=26)
Liver métastasés 
alone 
(n=43)
P-value
Demographics
Age (years) 69(62,73)
(64,73)
70 (65, 74) 0.38
Sex (male/female) 18/8 24/19 0.32
Hepatic artery
Time-average velocity 
(cm/s)
26.7 (12, 89.1) 
(20.1,42)
24.2 (8.3, 104) 
(20.1,31.5)
0.281
Cross sectional area 
(cm^)
0.24 (0.07, 0.73) 
(0.19,0.28)
0.22 (0.07,0.71) 
(0.19, 0.26)
0.281
Blood flow (ml/min) 394 (173, 1216) 
(307, 524)
313 (6 8 , 1798) 
(248,408)
0.189
Portal vein
Time-average velocity 
(cm/s)
11.1 (5.4,21) 
(9.9, 13.7)
11.9 (4.8,31.5) 
(9.1, 12.8)
0.139
Cross sectional area 
(cm )^
0.81 (0.40, 2.02) 
(0.70, 1.06)
0.81 (0.08, 1 .8 ) 
(0.68, 0.95)
0.504
Blood flow (ml/min) 530 (337,2115) 
(419, 724)
542(112, 1455) 
(423,642)
0.310
Whole liver
Blood flow (ml/min) 958(579,2851)
(803,1180)
900 (327,3148) 
(724,1008)
0.809
Doppler Flow Ratio 0.70 (0.18, 1.99) 
(0.49,0.91)
0.55 (0.17, 8.2) 
(0.41, 0.79)
0.620
Doppler Perfusion Index 0.41 (0.15, 0.67)
(0.33, 0.48)
0.36 (0.14,0.89) 
(0.29, 0.44)
0.488
Data given as median (interquartile range); (95% confidence inteiwals).
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Table 2.3 Coefficients of the regression equations relating hepatic arterial and portal
venous blood flow to age and patient group.
Dependent
variable
Independent
variable
Coefficient 95% Cl P-value
Log(HAF) Constant Ao 5.26 4.77,5.75 <0 . 0 0 1
Group A] 0.87 0.54, 1.21 <0 . 0 0 1
Age (yr) A2 -0.004 -0.014, 0.006 0.43
Log(PVF) Constant Ao 6.99 6.62, 7.37 <0 . 0 0 1
Group Al -0 . 1 2 -0.37, 0.14 0.37
Age (yr) A2 -0.008 -0.016, -0 . 0 0 1 0.027
Cl, confidence inteiwal; HAF, hepatic arterial blood flow (ml/min); PVF, portal venous 
blood flow (ml/min). For definition of regression equation and coefficients, see text.
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Table 2.4 Coefficients of the regression equations relating hepatic arterial flow to
portal venous flow and patient gi'oup, with and without age correction.
Dependent
variable
Independent
variable
Coefficient 95% Cl P-value
Uncorrected
Log(HAF) Constant Bo 2.31 0.76, 3.87 0.004
Group Bi 0.91 0.66, 1.16 <0.001
log(PVF) Bz 0.42 0.18, 0.66 0.001
Age-corrected
Log(HAFyo) Constant Bo 2.32 0.76,3.88 0.004
Group Bi 0.92 0.68, 1.16 <0.001
log(PVF?o) B2 0.42 0.18,0.66 0.001
CÏ, confidence inteiwal; HAF, hepatic arterial blood flow (ml/min); PVF, portal venous 
blood flow (ml/min). For definition of regression equation and coefficients, see text.
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Table 2.5 Coefficients of the logistic regression model of the relationsliip between the 
presence of liver métastasés and hepatic arterial and portal venous blood flow.
Independent
variable
Coefficient 95% Cl P-value
Uncorrected Constant Co 6.05 -2.81, 14.92 0.18
log(HAF) Cl 3.21 1.93,4.49 <0 . 0 0 1
log(PVF) Cz -3.53 -5.26,-1.80 0.001
Age-corrected Constant Co -0.27 -8.93, 8.39 0.95
log(HAFyo) Cl 3.10 1.89, 4.31 <0 . 0 0 1
log(PVFyo) Cz -2.48 -4.10, -0.86 0.003
Cl, confidence interval; HAF, hepatic arterial blood flow (ml/min); PVF, portal venous 
blood flow (ml/min). For definition of regression equation and coefficients, see text.
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Table 2.6 Sensitivity, specificity and accuracy of diagnostic indices derived from 
blood flow measurements.
Variable
No. (%) of subjects correctly classified
Threshold
Métastasés
(sensitivity)
Control
(specificity)
All subjects 
(accuracy)
Uncorrected
PVF (ml/min) <620 45/69 (65%) 24/37 (65%) 69/106 (65%)
HAF (ml/min) >230 53/69 (77%) 28/37 (76%) 81/106 (76%)
DPI >0.25 58/69 (84%) 33/37 (89%) 91/106 (86%)
DFI >0.40 61/69 (88%) 32/37 (86%) 93/106 (88%)
Age-corrected
PVF70 (ml/min) <550 39/69 (57%) 22/37 (59%) 61/106 (58%)
HAF70 (ml/min) >205 55/69 (80%) 29/37 (78%) 84/106 (79%)
DPI70 >0.25 57/69 (83%) 30/37 (81%) 87/106 (82%)
DFI70 >0.50 57/69 (83%) 32/37 (86%) 89/106 (84%)
PVF, portal venous blood flow;. HAF, hepatic arterial blood flow; DPI, Doppler perfusion 
index; DFI, Doppler flow index.
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Table 2.7 Comparison of blood flow parameters in the present study with previously 
reported values.
Variable Leen et ai. Guadagni et al. Present
1993a 2000 study
Control patients n-50 11=18 11=37
HA time-average velocity (cm/s) 19.0 (5.0) 18.3 (12.8)
HA cross sectional area (mm^) 17.0(10.0) 17.8 (6.2)
HA blood flow (ml/min) 194(125) 245(87) 187 (109)
PV time-average velocity (cm/s) 15.0(6.0) 13.2 (3.9)
PV cross sectional area (mm^) 129.0 (36.0) 102.3 (40.3)
PV blood flow (ml/min) 1200 (570) 503 (153) 797 (318)
Total liver blood flow (ml/min) 1390 (640) 984(361)
DPI 0.14(0.06) 0.33 (0.10) 0.19(0.10)
Métastasés patients 11=67 11=19 n=69
HA time-average velocity (cm/s) 33.0(12.0) 29.5 (16.7)
HA cross sectional area (mm^) 32.0 (14.5) 25.2 (12.8)
HA blood flow (ml/min) 630 (330) 362 (107) 440 (337)
PV time-average velocity (cm/s) 1 1 . 2  (4.0) 12.0 (4.7)
PV cross sectional area (mm^) 99.0 (26.6) 88.4 (36.1)
PV blood flow (ml/min) 670 (340) 655 (414) 625 (364)
Total liver blood flow (ml/min) 1300 (580) 1065 (601)
DPI 0.49 (0.13) 0.38(0.11) 0.40 (0.15)
Data given as mean (SD). HA, hepatic arterial; PV, portal venous; DPI, Doppler perfusion 
index.
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Figure 2.1 Correlation of duplicate Doppler Perfusion Index (DPI) 
for a single observer.
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Figure 2.3 Relationship between hepatic arterial blood flow (HAF) and 
age in control subjects and patients with liver métastasés. Regression lines 
for the two groups are also shown.
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Figure 2.4 Relationship between portal venous blood flow (PVF) and 
age in control subjects and patients with liver métastasés. Regression lines 
for the two groups are also shown.
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Figure 2.5 Relationship between raw hepatic arterial (HAF) and portal 
venous blood flow (PVF) in control subjects and patients with liver 
métastasés. Regression lines for the two groups are also shown.
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Figure 2.6 Relationship between age-corrected hepatic arterial (HAF) 
and portal venous blood flow (PVF) in control subjects and patients with 
liver métastasés. Regression lines for the two groups are also shown.
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Figure 2.7 Schematic diagram illustrating how the DFI can potentially 
improve on the DPI in discriminating between patient groups. The 
ellipses represent the distribution of hepatic arterial (HAF) and portal 
venous (PVF) blood flow in the two groups. Lines of constant DFI have a 
gradient similar to the boundary zone between groups. Lines of constant 
DPI have a gradient of one, and do not necessarily parallel the boundary 
zone.
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Figure 2.8 Distribution of Dual Flow Index (DFI) in control subjects and 
patients with liver métastasés, with and without age correction.
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Figure 2.9 Distribution of Doppler Perfusion Index (DPI) in control subjects 
and patients with liver métastasés, with and without age correction.
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Figure 2.10 Receiver-operator characteristic (ROC) curves for the 
raw Dual Flow Index (DFI), hepatic arterial flow (HAF) and portal 
venous flow (PVF) distinguishing between control subjects and 
patients with liver métastasés.
117
>
'wC0)(/)
'kU  '" f  *)
S & a l
 DFI
HAF 
 PVF
20 40 60 80
S p e c i f i c i t y  (% )
100
Figure 2.11 Receiver-operator characteristic (ROC) curves for the 
age-corrected Dual Flow Index (DFI), hepatic arterial flow (HAF) and 
portal venous flow (PVF) distinguishing between control subjects and 
patients with liver métastasés.
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Figure 2.12 Hepatic arterial blood flow (HAF) in control subjects, 
patients with primary colorectal cancer and patients with liver métastasés 
(age-coixected data).
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Figure 2.13 Poital venous blood flow (PVF) in control subjects, patients 
with primary colorectal cancer and patients with liver métastasés (age- 
corrected data).
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Figure 2.14 Doppler Perfiision Index (DPI) in control subjects, patients 
with primary colorectal cancer and patients with liver métastasés (age- 
corrected data).
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Figure 2.15 Dual Flow Index (DFI) in control subjects, patients with 
primary colorectal cancer and patients with liver métastasés (age-coiTected 
data).
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Chapter 3 : Liver blood flow in patients with 
colorectal liver métastasés as measured by 
Computerised Tomography (CT).
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3.1 Introduction and Aims
The measurement of liver blood flow by Doppler ultrasound is generally recognised 
to be an operator-dependent procedure that requires considerable training, and is probably 
unsuitable for routine use outside specialist centres. There is therefore an interest in 
developing alternative methods of measurement that are less operator-dependent.
Miles and co-workers (1993) described a method based on single-slice dynamic 
computerised tomography (CT) scanning. Measurements of enhancement were performed 
after a bolus injection of contrast medium by placing regions of interest over the liver, aorta 
and spleen. Estimates of hepatic arterial and portal venous liver perfusion were obtained by 
dividing the maximum slope of the liver enliancement curve by the peak aortic 
enliancement, the splenic peak being used to separate the arterial and portal venous phases 
of enhancement. Significant changes in perfusion were detected in patients with various 
conditions, including liver métastasés. However a limitation of the teclmique was that it 
required a different protocol from standard diagnostic imaging CT scans, and hence 
imposed an additional burden on hospital resources as well as increasing the exposure of 
patients to ionising radiation.
Subsequently, Platt and colleagues (1997) described a method based on dual-phase 
spiral CT scanning using a protocol that was also appropriate for routine diagnostic 
imaging studies, and similar to that used for clinical CT scamiing of the liver in Glasgow 
Royal Infirmary. The ratio of liver attenuation at specific time points during the arterial 
phase to peak liver attenuation was found to be significantly increased in colorectal cancer 
patients who went on to develop liver métastasés within 18 months relative to those who 
did not, with an overall prognostic accuracy of 89%. It was suggested that tliis could be
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attributed to increased hepatic arterial flow associated with occult liver métastasés (Platt et 
ah, 1997).
The aim of the present study was to evaluate perfusion-related measurements 
similar to those described by Platt and colleagues (1997), derived from clinical dual-phase 
CT scans of the liver in patients with and without liver métastasés.
Null Hypotheses
It has previously been shown that CT liver perfusion data has a high prognostic 
accuracy in determining patients who are harbouring occult liver métastasés (Miles et al., 
1993; Platt et al., 1997). This study was designed to test the null hypothesis that liver 
perfusion data, as measured by dual-phase CT scans, can be used to discriminate between 
patients with colorectal liver métastasés and normal subjects.
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3.2 Patients and Methods
S. 2.1 Patients
Patients with colorectal cancer who nndeiivent dual-phase spiral CT scanning of the 
abdomen at Glasgow Royal Infirmary between April 1999 and April 2003 were studied. 
They were classed as having either (a) overt liver métastasés or (b) a clear liver on the basis 
of radiological and surgical findings. Those with liver métastasés were further classified 
according to whether or not the primary tumour was still present. The control gioup 
comprised of (c) patients with small hepatic haemangiomas who underwent a similar CT 
scaiming protocol.
Inclusion criteria consisted of : (a) Histologically proven colorectal cancer; Liver 
métastasés confirmed histologically, by progression on CT or Ultrasound; (b) 
Histologically proven colorectal cancer; No evidence of liver métastasés on CT, Ultrasound 
or intraoperative investigation; (c) Radiologically confiimed liver haemangioma of 
insignificant size and position relative to the liver parenchyma.
Exclusion criteria consisted of : Anticancer treatment during the study period or 
during the preceding month; Patients currently receiving or who have had non-steroidal 
anti-inflammatory drugs in the last two weeks; Patients receiving warfarin; Diagnosis of 
other liver disease or suspected ciniiosis.
All subjects were informed of the puipose and procedure of the study and were 
given a patient infonnation sheet, hiformed consent was given by all subjects included the 
study.
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3.2.2 Methods
CT scanning of the abdomen was performed using a Somatom Plus 4 spiral seamier 
(Siemens AG, Munich, Germany). Patients received 30 ml of iodine contrast medium 
(Gastrogi'afm, Schering AG, Berlin, Germany) prior to the scan. A dual-phase (arterial and 
venous) scan was performed during and after the infusion of 150 ml of a non-ionic contrast 
medium (Omnipaque; Nycomed Imaging AS, Oslo, Norway) which was administered 
intravenously at 3ml/s using a pump injector (Medrad Inc., Indianola, PA, USA). Arterial 
phase scamiing was started 27 seconds after the start of contrast injection and portal phase 
scamiing was started at 60 seconds. Contiguously reconstmcted sections (pitch 1:0.5) were 
obtained through the liver with 5 mm collimation, with a table speed adapted to cover the 
entire liver with a single breath hold and a reconstruction interval of 5-10 mm. All scans 
were saved to Magneto Optical (MO) disk and were analysed offline using a Magic-View 
workstation (Siemens AG, Munich, Gemiany).
Circular regions of interest (ROI) were mapped over the lumen of the aorta and over 
the right lobe of the liver using a mouse-controlled cursor, avoiding any major intrahepatic 
vessels or visible lesions. A further region was diawn around the inside edge of the liver 
encompassing the whole organ. Mean attenuation in Hounsfield units (HU) was measured 
for each ROI in each section that included part of the liver.
The parameters for evaluation were selected to be similar to those of Platt and co­
workers (1997), who measured attenuation 25 and 40 seconds after the start of contrast 
injection. However, in the present study, acquisition of images did not start until 27 
seconds after the start of injection, and in several patients liver tissue was not imaged until 
more than 30 seconds after the start of the injection. The time points selected for analysis 
were tlierefore adjusted to 35 and 45 seconds. At each of these time points, liver
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attenuation in Hounsfield Units was measured for both the selected ROI and the whole 
liver. The peak attenuation attained over both phases of the scan was also determined for 
the liver ROI, the whole liver and the aorta.
As baseline unenhanced scamiing was not available in the present study, it was not 
possible to perform measurements of enhancement by subtraction of baseline attenuation 
measurements.
3.2.3 Statistical Analysis
Demographic data were analysed using the Kixiskal-Wallis test and the chi squared 
test. Liver attenuation data were also initially analysed using the Kiiiskal-Wallis test. As 
there was a substantial age imbalance between patient gi'oups, liver attenuation variables 
were adjusted for age using the same method (i.e. analysis of covariance) as was used for 
the blood flow variables in Chapter 2. A P-value of 0.05 or less was defined as significant. 
All statistical analysis was performed using SPSS (SPSS, Chicago, USA).
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3.3 Results
Forty four patients with liver métastasés, 14 colorectal cancer patients with 
apparently clear livers and 10 haemangioma (control) patients were studied. Their 
demogi'aphic and clinical characteristics are shown in Table 3.1. The cancer patients were 
significantly older than the control patients (p<0.01).
The results of the attenuation measurements in the liver ROI in tiiese patient groups 
are shown in Table 3.2. Attenuation at both time intervals was lower in both cancer gi'oups
I
than in controls whether expressed in absolute units, as a percentage of the liver peak or as 
a percentage of the aortic peak. This was statistically significant before age adjustment. s
However, analysis of covariance showed that these differences were largely due to the Ieffect of age, and, after adjusting for age, none of the measures of liver attenuation differed
3significantly between patient groups.
The results of the whole liver attenuation measurements in the same thi'ee gi'oups 
are shown in Table 3,3. They were similar to those of the regional liver measurements, and 33
showed no significant differences between groups after age adjustment.
Liver ROI attenuation measurements in métastasés patients with (n=14) and without 
(n=30) a colorectal tumour are compared in Table 3.4. Without age adjustment, absolute 
attenuation measurements at 35 seconds (p<0.05) and 45 seconds (p<0.01) were 
significantly higher in patients without colorectal tumours. After age adjustment, only the 
difference at 45 seconds remained significant (p<0.05). Attenuation expressed as a 
percentage of the liver or aortic peak did not differ significantly between goups with or 
without age adjustment.
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The coiTesponding measurements in the whole liver are shown in Table 3.5. Only 
the difference in absolute attenuation at 45 seconds was significantly different between 
these two patient groups before age adjustment, and none differed significantly when 
adjusted for age.
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3.4 Discussion
111 this study of dual-phase coiitrast-eiilianced CT scanning, hepatic attenuation at 35 
seconds after the start of contrast injection was found to be substantially lower in colorectal 
cancer patients with and without liver métastasés than in a considerably younger goup of 
patients with hepatic haemangiomas, who were ti'eated as controls. This difference became
more marked when attenuation was expressed as a percentage of the liver or aortic peak
■■■attenuation.
Selection of a control goup for this study was problematical since very few patients 
undergo abdominal CT scamiing without a condition that could potentially affect 
splancluiic blood flow, while the associated radiation dose precluded the use of nonnal 
volunteers. Patients with small haemangiomas were chosen because these benigi tumours 
are not known to significantly alter total perfusion to the liver. Haemangiomas, which are
present in 5-20% of the population, produce a vascularity that is different from nonnal liver 
parenchyma. Under procedures such as contrast enhanced ultrasound for example, these 
benigi lesions may demonstrate peripheral nodules, an increased arterial and a less 
common increased venous enliancement within the lesion compared to nonnal liver 
parenchyma (Braimigan et al., 2004). It is important to note that attenuation measurements 
were performed on both nonnal liver parenchyma (region of interest) avoiding any major 
vessels, visible lesions or sunounding nodules, and separately on the surrounding whole 
liver perimeter. Tliis was desigied to minimise any unexpected false representation of 
altered perfusion to the whole liver in such patients. By selecting patients with small and 
few haemangiomas it could be expected that relatively normal perfusion characteristics 
would be displayed.
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The limited numbers of patients with small benign lesions made the lack of age- 
matching unavoidable, but this had important consequences. In an analysis which corrected 
for the effect of age, no differences in liver attenuation between the tlrree patient groups 
were statistically significant.
It is unclear why liver attenuation as measured in this study should decrease with 
increasing age. In Chapter 2 it was found that hepatic arterial blood flow did not vary 
significantly with age. However, the delivery of contrast material to the liver does not 
depend solely on hepatic arterial blood flow but also on cardiac output and its distribution, 
and on the amount of contrast that reaches the liver via the portal vein. Although the 
hepatic arterial route would be expected to be dominant during the first 35 seconds after the 
start of contrast injection, a substantial portal venous contribution camiot be excluded. 
Hence it may be that the geater attenuation in the younger haemangioma goup reflects a 
higher rate of early contrast delivery via the portal vein. As baseline unenlianced scaiming 
was not performed, it is unknown whether age-dependent differences in the attenuation of 
the liver tissue itself also contributed to the observed results. There are currently no reports 
in the literatui'e on the effect of age correcting during functional CT perfusion studies.
As nomial control subjects could not be studied, a sub-population of patients with 
colorectal cancer and no overt liver métastasés were used as a reference group. It was 
expected that these patients would have lower hepatic arterial flow than patients with overt 
liver métastasés (Leen et al., 1993a), with whom they were well matched in age. The 
presence of occult liver métastasés in this sub-population could not be ruled out, however it 
was expected that a difference in attenuation would be observed between the two goups in 
general. However, there was little apparent difference in liver attenuation between these
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two goups at either time point. This may have been due to the presence of occult liver 
métastasés or the lack of sensitivity of the method as a whole.
Unexpectedly, the presence of a primary tumour in patients with liver métastasés 
was found to reduce absolute liver attenuation 45 seconds after the start of contrast 
injection, even after age correction. No difference in hepatic arterial or portal venous blood 
flow was found between patient sub goups with and without a colorectal tumour using 
Doppler ultrasomid (Chapter 2). Also, unlike the attenuation differences discussed above, 
this difference was reduced when attenuation was expressed as a percentage of the peak 
liver or aortic attenuation. A possible mechanism that could explain such a finding would 
be the accelerated arrival of contrast via the portal vein due to arterioportal shunting in 
patients who have undergone surgery to remove the primary tumour. However, in view of 
the large number of comparisons performed in this study, the atypical features of this 
difference and its marginal significance level, it is equally likely to represent a Type I 
statistical error.
The results of the present study appear to contradict those of Platt and co-workers 
(1997), who used a similar procedure to study patients with a variety of primary tumours in 
whom liver métastasés were not detectable at the time of scamiing. They reported a 
significantly elevated ratio of liver attenuation to peak liver attenuation at both 25 and 40 
seconds after the start of conti'ast injection in those patients who developed overt liver 
métastasés over the following eighteen months. If their findings reflected increased hepatic 
arterial blood flow in patients who developed métastasés, a similar increase in attenuation 
ratios would be expected in patients with overt liver métastasés relative both to normal 
controls and to colorectal cancer patients without liver métastasés. The different time
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points selected in the present study are unlikely to explain the difference in results as there 
was a substantial overlap in the time inteiwals studied.
A study perfonned in breast cancer patients by Sheafor and co-workers (2000) is in 
closer agreement with the present study. The authors reported a higher ratio of hepatic 
attenuation to peak hepatic attenuation at both 25 and 30 seconds in those patients who 
subsequently developed liver métastasés. However, when the results were conected for the 
time since chemotherapy using a method similar to the age correction in the present study, 
all statistically significant differences were lost. The authors concluded that there were too 
many variables that could potentially affect hepatic haemodynamics, and therefore the CT 
enliancement technique was not sufficiently robust to identify those at risk of developing 
liver métastasés.
There are several technical factors that may help to explain these contradictory 
findings. Basic differences in attenuation can occur between CT scamiers’ fields and 
within each individual seamier s' fields (McCullough et ah, 1983); and variations in patient 
weight or cardiac output may affect the overall rate and intensity of enliancement 
(Korniano et al., 1983; Chambers et al., 1993). To minimise the effect of these limitations, 
a similar protocol to Platt and co-workers (1997) was strictly adhered to, including the 
contrast amount and injection rate, and the CT seamier was calibrated as routine every 24 
hours. Measurements in the aorta were taken to provide a reference point specific to each 
patient, and normalising liver attenuation with respect to the aortic peak reduced variation 
within patient groups. The effect of variations in body weight and cardiac output were 
assumed to be of limited importance as similar variations were present in patients in the 
Doppler ultrasound liver studies.
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sAnother factor which may bias the results of CT liver perfusion studies is the 
selection of regions of interest. It is thought that each patient may have inherent differences 
in attenuation in different hepatic regions (Chambers et al., 1993). To minimise this effect, 
regions were drawn over the entire liver parenchyma and within a relatively constant single 
area of the right lobe, avoiding any vessels or lesions. Measurements were performed by a 
single obseiwer, reducing the degee of variation and both sets of data (ROI and entire liver) 
were then analysed separately.
Alternative protocols using a bolus injection of contmst and imaging in a single 
scanning plane appear to be more promising for the study of liver blood flow changes 
(Miles et al. 1993; Cuenod et al. 2001). Delivery of the contrast agent as a bolus allows 
better separation of the arterial and portal phases, while single plane imaging reduces the 
effect of regional variations in attenuation tliroughout the liver. However, such protocols 
impose a substantial radiation burden and caimot replace conventional CT scamiing for 
clinical puiposes; hence they are suitable only for experimental use.
The present study utilised CT scamiing data which had been acquired primarily for 
clinical purposes. If it had yielded information about liver perfusion similar to that 
provided by Doppler ultrasound it would have had major advantages over the latter 
teclmique in being less operator-dependent as well as being routinely perfonned in the 
relevant patient groups. However, tliis study failed to confirm its reported usefulness in 
this respect. Therefore, the null hypothesis camiot be rejected and further studies are
required to compare the potential roles of functional CT and Doppler ultrasound in 
assessing liver perfusion for the detection of occult liver métastasés.
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Future Studies
Measuring liver perfusion using functional CT scans is currently very time 
consuming and produces mixed results between centies that are difficult to interpret for the 
early detection of liver métastasés. The technique may be strengthened by a study protocol 
that includes baseline unenlianced CT scans, and corresponding liver blood flow 
measurements using ultrasound, thus providing valuable reference information. Automated 
software that can map a region of interest automatically throughout a whole CT scan would 
also have a positive impact on the teclmique. Finally, research into the differences between 
single-slice and volumetric CT perfusion would also provide further insight into the 
potential for this iimovative technique.
hiterest in this area has recently turned to magnetic resonance imaging (MRI). In 
comparison to CT, the lack of ionizing radiation, use of smaller volumes and safer contrast 
media indicate that MRI may be used as a safer research tool, hiitial studies by Totman and 
co-workers (2005) have reported promising results. A significantly reduced portal 
perfusion and increased HPI were reported in 12 patients with colorectal liver métastasés 
compared with 14 control subjects (referred for routine contrast spine imaging with no 
neoplastic disease). Unfoiiunately the initial report failed to investigate the differences in 
age between the colorectal cancer patients (mean 65 years) and the contiol subjects (mean 
45 years).
Whilst the potential for this teclmique is interesting, its success will rely on 
establishing a standard scaiming protocol from normal perfusion studies, and tlrrough long 
term follow-up scans on a large cohort of patients following excision of their primary 
tumour (Haiwey & Blomley, 2005; Totman et al., 2005).
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Table 3.1 Demographic and clinical data in CT study.
Control 
(n= 10)
Clear liver 
(n= 14)
Liver 
métastasés 
(n= 44)
P-value
Age (years) 52.5 (37-70) 75.5 (38-81) 72 (49-87) 0.003
(39,66) (57,81) (68,77)
Sex (male/female) 2 /8 7 /7 25/19 0.11
Site (colon/rectum) 9 /5
Dukes’ Stage (AB/C) 5 /9
Age expressed as median (range), (95% confidence intervals).
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Table 3.2 CT attenuation measurements in liver region-of-interest (ROI) in patients 
with haemangioma (control), non-metastatic colorectal cancer (clear liver) and colorectal 
liver métastasés.
Control Clear liver Liver
métastasés
Raw
P-value
Adjusted
P-value
(n = 10) (n = 14) (n = 44)
Absolute
attenuation
(HU)
35 secs 82.8(13.1) 
(65.8, 94.2)
74.4(11.3) 
(64.4, 88.0)
72.0(11.7)
(67.1,74.1)
0.05 0.30
45 secs 96.1 (23.4) 
(64.4, 117.7)
83/2(21.5)
(60.5, 109.1)
85.6 (20.3) 
(73.8, 88.3)
0.36 0.78
Percentage of 
peak liver 
attenuation
35 secs 57.0 (7.6) 
(42.7, 78.6)
47.8(7.1) 
(40.5, 52.8)
48.3 (7.7) 
(46.7,51.1)
0.013 038
45 secs 56.27 (24.13) 
(38.5, 93.8)
54.2(11.8) 
(43.8, 68.6)
57.4(10.5) 
(53.4, 63.3)
0.28 0.49
Percentage of 
peak aortic 
attenuation
35 secs 27.4 (5.7) 
(18.8,42.3)
21.4 (4.6) 
(40.5, 52.8)
21.0 (5.0) 
(18.8, 22.4)
0.009 035
45 secs 30.1 (6.9) 
(0,31.7)
24.2 (7.4) 
(43.8, 68.6)
25.2 (6.7) 
(21.2, 28.6)
0.11 038
Results expressed as mean (SD); (95% confidence intervals). P~values reported are for
difference between groups before (raw) and after adjustment for age.
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Table 3.3 CT attenuation measurements in whole liver in patients with haemangioma 
(control), non-metastatic colorectal cancer (clear liver) and colorectal liver métastasés.
Control 
(n -1 0 )
Clear liver 
(n = 14)
Liver 
métastasés 
(n = 44)
Raw
P-value
Adjusted
P-value
Absolute 
attenuation (HU)
35 secs 83.7 (14.5) 
(64.0, 95.1)
74.4 (11.7) 
(63.2, 88.5)
72.1 (11.2) 
(68.4, 77.8)
0.06 0.18
45 secs
Percentage of peak 
liver attenuation
98.2 (22.9) 
(75.0, 116.2)
85.0 (21.7) 
(62.0, 111.3)
83.6 (19.4) 
(72.4, 88.7)
0.19 0.51
35 secs 58.9 (8.1) 
(44.2, 85.6)
48.0 (7.2) 
(40.3, 68.3)
50.9(11.1) 
(45.0, 54.4)
0.008 0.34
45 secs
Percentage of peak 
aortic attenuation
65.3 (9.4) 
(45.8, 72.1)
55.6(11.8) 
(0, 62.5)
58.4 (12.4)
(0, 59.0)
0.15 0.49
35 secs 27.6 (5.6) 
(18.8, 42.2)
21.4 (4.7) 
(16.9, 29.0)
20.7 (4.5) 
(17.8, 22.0)
0.003 0.21
45 secs 30.7 (6.1) 
(21.0,31.2)
24.7 (7.5) 
(0, 33.7)
24.2 (6.3) 
(0, 24.8)
0.04 0.54
Results expressed as mean (SD); (95% confidence intervals). P-values reported are for
difference between gi'oups before (raw) and after adjustment for age.
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Table 3.4 CT attenuation measurements in liver region-of-interest (ROI) in patients
with colorectal liver métastasés with and without the presence of a primary tumour.
Liver métastasés + 
colorectal tumour
(n = 14)
Liver métastasés 
alone
(n = 30)
Raw
P-value
Adjusted
P-value
Absolute
attenuation (HU)
35 secs 66.4 (9.9) 74.7(11.7) 0.031 0.10
(60.6, 65.2) (70.8, 84.1)
45 secs 72.3 (13.0) 92.9 (20.1) 0.002 0.03
(67.8, 76.1) (85.3, 109.5)
Percentage of peak
liver attenuation
35 secs 47.8(11.1) 483(53) 0.59 0.78
(38.4, 45.3) (48.6, 52.8)
45 secs 54.5 (12.8) 58.9 (9.0) 0.30 0.86
(45.6, 54.9) (59.3, 70.9)
Percentage of peak
aortic attenuation
35 secs 21.5 (6.1) 203(43) 0.50 0.46
(15.8, 18.28) (21.2, 25.4)
45 secs 24.4 (7.4) 253 (6A) 0.80 0.99
(19.4, 23.7) (27.0,31.9)
Results expressed as mean (SD); (95% confidence intervals). P-values reported are for
difference between groups before (raw) and after adjustment for age.
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Table 3.5 CT attenuation measurements of whole liver in patients with colorectal liver
métastasés with and without the presence of a primary tumour.
Liver métastasés + 
colorectal tumour
(n = 14)
Liver métastasés 
alone
(n = 30)
Raw
P-value
Adjusted
P-value
Absolute
attenuation (HU)
35 secs 67.4(11.2) 74.2 (10.7) 0.08 036
(56.2, 66.7) (74.9, 78.9)
45 secs 73.7(13.5) 88.3 (20.3) 0.04 035
(63.5, 75.3) (83.6, 102.2)
Percentage of peak
liver attenuation
35 secs 49.6 (10.8) 51.4(11.3) 0.45 0.79
(35.1,42.9) (50.0,61.0)
45 secs 56.9(13.2) 59.1 (12.4) 0.66 0.96
(0,3940 (53.7, 65.2)
Percentage of peak
aortic attenuation
35 secs 20.8 (5.4) 20.6 (4.2) 0.71 0.57
(12.8, 17.1) (21.0, 23.6)
45 secs 23.7 (7.1) 24.4 (6.0) 038 0.72
(0, 17.4) (24.0, 28.5)
Results expressed as mean (SD); (95% confidence intervals). P-values reported are for
difference between gi'oups before (raw) and after adjustment for age.
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Chapter 4 : The relationship between tumour 
volume, the systemic inflammatory response and 
liver blood flow in patients with colorectal liver
métastasés.
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4.1 Introduction and Alms
There are a number of factors that are Imown to influence changes in liver blood 
flow. Serotonin (5-hydroxytryptamine or 5-HT) has been shown to increase the splanclmic 
blood flow and portal pressure (Lebrec, 1990; Hoyer et al., 1994; Li et al., 2006). The 
vasodilator nitric oxide, which is produced in the liver, is associated with an inverse 
relationship with hepatic resistance and portal pressure (Rockey et al., 1998; Moal et al., 
2006). In addition, the vasodilator prostaglandin has also been linked with nitric oxide in 
portal hypertensive rats (Fernandez et al., 1996). It has also been shown that tumour:liver 
blood flow is enhanced with the use of angiotensin II, noradrenaline and more recently with 
bradykinin receptor agonist (Hemingway et al., 1992; Dworkin et al., 1996; Shankar et al., 
1999; Emerich et al., 2001).
More recently, there has been evidence to show that the presence of an 
inflammatory response plays a significant role in the progression of a number of solid 
mmours (Coussens & Werb, 2002, Erlinger et al., 2004). Increased circulating 
concentrations of C-reactive protein, a marker of the systemic inflammatory response, are 
associated with decreased survival in patients with locally-advanced and metastatic 
gastrointestinal cancer (O’Gorman et ah, 2000; McMillan et al., 2001, McMillan et al., 
2003). It has also been shown that albumin concentrations are independently associated 
with C-reactive protein levels, but not with percentage hepatic replacement, in patients with 
colorectal liver métastasés (Al-Shaiba et al., 2004). Elahi and co-workers (2004) have also 
reported that a prognostic score combining elevated C-reactive protein concentrations and 
hypoalbuminemia may be of use for patients with gastrointestinal cancers.
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It is also laiown that C-reactive protein can be upregulated by pro-inflaininatory 
cytokines, interleukin-1, interleukin-6, and tumour necrosis factor, all of which have been 
linked to the malignant potential of tumours (Nozoe et ak, 1998; Mild et al., 2004). 
Furthermore, that pro-inflammatory cytokines, in particular interleukin-6, are released from 
colorectal tumours (Kinoslhta et ak, 1999; Miki et ak, 2004). It is possible that pro- 
inflammatory agents are associated with a hypermetabolic state in the liver, increasing 
oxygen demand and blood flow.
It remains unclear to what extent changes in liver blood flow in patients with 
colorectal liver métastasés can be explained simply by the metabolic demands of growing 
tumour tissue, whether they are related to changes in metabolic rate in normal liver tissue 
induced by pro-inflammatory cytokines, or whether they are influenced by inflammatory 
mediators in some other manner. The aim of the present study was therefore to examine 
the relationship between liver blood flow, tumour volume and the systemic inflaimiiatory 
response in patients with colorectal liver métastasés to shed further light on these issues.
Null Hypothesis
The study was designed to test the null hypothesis that increased Doppler Perfusion
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hidex, observed in patients with colorectal liver métastasés, is related to tumour volume 
and the systemic inflammatory response.
___
4.2 Patients and Methods
4.2.1 Patients
Patients who had undergone resection of a primary colorectal cancer, who then 
developed liver métastasés without evidence of extrahepatic disease and were referred for 
assessment for liver resection, were included in the study. None of the patients had 
received recent chemotherapy.
Inclusion criteria consisted of : Histologically-proven colorectal cancer; Liver 
métastasés confirmed histologically or by progression on CT.
Exclusion criteria consisted of: Anticancer treatment during the study period or 
during the preceding month; Patients cuiTently receiving or who have had non-steroidal 
anti-inflammatory drugs in the last two weeks; Patients receiving warfarin; Diagnosis of 
other liver disease or suspected cirrhosis.
All subjects were infonned of the puipose and procedure of the study and were 
given a patient information sheet, hiformed consent was given by all subjects included the 
study.
4.2.2 Outline o f Procedure
As part of their clinical workup, patients underwent contrast-enlianced dual-phase 
spiral computed tomography (CT) of the abdomen as described in Chapter 3, and these 
scans were used for the measurement of tumour and liver volume as described below. A 
blood sample was taken for the routine measurement of C-reactive protein, and in some 
patients an aliquot of serum was retained for the measurement of interleukin-6 (see Section 
4.2.4).
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Within one week of the CT scan, hepatic arterial and portal venous blood flow were 
measured using Doppler ultrasound as described in Chapter 2, and total liver blood flow 
and the Doppler Perfusion Index calculated. The blood flow measurements were 
performed without knowledge of the tumour and liver volume measurements.
The study was approved by the research ethics committee of North Glasgow 
University Hospitals NHS Trust.
fi
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4.2.3 Measurement o f Tumour and Liver Volumes and Percentage Hepatic Replacemen t |
Volume measurements were performed using a similar approach to that previously
'"41described (Purkiss & Williams, 1992; Dworkin et al, 1995). Contrast enhanced CT-scans 
were performed using a Somatom plus 4 spiral-CT scanner (Siemens AG, Munich, 
Germany). Sections were viewed on a Magic-View workstation (Siemens AG, Munich, 
Germany), and the cross-sectional areas of all the metastatic lesions in each 5 mm slice kV:
were measured by mapping their perimeters. The total tumour volume was calculated as I
the sum of the tumour area in all slices multiplied by the slice thickness. The total liver 
volume was measured in a similar manner by outlining the whole liver in each section.
Normal liver volume was calculated by subtracting the tumour volume from the total liver 1
volume. The percentage hepatic replacement was calculated as the ratio of tumour volume g
to total liver volume multiplied by 100.
To assess the reproducibility of the method used, two observers had previously 
independently measured tumour and liver volumes and percentage hepatic replacement in 
10 randomly selected patients from the above cohort. The intra-class conelation coefficient 
for agreement between obseiwers was 0.97 or greater for all comparisons. Tlmee quarters of
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4.2.5 Statistical Analysis
The relationships between blood flow variables and demographic, biochemical and 
tumour characteristics were analysed using the Mami-Whitney test and Spearman’s rank 
coiTelation analysis as appropriate, hi addition, linear regression analysis was used to 
obtain further information about tliese relationsMps. Variables were logaritlimically 
transfomied to nomialise their distributions in the regression analysis. SPSS for Windows 
(SPSS Inc., Chicago, USA) was used for analysis.
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the patient measurements were performed by Dr Al-Shaiba, as stated in the
■|
acknowledgements. |
4.2.4 Measurement o f Interleukin-6 Concentrations
hiterleukin-6 concentrations were measured using a sensitive solid-phase enzyme- 
linked immunosorbent assay (R&D Systems Europe Ltd, Abingdon, UK). The lower level 
of detection was 2.0 ng/1 and the intra-assay variability was less than 6% over the sample 
concentration range.
i
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4.3 Results
rï
Characteristics of the patients with colorectal liver métastasés (n=52) are shown in 
Table 4.1. The majority of patients were male, over the age of 65 years and had multiple 
liver tumours. The majority of patients had a percentage hepatic replacement of less than 
25% and a C-reactive protein concentration greater than lOmg/1.
Table 4.2 compares hepatic arterial flow, portal venous flow, total liver blood flow
and DPI in patients grouped by sex. and by number and localisation of métastasés. There
were no significant differences in any of the blood flow variables between each grouping.
.CoiTelation coefficients reflecting the strength of association between blood flow 
variables and continuous demogiaphic, biochemical and tumour-related variables are 
shown in Table 4.3. Hepatic arterial blood flow was correlated with tumour volume (Rs =
0.30, p=0.03, Figure 4.1), percentage hepatic replacement (Rg = 0.30, p=0.03) and C- 
reactive protein (Rg = 0.29, p=-0.04, Figure 4.2). Portal venous blood flow was not 
significantly correlated with either measure of tumour volume or with C-reactive protein.
Total liver blood flow was correlated with tumour volume (Rg = 0.31, p=0.03), percentage 
hepatic replacement (R g = 0.33, p=0.02) and C-reactive protein (R g = 0.28, p=0.05). There 
was no correlation between the blood flow variables and normal liver volume.
In patients whom interleukin-6 was measured (n=32), there was also a significant 
correlation between total liver blood flow and interleukin-6 (R g = 0.44, p=0.01, Figure 4.3).
The correlation between hepatic arterial flow and inteiieuldn-6 was not significant (R g =
0.34, p=0.06).
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Correlations between the Doppler Perfusion Index and the tumour-related and 
biochemical variables were all statistically non-significant, and were substantially weaker 
than those between hepatic arterial blood flow and the same variables.
Age-adjustment of the blood flow variables as described in Chapter 2 had minimal 
effect on the above correlation coefficients and did not alter any of the conclusions 
regarding statistical significance.
Among the biochemical and tumour variables, iiiterleuldn-6 was strongly correlated 
with C-reactive protein (R g  = 0.60, p<0.001) but not with tumour volume (R g = 0.17, 
p=0.35). However, C-reactive protein was significantly coixelated with tumour volume (Rg  
= 0.36, p=0.01).
Linear regression analysis was used to attempt to detennine which biochemical and 
tumour characteristics were independently associated with hepatic arterial and total liver 
blood flow. Associations between hepatic arterial flow and predictor variables were all of a 
similar magnitude, which failed to reach significance even in a univariate analysis 
(0.05<p<0.10). Total liver blood flow was significantly related to C-reactive protein 
(p=0.05) and interleukin-6 (p=0.01) on univariate analysis. Interleukin-6 was the strongest 
predictor of total liver blood flow, and no other variable added significant additional 
information on multivariate analysis (p>0.1).
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4.4 Discussion
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In the present study, hepatic arterial blood flow and total liver blood flow inereased 
significantly, though not strongly, with increasing tumour volume. This is consistent with 
the results of Hunt and co-workers (Hunt et ah, 1989b), who found a positive association 
between an index of hepatic arterial blood flow, derived from dynamic hepatic 
scintigraphy, and estimated percentage hepatic replacement in patients with colorectal liver 
métastasés.
A number of mechanisms could in principle explain such an association. Ridge and 
co-workers (1987) proposed the theory that métastasés are initially seeded in the liver via 
the portal venous system. As they grow they develop a vasculature derived from the 
hepatic arterial supply which increases to meet the metabolic demand. In addition, Purkiss 
(1998) proposed two theories of metastatic volume growth in the liver. The first suggests 
that metastatic growth replaces normal liver parenchyma and the second theory proposes 
normal parenchymal volume is maintained or displaced as métastasés enlarge. However it 
is likely that a combination of these factors occurs within a more complicated process and 
the growth may vary according to factors within the tumour or from factors within or 
outside the liver (Purldss SF, 1998). Larger tumours would be expected to require a greater 
arterial blood supply to meet the requirements of their own growth and metabolism. In 
addition, they might induce a progressive increase in the metabolic rate of normal liver 
tissue as an element of the host response. Furthennore, if the primary factor altering liver 
blood flow is the requirement for tumour growth and metabolism, it would be expected that 
liver blood flow would be more strongly coinelated with tumour volume than with systemic 
biochemical variables. However, the lack of coiTelation between hepatic arterial blood
flow and the volume of normal liver tissue suggests that tissue volume is not necessarily a 
reliable predictor of blood flow requirements. The contribution of tumour blood flow to the 
variations in hepatic arterial and total liver blood flow therefore remains uncertain.
It may also be possible that as growth occurs, the liver métastasés compress the 
portal venous chamiels and induce a compensatory increase in arterial blood flow (Hunt et 
ah, 1989b). This seems unlikely to be a major contributor in the present study as it would 
not explain the observed positive association between tumour volume and total liver blood 
flow. Indeed, increasing tumour volume tended to be associated with increased rather than 
reduced portal venous blood flow, although the relationship was not statistically significant.
An alternative theory is that larger tumours might alter the production of local or 
systemic vasoactive agents.
There are numerous reports that serotonin production is increased in colorectal 
cancer (Quimi et ah, 1979; Tutton & Barkla, 1982; Nitta et ah, 2001; Seretis et ah, 2001). 
Further evidence has shown a link between serotonin and liver cirrhosis and portal 
hypertension which suggests serotonin may in fact be influencing the splanclmic blood in 
these subjects (Lebrec, 1990; Hoyer et ah, 1994; Li et ah, 2006).
There has been increasing interest in the role of cyclooxygenase in the progression 
of colorectal cancer, specifically, there is increasing evidence of a linlc between 
overexpression of COX-2 in colorectal cancer tumorigenesis and other solid organ tumours 
(Taketo, 1998a, b; Hwang et ah, 1998; Uefuji et ah, 2000). Cyclooxygenase plays a key 
role in the production of prostaglandin. As an endogenous vasodilator its influence on liver 
blood flow has been shown to be linked with nitric oxide and portal hypertension 
(Fernandez et ah, 1996; Laleman et ah, 2005). It is clear that substances such as
151
prostaglandin, nitric oxide and serotonin may influence the liver blood flow in relation to 
tumour volume and further studies are required to clarify this.
Hepatic arterial and total liver blood flow had a positive association with plasma C- 
reactive protein concentration, and this was of a similar strength to their correlation with 
tumour volume. As C-reactive protein is synthesised exclusively in the liver, this 
association might reflect an increased metabolic rate in noiinal liver tissue. However, C- 
reactive protein concentration was itself correlated with tumour volume, as was also found 
by Al-Shaiba and colleagues (Al-Shaiba et ah, 2004), and it was not possible to detennine 
whether blood flow was independently related to this inflammatory marker.
There are few factors produced by liver métastasés which are loiown to evoke an 
acute phase protein response and that also have an effect on liver blood flow. The primary 
candidate is inteiieuldn-6 since it is produced by colorectal tumours, is related to tumour 
size and the presence of métastasés (Kinoshita et ah, 1999) and is a prime mediator of C- 
reactive protein production from the liver (Gabay & Kuslmer, 1999). In order to examine 
the above relationships in more detail, circulating interleukin-6 concentrations were 
analysed.
Interleukin-6 was most strongly correlated with total liver blood flow, which is 
consistent with the obseiwations of Lyngso and co-workers (2002) who reported that an 
infusion of interleukin-6 in healthy subjects was associated with an increase in splanclmic 
blood flow, hi their study, circulating interleukin-6 concentrations reached 35ng/l 
compared with approximately lOng/1 in the present study and a value of <2 ng/1 in healthy 
subjects (Wallace et ah, 2002). Therefore, elevated circulating concentiations of 
interleukin-6 may have contributed to increased total liver blood flow in the present study. 
This conclusion is strengthened by the fact tliat, unlike C-reactive protein, interleuldn-6 had
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little or no association with tumoui' volume, suggesting that its relationsliip with total liver 
blood flow was not due to a common dependence on tumour size.
Circulating interleukin-6 was more weakly correlated with hepatic arterial and 
portal venous blood flow individually, and these relationships did not reach statistical 
significance. This may be a consequence of limited numbers as there was not a large 
difference in the correlation coefficients, and a relationship with total liver blood flow 
logically implies a relationship with one or both of its two components. Lynsgo and 
colleagues concluded that the major effect of interleukin-6 on splanclmic blood flow was in 
the organs draining into the portal vein (Lynsgo et ah, 2002).
It is noteworthy that the Doppler Perfusion Index had virtually no association with 
tumour size, C-reactive protein or interleukin-6. This reflects the fact that both hepatic 
arterial and portal venous blood flow tended to increase in tandem with all of these factors. 
It is therefore likely that the mechanisms responsible for the relationships between liver 
blood flow, tumour size and the systemic inflanmiatory response witliin the population of 
patients with colorectal liver métastasés are different from those that cause an elevation of 
the Doppler Perfusion Index in these patients relative to normal controls, as described in 
Chapter 2. The fact that total liver blood flow varied with tumour volume in the present 
study, but did not differ significantly between métastasés and control patients in Chapter 2, 
as in previous studies (Leen et al., 1991b), further supports the concept that other influences 
on blood flow are involved.
This study cannot reject the null hypothesis, as increased Doppler Perftision Index 
had no association with tumour volume or the systemic inflammatory response. It is most 
likely that splanclmic blood flow is being influenced by a combination of these factors 
produced during the inflammatory process or directly by the primary tumour itself. Future
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studies investigating relationships between substances such as serotonin, bradykinin and
prostaglandins would help further elucidate the reasons for altered splanclmic 
haemodynamics in patients with colorectal liver métastasés.
Studv Limitations
The method of percentage hepatic replacement of tumour volume has yet to be 
accepted as a useful and accurate tool for the assessment of liver metastasis growth. Liver 
tumour volume is comprised of a number of components such as neoplastic cells, a vascular 
component and other stromal supporting tissues. This is also true for normal liver 
parenchyma wliich may consist of a number of components such as inti'ahepatic biliary 
system. A change in the size of a tumour expressed as either volume or percentage hepatic 
replacement could therefore be influenced by these otlrer components that may or may not 
reflect the underlying tumour cells (Purkiss SF, 1998).
A possible confounding factor in the above study is that vasoconstrictors and 
vasodilators may influence the observed alterations m liver blood flow. Further work is 
required in order to provide firm conclusions on the effects of these substances.
Unfbidunately interleukin-6 measurements were only available in 32 patients due to
■:v;
blood sample colleetion problems and time constraints. If this could have been avoided, a 
larger data set may have produced more significant results, for example shonger 
associations between hepatic arterial blood flow and interleukin-6 may have been observed.
It is also important to note that the tumour may not be the only souree of interleukin 
production. Interleukin is also secreted by phagocytic cells which in the liver are 
principally the Kuppfer cells of the reticuloendothelial system. However, it has been 
previously shown that serum interleukin-6 concentrations are strongly correlated with
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interleukin-6 concentration in the tumour tissue and with the primary tumour size 
(Kinoshita et ah, 1999).
hi summary, hepatic arterial and total liver blood flow may be modulated by 
circulating interleukin-6, a mediator of the systemic inflammatory response, in patients
-v:
with colorectal liver métastasés. They also vary with tumour volume, although the basis of 
this relationship remains unclear. It is unlikely that these mechanisms are responsible for 
the elevated Doppler Perfusion Index in patients with colorectal liver métastasés. I
%
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Table 4.1 Characteristics of patients with colorectal liver métastasés (n= 52 ).
Î
Age 71 (65-77) ■(68,74)
Sex (male / female) 30/22
Single / multiple tumours 14/38 :/
■Ï
Single / multiple lobes 33/19
Tumour volume (cm^) 75.4(16.3^01.9) „...
C26J, 178)
Percentage hepatic replacement 3.9 (1.1-16.8) ;
(2.5, 9.5) :3
(<25 / >25%) 43/9
7
C-reaetive protein (mg/1) 22(<5-87)
(8,48)
(<10 / >10 m g/1) 21/31 S
■;'ï
Interleukin-6 (ng/1)^ ' 8.9 (4.3-13.9) 1
(5.3, 11.7)
Hepatic arterial flow (ml/min) 325 (210-502)
■1
(269,428)
Portal venous flow (ml/min) 543 (416-718) ■ ?
(460,615) :
Total liver blood flow (ml/min) 927 (691-1172) ■|
(762, 1024)
i
■i'Doppler Perfusion Index 0.36 (0.28-0.48)(0.31,0.44)
Data given as median (interquartile range), (95% Confidence Inteiwals). * n=32;
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Table 4.2 Blood flow parameters in patients with liver métastasés grouped according 
to demographic and tumour characteristics.
N HAF
(ml/min)
PVF
(ml/min)
TLBF
(ml/min)
DPI
Sex
Male 30 325 524 916 0.34
(197, 495) (404, 695) (691, 1103) (0.26, 0.48)
(248, 390) (428, 652) (744, 1028) (0.28, 0.46)
Female 22 324 550 930 0.39
(223, 601) (421, 754) (643, 1436) (0.32, 0.56)
(233,599) (423,728) (656, 1432) (0.32, 0.56)
P-value 0.52 0.63 0.63 0.22
No. métastasés
Single 14 290 552 947 0.35
(188,571) (478, 754) (683,1248) (0.24, 0.42)
(179, 599) (416,833) (677,1432) (0.24, 0.44)
Multiple 38 330 523 916.26 0.36
(248, 497) (412,675) (691, 1087) (0.30,0.51)
(270, 439) (428,615) (761, 1024) (0.31,0.46)
P-value 0.63 0.39 0.74 0.36
Location of
métastasés
1 Lobe 33 325 558 938 0.35
(185,499) (407, 781) (602, 1212) (0.29, 0.44)
(203,471) (475, 700) (685, 1145) (0.30, 0.42)
2 Lobes 19 325 493 858 0.40
(258,493) (426,662) (756, 1013) (0.30, 0.50)
(248, 546) (423,672) (751, 1049) (0.28,0.51)
P-value 0.61 0.64 0.98 0.41
Data given as median (interquartile range), (95% Confidenee Intervals). HAF, hepatic 
arterial blood flow; PVF, portal venous blood flow; TLBF, total liver blood flow; DPI, 
Doppler Perfusion Index.
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Table 4.3 CoiTelations between blood flow parameters and demographic, biochemical 
and tumour characteristics (n=52).
HAFV PVFV TLBF DPI
Age
Rs 0.21 -0.13 0.07 0.23
P-value 0.14 0.34 0.62 0.11
NLVoI
Rs 0.07 0.08 0.13 -0.01
P-value 0.60 0^8 0.35 0.92
Tvol
Rs 0.30 0.19 0.31 0.16
P-value 0.03 0.17 0.02 0.25
PHR
Rs 0.30 0.22 0.33 0.16
P-value 0.03 0.12 0.02 0.27
CRP
Rs 0.29 0.13 OJ# 0.19
P-value 0.04 0.37 0.05 0.18
IL-6
Rs 0.34 R28 0.44 0.11
P-value 0.06 0.13 0.01 0.56
II
1
;
%
I
tw
Data given as Speamian rank correlation coefficient and p-value. * n=32; HAF, hepatic 
arterial blood flow; PVF, portal venous blood flow; TLBF, total liver blood flow; DPI, 
Doppler perfusion index; NLVol, nonnal liver volume; TVol, tumour volume; PHR, 
percentage hepatic replacement; CRP, C-reactive protein; IL-6, interleukin-6.
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Figure 4.1 Relationship between hepatic arterial blood flow (HAF) and 
tumour volume (TV) in patients with liver métastasés. The equation of the
regression line is HAF = 230 x TV^^ ml/min
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Figure 4.2 Relationship between hepatic arterial blood flow (HAF) and 
plasma C-reactive protein (CRP) in patients with liver métastasés. The
equation of the regression line is HAF = 233 x CRP° ml/min
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Figure 4.3 Relationship between total liver blood flow (TLBF) and 
plasma interleukin-6 (IL-6) in patients with liver métastasés. The equation
of the regression line is TLBF = 614 x IL-6® ml/min
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Chapter 5 : The effect of anti-inflammatory 
treatment on liver blood flow in patients with 
colorectal liver métastasés.
■
1■Î5;I
":c
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5.1 Introduction
response in patients with colorectal liver métastasés.
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The mechanisms by which the presence of metastatic disease might stimulate 
both alterations in liver blood flow and a systemic inflammatory response have not as 
yet been clearly defined. As noted in the previous chapter, there is increasing evidence 
that pro-inflammatory cytokines, in particular interleukin-6, are released from the
tumour (Kinosliita et al., 1999; Miki et al., 2004). It may be that this release of pro-
................................................inflammatory cytokines is associated with a hypermetabolic state in the liver increasing
oxygen demand within tire liver. Indeed, interleukin-6, the principal regulator of the
acute phase protein response (Gabay & Kuslmer, 1999), is associated with an increase
in liver blood flow (Lyngso, 2002). It is therefore possible that changes in liver blood
flow are at least partly secondary to a systemic inflammatory response in patients with
colorectal cancer.
In Chapter 4 it was suggested that, although hepatic arterial and total liver blood 
flow were correlated with circulating levels of C-reactive protein and interleukin-6, the 
influence of inflammatory mediators on blood flow was unlikely to account for the
.■=
increase in DPI in patients with colorectal liver métastasés. The aim of the present 
study was to examine the effect of an anti-inflammatory treatment on liver blood flow 
in patients with colorectal liver métastasés in order to further elucidate the 
haemodynamic effects of the systemic inflammatory response. Therefore the study was 
designed to test the null hypothesis that there is no relationship between alterations in
liver blood flow, increased Doppler Perfusion Index, and the systemic inflammatory
5.2 Patients and Methods
5.2.1 Patients
Patients who had undergone resection of a primary colorectal cancer, who then 
developed liver métastasés without evidence of extrahepatic disease and were referred for 
assessment for liver resection, were included in the study. None of the patients had 
received recent chemotherapy.
métastasés confirmed histologically or by progression on CT; Baseline C-Reactive protein 
greater than lOmg/1; Baseline Doppler Perfusion Index greater than 0.30.
Exclusion criteria consisted of : Anticancer treatment during the study period or 
during the preceding month; Patients currently receiving or who have had non-steroidal 
anti-inflammatory dmgs in the last two weeks; Patients receiving warfarin; Previous 
adverse reaction to non-steroidal anti-inflammatory drugs; Prior history of peptic 
ulceration; Diagnosis of other liver disease or suspected cirrhosis.
5.2.2 Methods
Hepatic arterial and portal venous blood flow was measured using Doppler 
ultrasound, and total liver blood flow and the Doppler Perfusion Index calculated as 
described in Chapter 2. In addition a blood sample was taken for the routine measurement 
of C-reactive protein, and an aliquot of serum was retained for the measurement of 
interleukin-6 as described in Chapter 4. Percentage hepatic replacement was measured in 
the majority of patients, also as described in Chapter 4.
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Inclusion criteria consisted of : Histologically-proven colorectal cancer; Liver
‘13:i3
Patients were then randomly assigned to receive either ibuprofen (1200mg/day) or 
placebo for approximately one week. Liver blood flow and C-reactive protein and 
interleukin-6 measurements were then repeated. The study was conducted in a double­
blind manner, and the treatment each patient received was revealed only after all data had 
been recorded.
The principle outcome measures were Doppler Perfusion Index, absolute and 
change from baseline value; and C-reactive protein to confiim efficacy of treatment.
The study was approved by the research ethics committee of North Glasgow 
University Hospitals NHS Trust. All subjects were informed of the purpose and procedure 
of the study and were given a patient information sheet. Written informed consent was 
given by all subjects included the study.
5.2.3 Powder Calculation
A power calculation was performed to determine the number of patients to be 
recruited. The change in the Doppler Perfusion Index from baseline level was selected as 
the most important outcome measure. On the basis of pilot data, it was estimated that the 
standard deviation of this measure within a treatment group would be of the order of 0.10 
units. A standard power calculation showed that 16 patients per group would be required to 
detect a mean difference between the two groups of 0.10 units at the 5% significance level 
with 80% power. Allowing for a 10% dropout rate and a 5% increase in numbers to 
compensate for the use of non-parametric statistical analysis, it was plamred to recruit 40 
patients in total.
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5.2.4 Statistical Analysis
Comparisons between the two treatment groups were performed using the Mami- 
Whitney test and Fisher’s exact test. Comparisons between baseline and post-treatment 
data within each group were perfomied using the Wilcoxon signed ranlc test. SPSS for 
Windows (SPSS Inc., Chicago, IL, USA) was used for analysis.
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5.3 Results
Recruitment was slower than expected, and within the time available only 29 
patients entered the study. Post-treatment blood flow measurements could not be 
performed in 6 of these patients as they subsequently underwent procedures such as 
surgical resection, tiunour ablation or the administration of chemotherapy. Of the 23 
patients who completed the study, 12 received ibuprofen and 11 received placebo.
Baseline demographic, blood flow and biochemical characteristics for the two 
treatment groups are shown in Table 5.1. There were no significant differences in any of 
these variables between the groups before starting treatment. Twenty patients in total had a 
Doppler Perfusion Index of greater than 0.25 at baseline. However only 8 patients (67%) in 
the ibuprofen group and 8 patients (73%) in the placebo group that had a DPI of greater 
than 0.25, completed the study. Unexpectedly, however, only 11 patients in total (3 in the 
ibuprofen group and 6 in the placebo group of which completed the study) had a baseline 
C-reactive protein concentration of gireater than 10 mg/l, and only 8 patients (one in the 
ibuprofen group and 5 in the placebo group of which completed the study) had a baseline 
interleukin-6 level above the detection tlireshold of 2 ng/1.
The second set of measurements was performed after a median of 7 days of 
treatment in each group (range 5-8 days for ibuprofen and 4-8 days for placebo). Changes 
from baseline values in the blood flow and biochemical variables are shown in Table 5.2. 
There were no statistically significant changes from baseline values in any of the variables 
in either group. There were also no significant differences between groups in the changes 
in any of the variables. After treatment, 5 patients (42%) in the ibuprofen group and 8 
patients (73%) in the placebo group had a Doppler Perfusion Index of greater than 0,25.
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5.4 Discussion
In the present study, there was no significant alteration in circulating levels of C- 
reactive protein or interleukin-6 following treatment with either ibuprofen or placebo. 
However, only 9 of the 23 patients entered into the study had evidence of a systemic 
inflammatory response at baseline, and only 3 of these received ibuprofen. This was 
surprising, since in the previous chapter as well as in previous studies (Kinoshita et al. 
1999; Al-Shaiba et al. 2004) the majority of patients with colorectal liver métastasés had 
elevated concentrations of interleuldn-6 and/or C-reactive protein. It would appear that, in 
this treatment study, a subpopulation with a low prevalence of systemic inflammation was 
recmited. This is consistent with the low median percentage hepatic replacement, 
approximately 2%, compared with a median of 7% in the study by Al-Shaiba and 
colleagues, for example (Al-Shaiba et ah, 2004). Possible explanations for this pattern 
include an unconscious bias towards the selection of fitter patients for this study, or a 
greater tendency of patients with more inflaimnation to fail to complete it.
In view of the low level of inflaimnation at baseline, it is perhaps not smprising that 
treatment with ibuprofen, as with placebo, did not result in a significant change in hepatic 
arterial, portal venous or total liver blood flow. It was therefore not possible to confirm that 
any component of liver blood flow is modulated by mediators of the inflammatory response 
in patients with liver métastasés.
Approximately 70% of patients in each treatment group had a baseline Doppler 
Perfusion Index greater than 0.25, the tlneshold identified in Chapter 2 as providing the 
best discrimination between patients with liver métastasés and normal controls. After 
treatment with ibuprofen the proportion with an elevated Doppler Perfusion Index fell non-
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significantly to 42%, while in the placebo group it remained static. This is consistent with 
the conclusion reached in Chapter 4 that the systemic inflaimnatory response is unlikely to 
be primarily responsible for the increase in the Doppler Perfusion Index in patients with 
liver métastasés, although the low level of inflammation in the present study limits its 
power to test that conclusion.
The power of this study was also limited by a lower than expected rate of 
recruitment and the failure of 20% of patients recruited to complete the study. The effect of 
this was to increase the minimmn difference between groups in the change in Doppler 
Perfusion Index that could be detected with 80% power from 0.10 to 0.12. Hence a large 
treatment effect, for example a reduction of the Doppler Perfusion Index in tire ibuprofen 
group to normal control level, would still have been detectable.
It is therefore reasonable to conclude that this study confirms that the systemic 
inflammatory response does not wholly explain the abnormalities in liver blood flow in 
patients with colorectal liver métastasés, and that its contribution to the elevated Doppler 
Perfusion Index in these patients is likely to be small. The null hypothesis cannot be 
rejected on this basis and further work is required in this area.
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Future Studies
It is clear that further work in this area is required to provide more conclusive data. 
In particular, a similar investigation with a larger patient population and a longer duration 
of study would be beneficial. One limiting factor was the availability of time to study each 
patient. Ideally, a 14 day period at least would have provided the opportunity for each 
patient to act as their own control. For example, administering placebo for 7 days, 
performing study measurements and then administering ibuprofen for a further 7 days 
before performing the final set of measurements. This study time frame was not possible 
within the range of this project as, understandably, medical or surgical intervention often 
occuiTed within a very short period from diagnosis.
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Table 5.1 Baseline characteristics and liver blood flow in patients with colorectal liver 
métastasés receiving ibuprofen or placebo, including subjects who did not complete the 
trial.
Ibuprofen
(n=14)
Placebo
(11=15)
P-value
Age (years) 74 (66, 77) 72 (64, 74) 0.33
(66, 75) (65, 80)
Sex (male/female) 8/6 9/6
Percentage hepatic 1.6 (0.9, 10.1) 3.0 (0.6, 62.9) 0.76
replacement (%)* (0.7, 13) (0.5, 90)
C-reactive protein (mg/l)** 7.0 (1.6, 33) 14.0 (-2.0, 99) 0.63
(6.0, 25) (6.0, 160)
Interleukin-6 (ng/1)** 2.0 (1.0, 6.9) 3.75 (-4.8, 43) 0.13
(2.0, 12) (2.0, 34)
Hepatic arterial blood flow 280 (187, 469) 277 (206, 332) 0.16
(ml/min) (107, 495) (167, 346)
Portal venous blood flow 516 (439, 667) 537 (403, 843) 1.0
(ml/min) (374, 700) (318,817)
Total liver blood flow 803 (702, 1059) 762 (630,1154) 0.69
(ml/min) (691, 1096) (584, 1073)
Doppler Perfusion Index 0.42 (0.27, 0.46) 0.31 (0.26, 0.37) 0.49
(0.14,0.51) (0.24, 0.40)
%
Data given as median (interquartile range), (95% confidence intervals). * n=9 in each 
group; n=10 Ibuprofen; n=12 Placebo.
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Ibuprofen
(n=12)
Placebo
(n=ll)
P-value
C-reactive protein (mg/l) 0.0 (-3.5, 0.0) 0.0 (-1.5, 0.0) 0.51
(-9, 0.0) (-5, 24)
Interleukin-6 (ng/1) 0.0 (0.0, 0.0) 0.0 (0.0, 11.5) 0.72
(-2, 0.0) (-4.5, 16.3)
Hepatic arterial blood flow -28 (-157, 95) 13 (-55, 126) 0.41
(ml/min)
(-257, 126) (-55, 152)
Portal venous blood flow -3 (-122, 173) -25 (-192, 125) 0.76
(ml/min)
(-139, 362) (-198, 142)
Total liver blood flow -121 (-214, 127) 56 (-157, 262) 0.45
(ml/min)
(-253, 194) (-252,317)
Doppler Perfusion Index -0.03(-0.12, 0.01) 0.09 (-0.05,0.13) 0.14
(-0.28, 0.02) (-0.06, 0.18)
Table 5.2 Changes in blood flow and biochemical data following treatment in patients 
receiving ibuprofen or placebo.
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Data given as median (interquartile range), (95% confidence intervals). Positive and 
negative changes represent increases and decreases respectively relative to baseline values.
None of these changes was significantly different from zero (p>0.05). Tabulated p -values 
ai'e for comparison of changes between ibuprofen and placebo.
171
Chapter 6 : Discussion and Conclusions
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Since its development in 1991, the Doppler Perfusion Index has been evaluated by a 
number of research groups interested in the blood flow changes associated with colorectal 
liver métastasés. The majority of studies agree that the Doppler Perfusion Index is 
increased in patients with colorectal liver métastasés relative to normal controls, and that 
this is due partly or wholly to an increase in hepatic arterial blood flow (Leen et ah, 1991a; 
Guadagni et al., 2000; Kruger et al., 2000). There is conflicting evidence however, on 
whether portal venous blood flow is reduced or unchanged (Di Giulio et al. 1997; Oktar et 
al., 2006). The results of Chapter 2 confiiin the increase in hepatic arterial blood flow and 
Doppler Perfusion Index, but suggest that portal venous blood flow would not have differed 
significantly had a fully age-matched gi'oup of controls been studied. Although a reduction 
in portal venous blood flow and total liver blood flow with age has been reported in the 
gerontological literature (Zoli et al., 1989; Zoli et al., 1999), it has not previously been 
noted in studies of liver blood flow in cancer, and it is imclear whether the conflicts in the 
literature noted above reflect differences in the degree of age matching. It is clear 
therefore, that age should be considered when interpreting the Doppler Perfusion hidex and 
similar indices in clinical practice. Furthermore, it is Imown that colorectal tumours are 
more aggressive when occurring in younger patients (Leff et al., 2007). For example, 
young patients with a Duke’s stage B tumour are more likely to be treated aggressively 
with chemotherapy than older patients. Age coiTecting the Doppler Perfusion Index for this 
reason may have positive implications on prognostic accuracy.
The strongest evidence for a reduction in portal venous blood flow associated with 
liver métastasés comes from animal studies. Hepatic Perfusion Index was previously 
measured in rats inoculated with hypeiwascular Walker 256 carcinosarcoma cells. It was 
shown that an increased HPl was as a result of decreased portal venous flow, resulting in
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elevated portal pressure, splanchnic vascular resistance and portal venous resistance (Nott 
et ah, 1987; Nott et ah, 1989). Subsequently, studies utilising the hypo vascular HSN 
sarcoma cells, which are more representative of human metastasis, were performed in rats. 
A significant increase in HPl was reported again as a result of decreased portal venous 
flow. However, in contrast to previous findings there was no evidence of an increase in 
portal venous pressure or arteriovenous shunting (Hemingway et al., 1991). Furthermore, 
Yannenitis and co-workers (2000) reported increased Doppler Perfusion Index, increased 
hepatic arterial flow and a less prominent decrease in portal venous flow in rats bearing 
Walker 256 earcinosareoma cells.
It can be concluded that the Hepatic Perfusion Index and Doppler Perfusion Index 
are increased in animals bearing liver métastasés, however the mechanisms behind these 
changes are contradictory. The hypeiwascular tumour model has been shown to alter liver 
blood flow as early as 4 days from inoculation (Yannenitis et al., 2000) and cause a degree 
of arteriovenous shunting (Nott et al., 1987; Nott et al., 1989) however, the growth pattern 
of this tumour type is atypical of the majority of human colorectal liver métastasés (Taylor 
et al., 1978; Goldberg et al., 1987; Braimigan et al., 2004). It has also been shown that the 
blood vessels supplying colorectal liver métastasés are typically immature and lacldng in 
both smooth muscle cells and immunoreactive neiwes (Asliraf et al., 1997). These 
observations led to the alternate hypothesis that systemic humoral vasoactive agents are 
responsible for mediating the changes in liver blood flow through vasoconstriction in the 
splanclmic system, however exactly which substances are linlced remains to be seen. The 
results of Chapter 2 do not exclude the possibility that such agents play a role, but refocus 
attention on the increase in hepatic arterial blood flow, which cannot be attributed entirely 
to a response to reduced portal venous blood flow.
174
It is known that the hepatic buffer response maintains total hepatic flow, in 
particular, hepatic arterial flow is autoregulated to compensate for any alterations in portal 
venous flow. Portal venous flow is also regulated by splanclmic blood flow and hepatic 
arterial resistance (Lautt, 1985; Lautt, 1996). It could be expected therefore that discrete 
alterations in hepatic arterial or portal venous flow are less effective in Inglilighting trends 
compared to haemodynamic ratios such as the Hepatic Perfusion Index and Doppler 
Perfusion Index. That provides no guarantee, however, that the Doppler Perfusion Index is 
an optimum index. Logistic regression analysis yielded the Dual Flow Index (DFl), which 
was objectively derived to maximise discriminatoiy power. However, the gain in accuracy 
was not enough to justify its greater complexity in practical use.
There was no evidence in this study that liver blood flow was mediated by the 
presence of a primary colorectal tumour. This is consistent with a previous report by Oppo 
and co-workers (2000). It is of interest that the presence of a primary colorectal tumour in 
humans has been shown to inliibit angiogenesis of its liver metastasis and that peritumoural 
and intratumoural vascular density are increased significantly following subsequent 
removal of the primary tumour (Peeters et al., 2004). Fuither work in this area may yield 
mteresting results by studying liver blood flow in patients with liver métastasés before and 
after removal of a primary tumour; moreover by documenting hepatic alterations in patients 
pre- and post-resection/ ablation of liver métastasés.
CuiTently there is no reliable method for the detection of occult liver métastasés and 
clinicians rely on a number of prognostic factors when treating patients. The Doppler 
Perfusion Index however has not gained wide acceptance as a teclmique for routine use in 
the evaluation of patients with colorectal cancer, and this must be partly attributable to its 
perceived operator dependence (Glover et al., 2002; Roumen et al., 2005). As contrast-
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7enlianced CT imaging has become more widely used, it potentially offers the opportunity to 
utilise infonnation regarding blood flow encoded in the contrast uptake cuiwes in the liver. 
There is stiong evidence in the literature that single-slice bolus contrast injection CT 
protocols can provide that information in an accessible form (Miles et al., 1993), but it is 
far less certain that it can be obtained as a by-product of CT studies designed to image the 
whole liver (Sheafor et al., 2000). The results of Chapter 3 suggest that this teclmique is 
not as robust as the Doppler ultrasound method in detecting differences in blood flow 
between different patient gioups, and that further studies are required using age matched 
normal subjects as a reference.
There were difficulties in obtaining appropriate control data for this CT study that to
some extent limit the conclusion. Most incidental patients with no abnormality were
filtered out at the first stages of clinical investigation such as ultrasound or X-ray. Patients
with small benign liver haemangiomas who required dual-phase CT for lesion
characterisation were chosen as one control gi'oup, however, numbers were limited and they
.were poorly age matched with patients with liver métastasés. Differences in CT parameters 
were found, but they were in the opposite direction to what was expected, and they 
disappeared after age adjustment. Patients who had a negative follow up scan after 
resection of a primary colorectal tumour provided an alternative study cohort, as they were 
both more numerous and well matched for age. Although the presence of occult 
micrometastases in these patients could not be ruled out, liver blood flow was expected to 
differ from patients with overt liver métastasés. However, no differences in their CT 
parameters were obseiwed. This may have been a consequence of micrometastatic disease 
or a lack of sensitivity of the protocol and teclmique as a whole.
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In future, alternative methods such as Magnetic Resonance Imaging (MRI) may 
prove more useful. MRI can provide the means of assessing liver perfusion without the 
radiation burden associated with CT, allowing valuable data to be collected on noiinal 
control subjects. Fuilhermore, software developments in both MRI and CT may provide a 
faster and more automated means of measuring regions of interest in every slice, 
throughout a whole scan. Initial studies using MRI by Totman and co-workers (2005) have 
reported promising results. A significantly reduced portal perfusion and increased HPl was 
reported in patients with colorectal liver métastasés compared to control subjects (referred 
for routine contrast spine imaging with no neoplastic disease).
There is likely to remain some degree of conflict between the requirements of 
conventional imaging studies and protocols optimised for obtaining haemodynamic 
information. Further work investigating liver blood flow by Doppler ultrasound 
concuiTently with liver perfusion studies by CT or MRI, may generate interesting data and 
help produce a standardised technique for the early detection of occult liver métastasés.
The mechanisms underlying the blood flow changes associated with colorectal liver 
métastasés remain a subject of interest. There is growing evidence that the presence of a 
systemic inflammatory response is an important stage-independent prognostic factor in 
colorectal cancer (O’Gorman et al., 2000; McMillan et al., 2001, McMillan et al., 2003). 
lnterleukin-6, a mediator of this response, is known to alter splanchnic blood flow (Gabay 
& Kuslnier, 1999; Lyngso et al., 2002). It is also of interest that, as part of the systemic 
inflammatory response following sui'gical injury, portal venous blood flow has been 
reported to fall whereas hepatic arterial flow is increased (Souba & Wilmore, 1983). The 
studies in Chapters 4 and 5 were designed to clarify the role of the systemic inflammatory 
response in the blood flow changes associated with colorectal liver métastasés. The results
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of the first study suggest to some degree, that total liver blood flow is modulated by 
iiiterleukin-6, probably by an effect on both the hepatic arterial and portal venous 
components. It is also possible that numerous other factors may be influencing liver blood 
flow, for example, nitric oxide, serotonin and endothelin-1 (Quinn et ah, 1979; Mylne et 
ah, 1993; Hongzhi et al., 2005; Kuro et al., 2006). The modulation of liver blood flow by 
interleukin-6 cannot however account for the differences in hepatic arterial flow and 
Doppler Perfusion Index obseiwed in patients with colorectal liver métastasés and controls.
The hypothesis that hepatic arterial blood flow is increased simply to meet the 
metabolic demands of growing hepatic tumours was one of the earliest to be proposed 
(Ridge et al., 1987; Purkiss SF, 1998). The observed correlation between hepatic arterial 
blood flow and tumour volume is consistent with this mechanism playing some part in the 
increase, but it seems unlikely to account for it entirely. It would be expected that total 
liver blood flow would be more strongly corrolated with tumour volume than with systemic 
biochemical variables. The contribution of tumour blood flow to the variations in hepatic 
arterial and total liver blood flow therefore remains uncertain
Hence, the tumour volume effect, like the interleukin-6 effect, may influence 
hepatic haemodynamics to some degree but does not elucidate the alterations in liver blood 
flow observed to date. The hypothesis that the increase in hepatic arterial blood flow is 
secondary to compression of portal venous channels by tumour is likewise unsupported by 
this study.
Despite the limitations of the inteiwention study with ibuprofen, the results indicate 
consistency with the conclusion that the systemic inflammatory response cannot fully 
account for the changes in liver blood flow in patients with colorectal liver métastasés. 
Unfortunately recruitment was lower than expected and the time frame in which to study
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each patient was restiictive. Furthennore, unexpected low levels of baseline C-reactive 
protein and Doppler Perhision Index values in the study patients limit the power to draw 
film conclusions. Possible explanations for this include the unconscious bias to select fitter 
patients for the study. Further work in this area would benefit from a similar study using a 
large cohort of liver métastasés patients iixespective of status, with a longer period of 
investigation for each patient.
Future studies should also be directed towards alternative mechanisms that might 
alter hepatic arterial blood flow without a substantial alteration in portal venous blood flow. 
For example, it is possible that the presence of liver métastasés dismpts the set point of the 
hepatic arterial buffer response. It is Imown that adenosine and ATP (adenosine-5- 
tiiphosphate) are key mediators in the hepatic arterial buffer response, influencing hepatic 
artery dilation to maintain total hepatic blood flow at a constant level (Lautt, 1985; Lautt, 
1996; Dominic et al., 2003). Indeed, there is evidence that patients with liver métastasés 
have a relative decrease in liver ATP levels, as measured by Magnetic Resonance 
Spectroscopy, compared with nonnal subjects (Brinkmann et al., 1997; Bell & Bhakoo, 
1998).
A comparison of the changes in liver blood flow, as measured by colour Doppler 
ultrasound, and changes in liver adenosine, ATP and nitric oxide levels, would be of 
considerable interest in patients with colorectal liver métastasés.
Î•:S'
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Appendix 1 Reproducibility studies
Table A Intra-obseiwer variation between Doppler Perfusion Index (DPI)
measurements.
Patient
No.
1®^ Observation 2”*’ Observation Mean Difference
1 0.19 0.21 0.20 -0.02
2 0.59 0.44 0.52 0.15
3 0.35 0.33 0.34 0.02
4 0.31 0.49 0.40 -0.18
5 0.57 0.52 0.54 0.05
6 0.30 0.24 0.27 0.06
7 0.36 0.33 0.34 0.03
8 0.34 0.27 0.30 0.07
9 0.56 0.27 0.41 0.29
10 0.24 0.20 0.22 0.04
11 0.30 0.21 0.26 0.09
12 0,46 0.58 0.52 -0.12
13 0.32 0.55 0.43 -0.22
14 0.48 0.69 0.59 -0.22
15 0.09 0.07 0.08 0.02
16 0.21 0.30 0.25 -0.09
17 0.28 0.39 0.33 -0.11
18 0.30 0.32 0.31 -0.02
Mean 0.35 0.36 0.35 -0.01
SD 0.14 0.16 0.13 0.13
Î1viaI
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Table B Inter-obsei*ver variation betv^een liver blood flow values measured by 
Doppler ultrasound.
No.
TLBF
1
TLBF
2
HAF
1
HAF
2
PVF
1
PVF
2
HA
TAM
1
HA
TAM
2
HA
XSA
1
HA
XSA
2
PV
TAM
1
PV
TAM
2
PV
XSA
1
PV
XSA
2
I 750.00 670.50 324.00 346.50 426.00 706.92 22.50 27.50 0.24 0.21 10.00 13.70 0.71 0.86
2 762.00 585.84 207.00 378.84 555.00 590.64 15.00 15.40 0.23 0.41 12.50 10.70 0.74 0.92
3 685.23 354.03 166.83 187.20 518.40 1035.72 8.30 12.00 0.34 0.26 7.20 12.60 1.20 1.37
4 602.49 359.76 86.52 273.24 515.97 1109.76 10,30 20.70 0.14 0.22 9.10 13.60 0.95 1.36
5 990.96 524.40 191.76 332.64 799.20 1382.40 18.80 19.80 0.17 0.28 14.80 18.00 0.90 1.28
6 439.20 146.52 48.60 97.92 390.60 615.60 13.50 10.20 0.06 0.16 9.30 10.80 0.70 0,95
7 915.54 386.76 193.38 193.38 722.16 722.16 29.30 29.30 0.11 0.11 10.20 10.20 1.18 1.18
8 1233.90 716.58 348.30 368.28 885.60 1098.36 21.50 19.80 0.27 0.31 18.00 16.20 0.82 1.13
9 626.40 459.00 135.00 324.00 491.40 922.32 9.00 18.00 0.25 0.30 9.00 12.60 0.91 1.22
10 1203.66 475.44 153.90 321.54 1049.76 1069.20 17.10 23.30 0.15 0.23 16.20 16.20 1.08 1.10
11 1276.38 308.04 135.24 172.80 1141.14 1350.00 9.80 14.40 0.23 0.20 14.30 18.00 1.33 1.25
TLB F Total liver blood flow (nil/min); HAF Flepatic artery flow volume (ml/min); PVF 
Portal venous flow volume (ml/min); HAT AM Hepatic artery time-averaged velocity 
(cm/s); HAXSA Hepatic artery cross sectional area (cni^); PVT AM Portal vein time- 
averaged velocity (cm/s); PVXSA Portal cross sectional area (cni^).
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Table c  Inter-obseiver variation between Doppler Perfusion Index (DPI) 
measurements.
Patient
No.
1®* Observer 
(JM)
2”^  Observer 
(PG)
Mean Difference
1 0.43 0.33 0.38 0.10
2 0.27 0.39 0.33 -0.12
3 0.24 0.15 0.20 0.09
4 0.14 0.20 0.17 -0.05
5 0.19 0.19 0.19 0.00
6 0.11 0.14 0.12 -0.03
7 0.21 0.21 0.21 0.00
8 0.28 0.25 0.27 0.03
9 0.22 0.26 0.24 -0.04
10 0.13 0.23 0.18 -0.10
11 0.11 0.11 0.11 -0.01
Mean 0.21 0.22 0.22 -0.01
SD 0.10 0.08 0.08 0.07
D'Observer JM, John MacQuarrie; 2"^  Observer PG, Paul Glen.
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Appendix 2 Liver blood flow values as measured by Doppler ultrasound
T able A Control Subjects.
No
MO
FI Date DPI Age DPI TLBF HAF PVF HATAM PVT AM HA XSA PVXSA
1 1 13-Jul-OO 50 0.20 2016.75 409.41 1607.34 23.78 8.90 0.29 3.01
2 1 08-Aug-00 60 0.21 1120.96 236.44 884.52 25.10 16.80 0.16 0.88
3 1 08-Aug-00 38 0.06 1201.30 68.33 1132.97 15.60 17.05 0.07 1.11
4 0 10-Aug-00 25 0.20 1619.53 321.30 1298.23 19.13 19.23 0.28 1.13
5 0 07-Sep-00 68 0.19 845.10 162.00 683.10 10.80 9.00 0.25 1.27
6 1 12-Dec-OO 29 0.15 563.87 83.87 480.00 13.10 10.00 0.11 0.80
7 0 13-Jan-01 25 0.21 671.93 140.45 531.48 8.67 10.30 0.27 0.86
8 1 19-May-Ol 54 0.17 506.52 85.32 421.20 7.90 15.60 0.18 0.45
9 1 20-Jun-01 33 0.14 1681.56 233.28 1448.28 16.20 16.20 0.24 1.49
10 0 21-Jun-01 24 0.12 627.62 78.08 549.55 8.68 10.07 0.15 0.91
11 1 10-Jul-01 28 0.13 915.77 119.02 796.76 16.53 13.69 0.12 0.97
12 1 16-Aug-01 65 0.14 963.84 137.28 826.56 17.60 16.80 0.13 0.82
13 0 17-Aug-01 25 0.16 929.94 147.90 782.04 14.50 13.30 0.17 0.98
14 0 08-Sep-01 57 0.17 915.30 153.00 762.30 12.75 12.10 0.20 1.05
15 0 11-Oct-Ol 37 0.34 1068.12 368.28 699.84 34.10 16.20 0.18 0.72
16 1 01-Feb-02 28 0.24 812.08 197.44 614.64 15.67 7.88 0.21 1.30
17 1 01-Feb-02 30 0.13 573.41 74.38 499.03 10.33 9.56 0.12 0.87
18 0 01-Feb-02 25 0.22 1173.09 260.48 912.61 14.97 12.89 0.29 1.18
19 0 21-May-02 47 0.25 742.68 182.70 559.98 17.40 15.30 0.18 0.61
20 1 14-Oct-02 57 0.28 1233.90 348.30 885.60 21.50 18.00 0.27 0.82
21 1 14-Oct-02 43 0.11 1359.90 151.20 1208.70 18.00 19.75 0.14 1.02
22 0 14-Oct-02 77 0.22 626.40 135.00 491.40 9.00 9.00 0.25 0.91
23 0 15-Oct-02 34 0.13 1203.66 153.90 1049.76 17.10 16.20 0.15 1.08
24 1 15-Oct-02 21 0.11 1276.38 135.24 1141.14 9.80 14.30 0.23 1.33
25 0 18-Oct-02 49 0.15 1155.42 177.24 978.18 21.10 13.70 0.14 1.19
26 0 18-Oct-02 50 0.20 1101.96 214.92 887.04 19.90 17.60 0.18 0.84
27 1 18-Oct-02 56 0.17 761.40 129.60 631.80 12.00 13.50 0.18 0.78
28 1 24-Oct-02 29 0.19 990.96 191.76 799.20 18.80 14.80 0.17 0.90
29 1 29-Oct-02 58 0.11 439.20 48.60 390.60 13.50 9.30 0.06 0.70
30 0 29-Oct-02 56 0.21 915.54 193.38 722.16 29.30 10.20 0.11 1.18
31 1 29-Oct-02 49 0.13 1448.76 192.96 1255.80 13.40 16.10 0.24 1.30
32 0 05-Mar-01 88 0.16 521.94 82.38 439.56 13.73 11.10 0.10 0.66
33 0 17-Jan-02 66 0.12 783.10 90.21 692.89 9.70 10.13 0.16 1.14
34 0 19-NOV-02 63 0.13 1318.80 165.12 1153.68 17.20 21.85 0.16 0.88
35 0 17-Jan-02 68 0.21 569.76 120.96 448.80 14.40 9.35 0.14 0.80
36 0 08-0ct-01 70 0.51 699.96 357.96 342.00 31.40 6.00 0.19 0.95
37 0 30-Apr-01 45 0.54 1034.00 555.92 478.08 84.23 8.30 0.11 0.96
M Male F Female; DPI Doppler perfusion index; TLBF Total liver blood flow (ml/min); 
HAF Hepatic artery flow volume (ml/min); PVF Portal venous flow volume (ml/min); 
HAT AM Hepatic artery time-averaged velocity (cm/s); HAXSA Hepatic artery cross 
sectional area (cnf); PVT AM Portal vein time-averaged velocity (cm/s); PVXSA Portal 
cross sectional area (cm^).
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Table B Patients with liver métastasés alone.
No
MO
FI Date DPI Age DPI TLBF HAF PVF HATAM PVT AM HA XSA PVXSA
1 1 22-Aug-OO 72 0.59 3015.52 1782.27 1233.25 103.50 18.03 0.29 1.14
2 1 06-0ct-00 78 0.39 1448.13 561.96 886.17 44.60 10.90 0.21 1.36
3 23-Nov-00 62 0.79 1007.45 795.90 211.55 37.90 4.83 0.35 0.73
4 08-Dec-00 35 0.22 1185.90 266.28 919.62 31.70 9.00 0.14 1.70
5 1 11-Dec-00 81 0.44 971.88 429.48 542.41 17.60 11.23 0.41 0.81
6 1 28-Feb-Ol 79 0.42 1432.42 599.26 833.16 35.67 13.10 0.28 1.06
7 12-Mar-Ol 85 0.72 935.64 675.24 260.40 33.10 7.00 0.34 0.62
8 1 22-Mar-01 68 0.36 871.10 313.34 557.76 31.65 16.60 0.17 0.56
9 1 I2-Apr-01 77 0.36 656.07 233.07 423.00 22.85 14.10 0.17 0.50
10 09-May-01 68 0.55 741.83 407.75 334.08 25.17 8.70 0.27 0.64
11 1 29-May-Ol 67 0.34 825.48 282.96 542.52 13.10 13.70 0.36 0.66
12 1 30-May-01 65 0.21 921.41 193.46 727.96 16.97 16.62 0.19 0.73
13 11-Jun-Ol 78 0.33 1089.48 363.48 726.00 23.30 10.00 0.26 1.21
14 1 22-Jun-Ol 79 0.26 517.86 132.30 385.56 31.50 12.60 0.07 0.51
15 1 23-Jul-Ol 65 0.37 2319.56 864.26 1455.30 49.67 31.50 0.29 0.77
16 0 25-Jul-Ol 86 0.44 1145.34 503.82 641.52 46.65 12.15 0.18 0.88
17 0 14-Aug-Ol 68 0.31 1573.74 495.00 1078.74 25.00 23.05 0.33 0.78
18 0 20-Aug-01 67 0.27 933.24 247.80 685.44 23.60 11.90 0.18 0.96
19 0 03-Sep-01 65 0.24 723.84 177.12 546.72 14.40 6.70 0.21 1.36
20 1 12-Oct-Ol 70 0.23 394.20 91.80 302.40 9.00 14.40 0.17 0,35
21 1 17-Jan-02 74 0.36 938.31 333.96 604.35 24.20 12.75 0.23 0.79
22 0 07-Feb-02 65 0.23 690.60 160.20 530.40 26.70 13.00 0.10 0.68
23 0 04-Mar-02 70 0.34 602.16 202.80 399.36 16.90 6.40 0.20 1.04
24 1 04-Mar-02 52 0.38 500.94 191.52 309.42 16.80 5.40 0.19 0.96
25 1 25-Mar-02 50 0.56 1581.18 881.34 699.84 39.70 14.40 0.37 0.81
26 1 16-Apr-02 63 0.30 883.82 269.06 614.76 37.37 9.40 0.12 1.09
27 0 25-Apr-02 72 0.46 751.13 345.58 405.55 33.88 12.07 0.17 0.56
28 0 21-May-02 65 0.89 1027.74 915.90 111.84 21.50 23.30 0.71 0.08
29 0 24-May-02 83 0.51 969.78 494.52 475.26 31.70 8.90 0.26 0.89
30 0 03-Jul-02 73 0.21 327.24 68.04 259.20 16.20 9.00 0.07 0.48
31 0 04-Jul-02 SO 0.46 691.20 317.40 373.80 23.00 7.00 0.23 0.89
32 0 09-Jul-02 70 0.28 899.55 247.50 652.05 18.75 16.10 0.22 0.68
33 0 09-Jul-02 65 0.30 483.12 144.72 338.40 20.10 9.40 0.12 0.60
34 0 14-Aug-02 59 0.26 677.07 178.92 498.15 21.30 10.25 0.14 0.81
35 0 19-Aug-02 75 0.28 1237.86 341.46 896.40 27.10 18.00 0.21 0.83
36 0 05-Sep-02 78 0.51 584.15 297.00 287.15 19.80 9.03 0.25 0.53
37 0 ] O-Sep-02 47 0.29 1308.12 378.84 929.28 28.70 12.80 0.22 1.21
38 1 17-Oct-02 62 0.57 3147.72 1797.72 1350.00 42.20 12.50 0.71 1.80
39 1 05-Sep-02 73 0.57 1066.98 606.90 460.08 28.90 7.20 0.35 1.07
40 0 14-Jan-03 71 0.24 685.23 166.83 518.40 8.30 7.20 0.34 1.20
41 1 14-Jan-03 75 0.14 602.49 86.52 515.97 10.30 9.10 0.14 0.95
42 1 16-Dec-02 65 0.62 437.70 270.00 167.70 18.00 6.50 0.25 0.43
43 0 lO-Feb-03 78 0.27 762.00 207.00 555.00 15.00 12.50 0.23 0.74
M Male F Female; DPI Doppler perflision index; TLBF Total liver blood flow (ml/min); 
HAF Hepatic artery flow volume (ml/min); PVF Portal venous flow volume (ml/min); 
HATAM Hepatic artery time-averaged velocity (cm/s); HAXSA Hepatic artery cross 
sectional area (cm^); PVT AM Portal vein time-averaged velocity (cm/s); PVXSA Portal 
cross sectional area (cni^).
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Table C Patients with liver métastasés + primary colorectal tumour.
No
MO
FI Date DPI Age DPI TLBF HAF PVF HATAM PVT AM HA XSA PVXSA
1 0 12-Jul-OO 69 0.45 2725.61 1216.05 1509.56 58.24 16.03 0.35 1.57
2 0 12-Jul-OO 60 0.15 2496.84 381.90 2114.94 19.00 17.45 0.34 2.02
3 0 28-Aug-OO 70 0.40 1307.79 524.31 783.48 12.03 9.93 0.73 1.32
4 1 09-0ct-00 53 0.42 1023.48 428.40 595.08 42.00 11.40 0.17 0.87
5 0 03-Nov-00 63 0.18 1052.88 186.12 866.76 14.10 11.65 0.22 1.24
6 0 12-Feb-Ol 77 0.48 818.34 390.26 428.09 89.10 6.75 0.07 1.06
7 1 28-Feb-Ol 79 0.65 1180.35 764.82 415.53 60.70 12.15 0.21 0.57
8 0 20-Mar-01 46 0.56 977.58 546.06 431.52 47.90 11.60 0.19 0.62
9 1 21-May-01 73 0.42 579.12 241.92 337.20 16.80 14.05 0.24 0.40
10 0 30-May-01 73 0.51 858.18 438.96 419.22 23.60 13.70 0.31 0.51
11 1 25-Jun-01 87 0.29 587.52 172.80 414.72 19.20 10.80 0.15 0.64
12 0 08-Aug-01 66 0.24 744.12 177.12 567.00 16.40 10.50 0.18 0.90
13 0 13-Aug-01 51 0.41 2850.75 1167.48 1683.27 42.30 17.70 0.46 1.59
14 0 30-Aug-01 64 0.35 932.97 325.47 607.50 28.55 12.50 0.19 0.81
15 1 15-Oct-Ol 60 0.59 937.44 552.96 384.48 28.80 8.01 0.32 0.80
16 0 17-Oct-Ol 71 0.35 760.74 267.84 492.90 18.60 10.60 0.24 0.78
17 0 08-Nov-Ol 67 0.31 1048.81 325.13 723.67 20.07 15.87 0.27 0.76
18 0 08-No v-01 73 0.57 803.14 457.75 345.40 24.61 5.38 0.31 1.07
19 1 10-Jan-02 66 0.41 692.01 285.66 406.35 20.70 10.75 0.23 0.63
20 0 01-May-02 68 0.48 1285.20 613.20 672.00 36.50 7.00 0.28 1.60
21 1 01 -May-02 49 0.32 1461.39 470.67 990.72 54.10 19.20 0.15 0.86
22 1 05-Sep-02 71 0.40 762.06 307.02 455.04 30.10 9.60 0.17 0.79
23 0 04-Jul-02 74 0.31 1267.53 398.13 869.40 28.85 21.00 0.23 0.69
24 0 07-No v-02 69 0.33 877.68 290.16 587.52 24.80 9.60 0.20 1.02
25 0 lO-Feb-03 74 0.43 750.00 324.00 426.00 22.50 10.00 0.24 0.71
26 0 12-Feb-03 68 0.67 1131.00 753.00 378.00 50.20 9.00 0.25 0.70
M Male F Female; DPI Doppler perfusion index; TLBF Total liver blood flow (ml/min); 
HAF Hepatic artery flow volume (ml/min); PVF Portal venous flow volume (ml/min); 
HATAM Hepatic artery time-averaged velocity (cm/s); HAXSA Hepatic artery cross 
sectional area (cm^); PVT AM Portal vein time-averaged velocity (cm/s); PVXSA Portal 
cross sectional area (cm^).
218
Table D Patients with primary colorectal tumour.
No
MO
FI Date DPI Age DPI TLBF HAF PVF HATAM PVT AM HA XSA PVXSA
1 1 01-Jun-00 59 0.14 564.84 77.76 487.08 5.40 12.30 0.24 0.66
2 0 26-Jul-OO 56 0.33 997.54 329.48 668.06 19.10 8.75 0.29 1.27
3 0 07-Aug-00 51 0.15 1341.42 202.56 1138.86 21.10 17.10 0.16 1.11
4 0 14-Aug-OO 63 0.38 1612.66 620.05 992.61 18.13 26.90 0.57 0.62
5 0 01-Sep-00 72 0.07 1105.56 75.24 1030.32 11.40 16.20 0.11 1.06
6 1 07-Sep-00 85 0.10 746.62 71.44 675.18 13.23 17.05 0.09 0.66
7 0 08-Sep-00 68 0.17 1040.49 180.27 860.22 20.03 12.15 0.15 1.18
8 0 08-Nov-OO 56 0.14 1444.67 201.60 1243.07 12.00 19.13 0.28 1.08
9 0 19-Feb-Ol 78 0.77 1251.21 958.65 292.56 17.50 18.40 0.91 0.27
10 1 21-Feb-01 82 0.60 1079.81 650.15 429.66 31.87 11.55 0.34 0.62
11 0 12-Mar-Ol 54 0.19 1057.68 196.56 861.12 12.60 14.95 0.26 0.96
12 1 14-Mar-Ol 72 0.21 1003.82 212.78 791.04 27.28 10.30 0.13 1.28
13 0 22-Mar-Ol 79 0.09 1081.44 99.18 982.26 27.55 15.30 0.06 1.07
14 1 26-Apr-Ol 42 0.17 775.32 128.04 647.28 19.40 11.60 0.11 0.93
15 0 03-May-01 81 0.18 584.33 106.92 477.41 8.10 12.63 0.22 0.63
16 0 13-May-01 88 0.21 1448.28 301.32 1146.96 16.20 16.20 0.31 1.18
17 1 21-May-01 73 0.42 579.12 241.92 337.20 16.80 14.05 0.24 0.40
18 0 20-Jun-01 74 0.24 681.06 165.06 516.00 19.65 17.20 0.14 0.50
19 0 11-Jul-01 79 0.27 1491.21 396.00 1095.21 27.50 14.15 0.24 1.29
20 1 11-Jul-01 71 0.48 480.02 231.00 249.02 22.00 8.47 0.18 0,49
21 1 27-Aug-01 79 0.16 528.81 87.21 441.60 8.55 4.60 0.17 1.60
22 0 08-0ct-01 78 0.03 979.85 31.70 948.15 5.87 10.50 0.09 1.51
23 0 21-Oct-Ol 80 0.22 656.21 145.91 510.30 17.37 9.45 0.14 0.90
24 0 03-Jan-01 72 0.22 819.27 180.48 638.79 18.80 10.70 0.16 1.00
25 0 17-Jan-02 76 0.12 596.58 70.08 526.50 14.60 9.75 0.08 0.90
26 0 21-Jan-02 43 0.39 570.78 223.02 347.76 20.65 8.40 0.18 0.69
27 0 24-Jan-02 82 0.13 167.28 22.08 145.20 4.60 5.50 0.08 0.44
28 0 14-Mar-02 66 0.28 559.02 154.02 405.00 15.10 12.50 0.17 0.54
29 0 19-Mar-02 73 0.49 1067.88 520.38 547.50 41.30 12.50 0.21 0.73
30 1 21-Mar-02 63 0.18 1141.31 207.24 934.07 15.70 16.65 0.22 0.94
31 1 01-May-02 49 0.42 874.92 368.16 506.76 23.60 10.30 0.26 0.82
32 1 27-May-02 54 0.38 936.36 354.24 582.12 24.60 12.60 0.24 0.77
33 0 10-Jun-02 71 0.16 576.30 90.30 486.00 21.50 10.80 0.07 0.75
34 1 10-Jun-02 85 0.10 1118.22 115.68 1002.54 24.10 21.70 0.08 0.77
35 1 03-Jul-02 79 0.04 1732.11 77.76 1654.35 14.40 26.90 0.09 1.03
36 0 13-Jun-02 63 0.33 508.77 169.65 339.12 21.75 7.85 0.13 0.72
37 0 15-Oct-02 71 0.21 907.17 191.88 715.29 16.40 10.55 0.20 1.13
38 1 15-Oct-02 67 0.16 1397.61 228.75 1168.86 15.25 16.10 0.25 1.21
M Male F Female; DPI Doppler perflision index; TLBF Total liver blood flow (ml/min); 
HAF Hepatic artery flow volume (ml/min); PVF Portal venous flow volume (ml/min); 
HATAM Hepatic artery time-averaged velocity (cm/s); HAXSA Hepatic artery cross 
sectional area (cm^); PVT AM Portal vein time-averaged velocity (cm/s); PVXSA Portal 
cross sectional area (cm^).
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Appendix 3 Example of ultrasound images for the measurement of the Doppler 
Perfusion Index (DPI)
yaiC L2 8 5  2 8 6  
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Figure A Baseline intercostal ultrasound image of the right lobe of liver.
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Figure B Colour Doppler ultrasound image showing hepatic artery and liver.
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Figure C Colour Doppler ultrasound image and corresponding Doppler trace of 
hepatic artery. Example of time average mean velocity shown (F. Volume MnV : 
23.7cm/s).
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Figure D Baseline ultrasound image showing cross section of hepatic artery.
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Figure E Cross sectional area measurement of hepatic artery. Example of ellipse 
measurement (0.09cm^).
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Figure F Colour Doppler ultrasound image and corresponding Doppler trace of portal 
vein. Example of time average mean velocity shown (F. Volume MnV : 33.8cm/s).
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Figure G Baseline ultrasound image showing cross section of portal vein and right 
lobe of liver.
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Figure H Cross sectional area measurement of portal vein. Example of ellipse 
measurement (0.38cm^).
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Appendix 4 Computed Tomography (CT) attenuation measurements
Table A CT attenuation measurements in liver region-of interest (ROI) in conti'ol
subjects.
Patient Absolute % of Peak Liver % of Peak Aortic
No. Attenuation (HU) Attenuation Attenuation
35 secs 45 secs 35 secs 45 secs 35 secs 45 secs
1 86.18 92.36 59.83 64.13 32.62 34.96
2 65.80 64.40 45.85 44.88 18.38 17.99
3 94.16 117.67 50.28 6Z83 24.35 30.43
4 72.60 72.01 56.99 56.53 2288 2269
5 61.46 - 62.43 - 30.51 -
6 81.70 90.30 51.61 57.04 25.29 2296
7 105.01 140.02 57.43 76.57 26.08 34.78
8 8735 102.48 50.48 59.22 23.45 27.51
9 8538 104.96 69.23 85.21 33.07 40.70
10 88.50 81.00 66.24 60.63 37.12 33.98
■
£
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Table B CT attenuation measurements in liver region-of interest (ROI) in non­
metastatic colorectal cancer (clear liver).
Patient Absolute % of Peak Liver % of Peak Aortic
No. Attenuation (HU) Attenuation Attenuation
35 secs 45 secs 35 secs 45 secs 35 secs 45 secs
1 8298 - 51.18 - 24.27
2 64.37 65.59 35.34 36.01 13.67 13.93
3 70.95 80.99 52.32 59.72 20.38 23364 70.07 65^8 50.92 47.87 20.82 19.58
5 75.14 - 48.70 - 22.59 -
6 80.20 102.30 46.52 59.34 19.93 25.42
7 65.40 72.52 40.46 44.87 15.30 16.97
8 90.09 109.06 59.15 71.61 32.40 3932
9 76.49 92.50 41.76 50.50 20.03 2432
10 92.45 120.27 52.76 68.64 25.69 33.42
11 75.51 - 42,75 - 18.98 -
12 58.90 54.80 49.17 45.74 20.43 19.01
13 7&80 90.80 58.63 67.56 25.12 2834
14 55.00 60.50 39.83 43.81 19.85 21.83
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Table C CT attenuation measurements in liver region-of interest (ROI) in patients
with colorectal liver métastasés.
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Patient
No.
Absolute 
Attenuation (HU)
% of Peak Liver 
Attenuation
% of Peak Aortic 
Attenuation 1
35 secs 45 secs 35 secs 45 secs 35 secs 45 secs
Ï1 45.20 55.43 33.14 40.63 9.06 11.11
2 48.64 - 48.64 - 14.03 -
3 63.10 70.30 40.04 44.61 18.95 21.12 ■
4 71.48 - 44.29 - 20.95
5 78.69 73.76 48.63 45.58 21.25 19.92
6 66.82 77.78 57.13 66.50 25.30 29.45 :i7 58.64 67.25 32.07 36.77 12.46 14.29 7
8 74.02 85.29 49.05 56.51 25.75 29.67 ;9 57.14 61.16 53.70 57.48 25.44 27.23
10 71.98 - 41.37 - 19.62 -
11 63.75 71.72 43.40 48.83 20.61 23.19 7
12 67.85 - 40.27 - 16.22 - £
13 61.92 62.10 71.82 72.03 30.96 31.05 £14 64.32 68.28 51.69 54.87 24.32 25.82 115 85.25 102.75 63.02 75.96 29.79 35.91 ■/:
16 67.10 - 38.35 - 16.20 - £ . ; ;
17 87.30 8&25 55.08 55.68 26.03 26.32
18 84.74 - 52.63 - 23.28 - ;
19 72.50 80.07 48.38 53.44 21.49 23.73
20 80.74 94.47 49.21 57.58 20.50 23.99
21 80.06 86.78 54.89 59.50 22.38 24.26 7:
22 60.95 - 47.25 - 18.83 -
23 65.17 67.82 46.70 48.60 19.17 19.95 124 84.59 - 51.05 - 21.95 -
25 72.69 109.50 47.09 70.94 21.17 31.89
26 95.69 131.56 50.31 69.17 19.62 26.98
27 70.30 122.50 36.71 63.98 15.75 27.44 •7
28 80.85 127.44 45.30 71.40 23.28 36.70
29 60.62 75.76 44.56 55.69 15.76 19.70 i30 72.52 83.87 51.24 59.26 21.90 25.33 331 85.70 - 49.35 - 23.60 -
32 63.57 72.44 39.98 45.56 15.84 18.05 1
33 62.55 47.70 17.89 "'i
34 67.17 76.13 47.37 53.69 18.72 21.22
35 70.84 - 46.09 - 22.23 -
36 - - - - - - 7
37 69.48 74.41 47.03 50.37 14.03 15.03 i
38 69.18 - 48.72 - 18.28 -
39 99.75 126.87 61.74 78.52 31.64 40.24
40 67.32 78.20 3&28 44.47 16.69 19.38
41 84.05 86.78 52.76 54.47 28.99 29.93 ■
42 68.24 83.71 51.59 63.29 17.82 21.86 7
43 80.54 91.67 52.32 59.55 2&26 32.17
44 93.04 100.60 58.90 63.69 26.41 28.55 X
Table D CT attenuation measurements in whole liver in control subjects.
Patient
No.
Absolute 
Attenuation (HU)
% of Peak Liver 
Attenuation
% of Peak Aortic 
Attenuation
35 secs 45 secs 35 secs 45 secs 35 secs 45 secs
1 85.10 92.40 60.86 66.08 32.21 34.98
2 64.00 66.80 44.91 46.88 17.88 18.66
3 95.06 116.20 51.22 62.61 2A58 30.05
4 72.60 75.00 56.67 58^5 2Z88 23.63
5 61.79 - 66.55 - 30.67 -
6 85^0 99.60 55.50 64.42 26J6 30.84
7 110.51 142.15 60.51 77.83 27.45 35.31
8 89.14 112.53 54.02 68.20 23.93 30.20
9 8&29 94.32 72.61 77.57 34.24 36.58
10 85.10 85.00 65.92 65.84 35.70 35.65
a
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Table E CT attenuation measurements in whole liver in non-metastatic colorectal
cancer (clear liver).
Patient Absolute % of Peak Liver % of Peak Aortic
No. Attenuation (HU) Attenuation Attenuation
35 secs 45 secs 35 secs 45 secs 35 secs 45 secs
1 88.51 - 51.03 - 24.41 -
2 63.24 69.05 35.19 38.42 13.43 14.66
3 70.76 81.83 51.27 5R29 20.33 23.51
4 68.78 65.69 50.28 48.02 20.44 19.52
5 75.90 - 49.63 - 2282 -
6 81.50 105.20 46.41 59.91 20.25 26.14
7 67.31 75.03 41.38 46.13 15.75 17.55
8 91.10 111.34 60.73 74.23 32J6 40.04
9 72.32 95.03 40.14 52.75 18.93 24.88
10 94.88 120.68 54.39 69.18 26.37 33.54
11 75.26 - 43.07 18.92 -
12 59.30 55.30 50.25 46.86 20.57 19.18
13 76.90 93.80 57.65 70.31 24.51 29.90
14 55.50 62.00 41.26 46.10 20.03 22.37
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Table F
métastasés.
CT attenuation measurements in whole liver in patients with colorectal liver
233
Patient Absolute % of Peak Liver % of Peak Aortic
No. Attenuation (HU) Attenuation Attenuation
35 secs 45 secs 35 secs 45 secs 35 secs 45 secs
1 50.26 60.15 36.46 43.64 10.07 12.06
2 50.26 60.15 36.46 43.64 14.50 17.35
3 68.40 74.90 43.29 47.41 20.55 22.50
4 75.05 - 46.88 - 22.00 -
5 76.29 75.26 47.95 47.30 20.60 20.32
6 66.67 78.83 58.63 69.33 25.25 29.85
7 59.16 68.18 33.28 38.35 12.57 14.49
8 74.94 84.21 55.66 62.55 26.07 29.29
9 52.22 52.43 70.79 71.07 23.25 23.34
10 78.15 - 44.55 21.30 -
11 60.61 72.38 41.95 50.09 19.60 23.40
12 70.18 - 47.92 - 16.78 -
13 - - - - - -
14 56.23 68.20 51.99 63.05 21.26 25.79
15 87.97 102.21 65.84 76.50 30.74 35.72
16 68.48 - 39.92 - 16.54 -
17 78.48 83.61 52.03 55.43 23.40 24.93
18 86.13 - 53.45 - 23.66 -
19 78.30 70.08 55.85 49.99 23.21 20.77
20 82.34 97.76 50.45 59.90 20.91 24.82
21 77.80 - 93.79 - 21.75 -
22 63.21 - 52.98 - 19.53 -
23 63.30 70.34 45.87 50.97 18.62 20.69
24 77.53 - 53.99 - 20.12 -
25 74.93 108.55 48.87 70.80 2 1 .82 31.61
26 97.09 132.51 52.59 71.78 19.91 27.17
27 75.50 122.35 39.81 64.51 16.91 27.41
28 78.92 99.14 47.40 59.54 22.73 28.55
29 60.27 75.46 44.74 56.02 15.67 19.62
30 75.15 87.59 52.29 60.94 22.70 26.45
31 83.40 - 48.11 - 22.97 -
32 60.12 70.24 37.69 44.03 14.98 17.50
33 64.98 - 49.80 « 18.58 -
34 67.97 81.17 76.85 91.77 18.94 22.62
35 - - - - -
36 68.35 63.52 52,24 48.55 21.73 20.19
37 72.18 74.13 49.86 51.21 14.57 14.97
38 70.13 - 48.24 - 18.53
39 100.33 127.44 64.90 82.44 31.82 40.42
40 69.16 82.36 39.79 47.39 17.14 20.41
41 83.32 88.73 52.31 55.71 28.74 30.61
42 66.46 89.90 49.97 67.59 17.36 23.48
43 79.10 90.56 51.32 58.76 27.76 31.78
44 78.64 78.77 50.39 50.47 22.32 22.36
i
Appendix 5 Example of dual-phase CT scans for the measurement of hepatic 
perfusion
Figure A Dual-phase CT scan of abdomen, showing whole liver perimeter 
for attenuation measurement.
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Figure B Dual-phase CT scan of abdomen, showing liver Region of Interest 
(ROI) for attenuation measurement.
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Appendix 6 The relationship between tumour volume, the systemic inflammatory 
response and liver blood flow in patients with colorectal liver métastasés
Table A Characteristics of patients with colorectal liver métastasés (n=52).
Patient
No.
Tumour
Volume PHR CRP IL-6 HAT PVF TLBF DPI
1 709.40 35.90 28.00 13.10 470.67 990.72 1461.39 0.32
2 63.85 3.00 5.00 - 151.62 353.66 505.28 0.30
3 2&65 3.80 5.00 1.00 172.80 414.72 587.52 0.29
4 14.29 0.96 5.00 - 282.96 542.52 825.48 0.34
5 16.39 1.11 48.00 - 1216.05 1509.56 2725.61 0.45
6 1052.40 35.19 109.00 11.90 266.28 919.62 1185.90 0.22
7 563.26 10.70 141.00 - 606.90 460.08 1066.98 0.57
8 568.25 21.60 141.00 - 247.80 685.44 933.24 0.27
9 14.14 0.70 2.15 6.20 915.90 111.84 1027.74 0.89
10 315.50 14.91 6.00 3.90 202.80 399.36 602.16 0.34
11 7.90 0.50 2.47 4.00 68.04 259.20 327.24 0.21
12 69.42 3.91 5.00 2.60 363.48 726.00 1089.48 0.33
13 47.35 2.52 5.00 11.00 177.12 546.72 723.84 0.24
14 10.22 0.70 20.00 42.70 333.96 604.35 938.31 0.36
15 24.61 1.56 5.00 5.50 881.34 699.84 1581.18 0.56
16 130.80 6.00 55.00 - 1782.27 1233.25 3015.52 0.59
17 148.85 7.68 108.00 - 381.90 2114.94 2496.84 0.15
18 16.27 1.09 28.00 8.70 177.12 567.00 744.12 0.24
19 36.94 2.51 88.00 3.70 438.96 419.22 858.18 0.51
20 19.38 1.32 5.00 9.00 233.07 423.00 656.07 0.36
21 49.71 2.96 5.00 6.90 325.47 607.50 932.97 0.35
22 199.95 13.05 204.00 35.30 494.52 475.26 969.78 0.51
23 3223.80 90.00 135.00 41.70 345.58 405.55 751.13 0.46
24 613.39 21.80 19.00 - 546.06 431.52 977.58 0.56
25 89.50 3.75 21.00 3.70 178.92 498.15 677.07 0.26
26 101.69 5.87 24.00 11.70 1797.72 1350.00 3147.72 0.57
Tumour volume (cm^); PHR, percentage hepatic replacement; CRT C-reactive protein 
(mg/1); IL-6 lnterleukin-6 (ng/1); HAT hepatic arterial flow volume (ml/min); PVF portal 
venous flow volume (ml/min); TLBF total liver blood flow (ml/min); DPI Doppler 
perfusion index.
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Table A cont./
Patient
No.
Tumour
Volume PHR CRP IL-6 HAF PVF TLBF DPI
27 233.23 15.84 125.00 - 503.82 641.52 1145.34 0.44
28 87.00 4.80 8.03 144.72 338.40 483.12 0.30
29 2741.76 90.00 9.64 2.90 325.13 723.67 1048.81 0.31
30 2.70 030 64.00 - 297.00 287.15 584.15 0.51
31 7.74 032 45.00 191.52 309.42 500.94 0.38
32 13.75 1.00 5.00 6.40 166.83 518.40 68^23 0.24
33 2&63 1.19 5.00 7.60 269.06 614.76 883.82 0.30
34 250.83 16.98 155.00 - 599.26 833.16 1432.42 0.42
35 28.88 3.00 5.00 1.30 270.00 167.70 437.70 0.62
36 6&24 3.60 83.00 22.90 428.40 595.08 1023.48 0.42
37 939.78 26.10 938 14.10 613.20 672.00 1285.20 0.48
38 12.61 1.00 7.00 11.00 193.46 727.96 921.41 0.21
39 1111.82 55.80 214.00 - 307.02 455.04 762.06 0.40
40 81.30 4.40 5.00 - 495.00 1078.74 1573.74 0.31
41 11.98 1.05 189.00 - 764.82 415.53 1180.35 0.65
42 T65 0.70 76.00 5.90 8632 515.97 602.49 0.14
43 468.09 30.03 11.00 - 561.96 886.17 1448.13 0.39
44 516.70 16.20 28.00 — 390.26 428.09 818.34 0.48
45 409.25 2&90 176.00 20.60 675.24 260.40 935.64 0.72
46 3.46 0.24 7.00 429.48 542.41 971.88 0.44
47 18.32 1.05 32.00 10.10 160.20 530.40 690.60 0.23
48 161.30 7.14 13.00 10.70 317.40 373.80 691.20 0.46
49 1366.60 34.27 57.00 * 267.84 492.90 760.74 0.35
50 5.40 0T6 22.00 17.70 247.50 652.05 899.55 0.28
51 379.66 2T91 5.00 5.30 313.33 557.76 871.10 0.36
52 178.00 9.47 213.00 21.80 341.46 896.40 1237.86 0.28
Tumour volume (cm^); PHR, percentage hepatic replacement; CRP C-reactive protein 
(mg/1); IL-6 Interleukin-6 (ng/1); HAF hepatic arterial flow volume (ml/min); PVF portai 
venous flow volume (ml/min); TLBF total liver blood flow (ml/min); DPI Doppler 
perfusion index.
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Appendix 7 The effect of anti-inflammatory treatment on liver blood flow in
patients with colorectal liver métastasés
Table A Patient details and liver blood flow measurements pre- and post-treatment of 
placebo or non-steroidal anti-inflammatory drugs.
Patient
No. Age
Placebo
0
Ibuprofen
1
Exclude
0
Include
1
HAF 1 PVF 1 TLBF 1 DPI 1 HAF 2 PVF 2 TLBF 2 DPI 2
1 67 0 1 325.13 723.67 1048.81 0.31 669.60 695.75 1365.35 0.49
2 73 1 1 457.75 345.40 803.14 0.57 - - - 0.52
3 66 0 1 136.21 318.17 454.37 0.30 81.00 248.64 329.64 0.25
4 74 0 1 333.96 604.35 938.31 0.36 - - - 0.33
...
6 70 0 1 202.80 399.36 602.16 0.34 180.41 466.60 647.01 0.28
7 50 1 1 881.34 699.84 1581.18 0.56 297.36 810.54 1107.90 0.27
8 63 1 1 269.06 614.76 883.82 0.30 145.32 538.20 683.52 0.21
9 77 1 1 184.68 597.24 781.92 0.24 269.04 1070.88 1339.92 0.20
10 72 0 1 345.58 405.55 751.13 0.46 290.70 208.08 498.78 0.58
11 74 1 1 613.20 672.00 1285.20 0.48 779.76 345.60 1125.36 0.69
12 50 0 1 486.90 990.72 1477.62 0.33 316.26 262.44 578.70 0.55
13 65 1 1 103.20 992.58 1095.78 0.09 67.68 875.76 943.44 0.07
14 83 1 1 494.52 475.26 969.78 0.51 237.60 837.00 1074.60 0.22
15 65 1 1 144.72 338.40 483.12 0.30 124.56 269.10 393.66 0.32
16 80 1 1 317.40 373.80 691.20 0.46 - - - 0.18
17 72 0 1 68.04 259.20 327.24 0.21 169.92 401.58 571.50 0.30
18 70 0 1 247.50 656.88 904.38 0.27 399.90 635.04 1034.94 0.39P#
r s s T
* ' -
. ' i - A
22 72 0 1 166.83 518.40 685.23 0.24 115.92 637.20 753.12 0.15
23 76 1 1 86.52 515.97 602.49 0.14 106.59 579.36 685.95 0.16
H ‘ i r i 2 4 j à s : yt- . -  A :. ’ . . . :
25 78 0 1 207.00 555.00 762.00 0.27 255.00 828.36 1083.36 0.24
26 80 1 1 279.60 415.80 695.40 0.40 165.66 276.48 442.14 0.37
27 50 0 1 256.02 817.32 1073.34 0.24 372.84 627.30 1000.14 0.37
29 71 1 1 107.04 718.20 825.24 0.13 233.28 786.24 1019.52 0.23
# 5 Ë %
HAF 1, Baseline hepatic arterial flow volume (ml/min); HAF 2, Post-treatment hepatic 
arterial flow volume (ml/min); PVF 1, Baseline portal venous flow volume (ml/min); PVF 
2 Post-treatment portal venous flow volume (ml/min); TLBF 1, Baseline total liver blood 
flow volume (ml/min); TLBF 2, Post-treatment total liver blood flow volume (ml/min); 
DPI 1, Baseline Doppler perfusion index; DPI 2 post-treatment Doppler perfusion index.
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Table B Patient details, liver tumour details and biochemical measurements pre- and 
post-treatment of placebo or non-steroidal anti-inflammatory drugs.
Patient
No.
Placebo
0
Ibuprofen
1
Exclude
0
Include
I
Total
Liver
Volume
T umour 
Volume PHR CRPl CRP2 lL-6 1 lL-6 2
1 0 1 3046.40 2741.76 90.00 15.00 13 2.00 17.30
2 1 I - - - 6.00 - 2.00 -
3 0 1 2104.54 63.85 3.03 37.00 6 2.00 2.00
4 0 I 1433.12 10.22 0.71 259.00 - 33.90 -
A -.S : .;Cs I T T »
6 0 1 2115.94 315.50 14.91 16.00 136.90 -
7 1 1 1582.75 24.61 1.55 6.00 6 2.00 2.00
8 I 1 2240.28 26.63 1.19 6.00 6 2.00 2.00
9 1 1 1466.46 19.38 1.32 - 6 2.00 2.00
10 0 1 3582.00 3223.80 90.00 - - 22.00 -
11 1 1 3607.13 939.78 26.05 - 100 - 8.40
12 0 1 1976.60 709.40 35.89 6.00 40 15.40 10.90
13 I 1 2021.27 14.14 0.70 13 6 2.00 2.00
14 I 1 1532.43 199.95 13.05 6 25 - 95.90
15 I 1 1827.36 87.00 4.76 51 6 2.00 2.00
16 I I 2258.60 161.30 7.14 14.00 9 11.60 7.30
17 0 1 1580.03 7.90 0.50 - 6 2.00 2.00
18 0 I 1743.56 5.40 0.31 6.00 6 2.00 2.00
c r y
T Î
■ c.
# #
: - . 'j
22 0 1 1358.28 13.75 1.01 6.00 6 2.00 2.00
23 1 1 1089.55 7.65 0.70 - 6 2.00 2.00/'■> .*■ r. m : A L 1.1:»S
25 0 1 - 18.00 8 5.50 21.80
26 1 1 - - - 6.00 6 - 2.00
27 0 1 - - - 76 6 2.00 2.00
29 1 1 - - - - 21 2.00 3.20
Liver Volume (ml); Tumour Volume (ml); PHR, Percentage Hepatic Replacement, CRPl 
pre-treatment C-reactive Protein (mg/1); CRP2 post-treatment C-reactive Protein (mg/1); 
IL-6 I Pre-treatment Interleukin-6 (ng/1); IL-6 2 Post-treatment Interleukin-6 (ng/1).
C L /
J
